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Staphylococcus aureus is one of the most common causes of nosocomial (i.e. 
hospital-acquired) infection. Significantly, over 90% of S. aureus strains are resistant to 
penicillin, and since the mid-1980’s, methicillin-resistant S. aureus (MRSA) strains have 
become prevalent in hospitals worldwide, with resistance rates approaching 70%. In the 
U.S. alone, MRSA is responsible for over 100,000 invasive life threatening infections, 
such as necrotizing fasciitis, and causes 20,000 deaths annually. More worrisome, a 
variant known as community-acquired MRSA (CA-MRSA) is spreading in schools, 
gymnasiums, and even professional sports teams, where it infects otherwise healthy 
adolescents and young adults. Vancomycin is often considered the last antibiotic of 
choice against MRSA and other Gram-positive pathogens. However, rates of 
vancomycin-resistant enterococci (VRE) have already reached 30% and it is widely 





transfer during co-colonization of MRSA and VRE. Thus, alternative antimicrobial 
approaches are desperately needed. Endolysins, or peptidoglycan hydrolases, are phage-
derived enzymes that actively lyse bacterial cells upon direct contact and may be 
considered such an alternative option. Moreover, the inability of bacteria to evolve 
resistance to endolysins is due to the specificity of the N-terminal catalytic domain, 
which cleaves a conserved peptidoglycan bond, and the C-terminal cell wall binding 
domain, which binds a cell surface moiety. This thesis represents an investigation into the 
endolysin PlyGRCS, which displays potent bacteriolytic activity against all antibiotic-
resistant strains of S. aureus tested. This enzyme is active in physiologically relevant 
conditions (pH, NaCl, temperature), and its activity is greatly enhanced in the presence of 
calcium. PlyGRCS is the first endolysin with a single catalytic domain that cleaves two 
distinct sites in the peptidoglycan. Unlike antibiotics, PlyGRCS displays anti-biofilm 
activity, preventing, removing, and killing biofilms grown on abiotic and biotic surfaces. 
Engineering efforts were made to create an enzyme with a variable binding domain, 
which unfortunately displayed less activity than the wild type endolysin in the conditions 
tested. The antimicrobial efficacy of PlyGRCS was validated in a mouse model of S. 
aureus septicemia. The results from this study indicate that the endolysin PlyGRCS is a 
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Chapter I: Introduction and Literature Review 
Though much progress has been made in the last century towards combatting 
bacterial infections through the discovery of modern antibiotics, these types of maladies 
still account for the majority of the world’s morbidity and mortality (Woodford and 
Livermore, 2009).  Furthermore, the advances that have been made in the field seem to 
have contributed to the current predicament of increasingly antibiotic resistant bacterial 
infections and may be responsible for the undoing of the last 100 years of progress, 
compounding the situation even further (Livermore, 2009). Possibly the most infamous 
story related to antibiotic-resistant bacteria involves Staphylococcus aureus, which has 
the ability to cause a diverse array of life-threatening infections and the capacity to adapt 
to different environmental conditions. With this impending crisis upon us, researchers are 
turning to alternative methods for preventing and treating such bacterial infections.    
 
Staphylococcus aureus History and Characteristics 
Humankind has been constantly fighting the war against pathogenic bacteria, but 
it wasn’t until the 19
th
 century that we were able to establish a link between these 
organisms and infectious disease. This scientific progress led to an ability to identify and 
classify particular organisms and thus begin to understand our interactions with them.   
Staphylococcus was first discovered as the causative agent of a wound infection 
by Sir Alexander Ogston in 1880 (Ogston, 1881), although the official naming of 
Staphylococcus aureus four years later is credited to Anton Julius Rosenbach 





bacterium, commonly observed forming grape-like clusters under the microscope and 
gold colonies on agar plates (both characteristics from which its name is derived).  
The hardy nature of S. aureus enables it to survive in the environment on many 
types of surfaces.  S. aureus has been found to survive, on glass, wood, vinyl plastic, and 
cloth; for some of these materials, bacteria were isolated up to 90 days after inoculation 
(Neely and Maley, 2000). This persistence, combined with its commensal behavior with 
the host, make it a potentially frightening pathogen. By some estimates, up to 20% of 
healthy individuals constantly asymptomatically carry this bacterium in the anterior nares 
of their nasal passages, throats, and on their skin; in addition, 60% of the population is 
suspected to be transiently asymptomatically carrying at any particular time (Williams, 
1963). In normal healthy people, colonization usually does not lead to any symptoms or 
illness. However, S. aureus is a classic opportunistic pathogen in that it will take 
advantage of a compromised host to cause disease.    
 
Staphyloccocal Infections  
S. aureus has the capability to cause a wide range of illnesses, including skin, 
soft-tissue, ocular, brain, respiratory, bone, gastrointestinal, and endovascular disorders 
(Lowy, 1998) . While many groundbreaking medical advances have been made in the last 
century, non-healing wounds caused by S. aureus- induced skin and soft tissue infections 
still represent a significant burden to society. S. aureus skin and tissue infections can 
manifest themselves as the common pimple or can progress to the much more severe boil, 
abscess, folliculitis, impetigo, mastitis, cellulitis, or even necrotizing fasciitis; it is also 





caused by S. aureus include endophthalmitis, conjunctivitis, and keratitis, and usually 
occur after refractive or cataract surgery or LASIK (Chuang et al., 2012). While 
uncommon, S. aureus induced meningitis has a poor prognosis, with mortality rates up to 
80% (Durand et al., 1993). Staphylococcal pneumonia is becoming increasingly prevalent 
in hospitals (20%–40% of all nosocomial-acquired and ventilator-associated infections) 
and the community (Rubinstein et al., 2008). Staphylococcal food poisoning, caused by 
consuming food contaminated with enterotoxin, results in gastrointestinal distress and 
can be severe enough to necessitate hospitalization (Argudin et al., 2010).  S. aureus is 
also a leading cause of bacteremia, which has a high mortality rate, especially in patients 
who are older, not treated with antibiotics, or have a medical device that has not been 
removed; S. aureus bloodstream infections allow for metastasis to other sites in the body, 
causing endocarditis, osteomyelitis, or septic arthritis, all of which can be further 
complicated by the presence of an implant (Mylotte et al., 1987). Notably, S. aureus 
causes the life-threatening toxic shock syndrome, which was associated with super 
absorbent tampons in the 1980s allowing for the accumulation of staphylococcal toxins 
(Hanrahan, 1994); non-menstrual causes include localized infections, surgery, or insect 
bites  (Lowy, 1998).       
S. aureus infections are not just limited to humans; other animals are susceptible 
to staphylococcal diseases as well. Household companion animals, such as cats and dogs, 
manifest S. aureus skin and soft tissue infections in the same way as humans do. 
Interestingly, it was found that the same genetic strain of S. aureus was carried in humans 
and their pets, and researchers suggest that it likely can be passed between species.  





infected; rats may even play a role in spreading S. aureus on farms (van de Giessen et al., 
2009; Weese, 2010). Livestock are also not immune to S. aureus infections. Cows, and 
other milking animals such as buffalo and camels, are subject to intramammary infections 
(Schmidt et al., 2015). In sheep and goats, S. aureus commonly causes dermatitis, and in 
pigs, S. aureus may cause botryomycosis, urinary tract infections, or mastitis. In 
chickens, S. aureus is responsible for infections such as bumblefoot, gangrenous 
dermatitis and bacterial chrondronecrosis with osteomyelitis (Lowder et al., 2009). 
Horses are susceptible to the same wide range of infections as those observed in humans 
(Weese, 2010).   
 
Antibiotic Resistant S. aureus 
In the years between the discovery of S. aureus, but before the discovery of 
modern day antibiotics, S. aureus infections had a nearly 80% mortality rate (Dancer, 
2008). Upon the introduction and mass production of these traditional antibiotics, the 
mortality rate was dramatically reduced to 25% (Cosgrove et al., 2003; Fridkin et al., 
2003; Rubin et al., 1999).  However, in 2005, methicillin-resistant Staphylococcus aureus 
(MRSA) was responsible for an estimated 94,000 life-threatening infections and 18,650 
deaths in the U.S. alone, more than double the national estimate only five years earlier 
(Klevens et al., 2007).  
MRSA, which are also resistant to cephalosporins, was originally just a hospital 
acquired infection (HAI), due to the prevalence of elderly and immunocompromised 
individuals in this environment. Hospital-associated MRSA (HA-MRSA) represents 





20 years, MRSA has now become a greater problem in our communities, affecting 
children and healthy individuals including athletes, and especially thriving in areas where 
individuals are in close proximity with one another, such as prisons (David and Daum, 
2010). Community-associated MRSA (CA-MRSA) is genetically distinct from HA-
MRSA (Fey et al., 2003) and is endemic in some U.S. cities, reaching up to 50% of all S. 
aureus infections reported (Dukic et al., 2013).  Further complicating the MRSA situation 
is the emergence of livestock-associated MRSA (LA-MRSA), which has resulted in 
transmission of a new strain from animals to humans (Ballhausen et al., 2014; Fluit, 
2012; Hetem et al., 2013; Price et al., 2012) 
The increasing prevalence of MRSA led to greater use of vancomycin (originally 
a last resort antibiotic) in the 1980s; this, in turn led to the emergence of vancomycin-
resistant S. aureus (VRSA) in 2002 (Centers for Disease and Prevention, 2002). While 
there have only been 14 cases of VRSA (and no deaths) in the U.S., the CDC has labeled 
it a concerning threat. Reports of VRSA have emerged from around the world, indicating 
that this is a severe global issue (Melo-Cristino et al., 2013; Palazzo et al., 2005; Tiwari 
and Sen, 2006).  
S. aureus has also developed resistance to the newer antibiotics; linezolid-
resistant S. aureus (LRSA) and daptomycin-resistant S. aureus (DRSA) outbreaks have 
been reported, and while they are currently uncommon, it may only be a matter of time 
until their frequency reaches MRSA levels (Endimiani et al., 2011; Marty et al., 2006; 
Sanchez Garcia et al., 2010).   
As one can imagine, this antibiotic resistance crisis has had an immeasurable 





infections are associated with prolonged treatments, extended hospital stays, and require 
additional doctor visits and healthcare use compared to antibiotic-susceptible bacteria, all 
leading to a costly outcome. One study estimated average cost per MRSA patient to be 
$34,657, compared with $15,923 for patients with methicillin-sensitive S. aureus 
(MSSA) (Filice et al., 2010).  MRSA infections have been suggested to cost up to a total 
of $10 billion per year in the U.S. healthcare system alone (Klein et al., 2007).  
 
Biofilms  
S. aureus has an arsenal of virulence factors that allow it to cause the multitude of 
various illnesses described, hence its notoriety as a fearsome “nightmare bacteria” 
(Gordon and Lowy, 2008). One of the most important aspects of its virulence is the 
ability to form biofilms (Fig. 1-1). Biofilms are a microbial community of bacterial cells 
that are attached to a surface and each other, and are encased in extracellular polymeric 
substance (EPS) made up of extracellular DNA, proteins, and carbohydrates. They 
exhibit behaviors divergent from bacteria in the planktonic state of growth, due to the 
complex nature of physiologically distinct cells present in the population of a bacterial 
biofilm (Kiedrowski and Horswill, 2011; Parsek and Singh, 2003). Biofilms are 
notoriously difficult to eradicate, as they are resistant to antibiotics and are resilient 
against the host immune system (Scherr et al., 2014).  Furthermore, antibiotics have been 
shown to induce changes in planktonic bacteria that result in an increased proclivity for 
forming biofilms (de la Fuente-Nunez et al., 2014). Additionally, biofilms provide a site 
for cells to disperse from and colonize other areas or cause acute infections (Costerton et 






Figure 1-1. Staphylococcal biofilm lifecycle. Biofilms form by initial attachment of 
bacteria, through specific, protein-protein interactions with an abiotic surface or non-
specifically to an abiotic surface. The maturation process consists of the production of 
molecules including exopolysaccharide, teichoic acids, extracellular DNA, and proteins 
that connect the cells and provide structural integrity. The final step of detachment occurs 
through expression of quorum-sensing systems and surfactant-like molecules and aids in 







biofilms are  associated with many different types of chronic infections; furthermore, the 
ability of S. aureus to form biofilms on implanted medical devices complicates these 
infections and the only option is removal of the affected material (Darouiche, 2004; 
Francois et al., 1996).   
 
Management of S. aureus   
Throughout the last century scientists have developed numerous techniques to 
prevent and treat S. aureus infections; however, the current techniques lack the desired 
degree of efficacy. Furthermore, the overuse of the most commonly used treatment 
option, antibiotics, has resulted in the selection of antibiotic-resistant bacteria, which 
further compounds the problem.  
 
Antibiotics 
After all these years, the gold standard for treatment of bacterial infections 
remains traditional antibiotics. The drug of choice for treatment of S. aureus infections is 
still penicillin, one of the first commercially available antibiotics, even though 90% of 
isolates are now resistant (Lowy, 2003; Tong et al., 2015; Vardakas et al., 2014). In the 
likely case that resistance to penicillin is encountered, penicillinase-resistant β-lactams 
such as methicillin, oxacillin, dicloxacillin or flucloxacillin are available as second 
options (Rayner and Munckhof, 2005). However, the ubiquity of S. aureus resistant to 
methicillin resulted in physicians having to use “last resort” antibiotics, such as the 
glycopeptide vancomycin, as a first course of action. Once strains with partial or total 





found to be effective against vancomycin-intermediate Staphylococcus aureus (VISA) 
and trimethoprim/sulfamethoxazole was shown to have efficacy in treating VRSA. Other 
new treatment options for invasive MRSA infections include linezolid, daptomycin, 
tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti-MRSA 
compounds have been recently approved by the FDA: novel lipoglycopeptides telavancin 
in 2009, dalbavancin and oritavancin in 2014, and the oxazolidinone tedizolid phosphate 
in 2014 or are under development (iclaprim) (Higgins et al., 2005; Krievins et al., 2009; 
Louie et al., 2011; Schwalbe et al., 1996; Steiert and Schmitz, 2002). However, if the 
lessons of methicillin- and vancomycin-resistant S. aureus are any indication, replacing 
one antibiotic treatment with another will just perpetuate the cycle.  It is only a matter of 
time before resistance to these new treatments is observed as well.  Additionally, these 
new antibiotics often come with undesirable side effects.  Linezolid has been associated 
with thrombocytopenia, vision problems and serotonin toxicity (Garazzino et al., 2007; 
Lawrence et al., 2006), quinupristin/dalfopristin causes a high rate of adverse venous 
events (Nichols et al., 1999), and televancin causes adverse renal effects (Stryjewski et 
al., 2008).       
 
Vaccine development 
 The holy grail in the war against staphylococcal infections would be a vaccine; 
however, there is currently no safe and effective vaccine despite the numerous attempts at 
developing one. Many of these vaccines have failed in late stage clinical trials, after much 
time, effort, and money had already been spent. A majority of the failures have been due 





functional redundancy to downregulate the targeted virulence factor and upregulate 
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resulted in no difference in clinical end points  in 
infants and adults (Shah and Kaufman, 2009; Weems et al., 2006). However, when 
vaccines against capsular polysaccharide and clumping factor A were given in 
conjunction with each other, a greater level of protection was afforded, indicating the 
necessity of a multivalent vaccine (Tuchscherr et al., 2008). Based off of those preclinical 
results, Pfizer developed SA3Ag
®
, which performed well in a phase I clinical trial, 
proving to be safe and immunogenic, and will proceed to phase II (Nissen et al., 2015).  
A vaccine from Merck (V710
®
) against iron surface determinant B was assessed for its 
ability to prevent S. aureus infections, and it was found that patients actually fared worse 
upon receiving this vaccine (Allen et al., 2014). Aurograb
®
 from NeuTec, a vaccine 
against an ATP-binding cassette transporter, failed to treat MRSA infections in a phase II 
clinical trial (Otto, 2010). Pagibaximab
®
 by Biosynexus, a vaccine against lipoteichoic 
acid, shows great promise having passed three rounds of clinical trials; results showed 
reduced rates of sepsis in infants and so far it is safe and well-tolerated (Patel and 
Kaufman, 2015). Nabi recently conducted phase I/II clinical trials using vaccines against 
α-toxin and LukS-PV and showed good immunogenicity and safety profiles (Lalani et al., 
2013). Integrated Biotherapeutics just completed phase I clinical trials using STEBVax
®
 
against enterotoxin B, and results are pending (Larkin et al., 2010). Novadigm’s 
candidate NDV-3
®





in phase I/Ib clinical trials (Schmidt et al., 2012). In all, the efforts to create safe and 
effective vaccines for S. aureus are numerous and represent a promising approach to 
combating these infections. Furthermore, many of the pitfalls experienced in the earlier 
iterations have allowed scientists to learn from these mistakes and strategically improve 
upon future vaccine candidates.  
  
Metals and metal chelation 
The use of metals against multiple species of bacteria has been exploited since 
ancient times, and more recently with some basic understanding of mechanism.  Referred 
to as the oligodynamic effect, the mechanism of action is thought to be that the metal ion 
(especially from heavy metals) binds to the reactive (thiol) groups of proteins involved in 
metabolism, resulting in precipitation and thereby inactivation (Gibbard, 1937). While 
many different types of metals have been utilized for their antimicrobial characteristics, 
silver and copper are most widely used due to their lower toxicity against eukaryotes 
(Singh et al., 2011). Metal ions have an application in treating burn wounds and in 
impregnation of medical devices (Church et al., 2006), and also as disinfectants in non-
medical appliances (Jung et al., 2008). Metal ion therapy has been particularly useful in 
prevention and treatment of biofilm bacteria (Nan et al., 2015; Roe et al., 2008). While 
research into metal ions as antimicrobials has been somewhat promising, resistance has 
been observed. Even more discouraging is the observation of cross- and co-resistance to 
traditional antibiotics upon exposure to metal ions, indicating that this therapy may be 





 At the opposite end of the spectrum, removal of metals from the bacterial 
environment has also been somewhat successful in treatment of infections. Because metal 
acquisition is important during pathogenesis, scientists have experimented with the use of 
metal chelators as antimicrobials (Hammer and Skaar, 2012). Several compounds have 
shown antimicrobial efficacy against S. aureus (Prachayasittikul et al., 2013; Qiu et al., 
2011; Short et al., 2006) and may also have a role in biofilm disruption (Abraham et al., 
2012). However, as metal chelators could potentially be cytotoxic, can interfere with 
immunodefense, and some may not be able to be used systemically, they may not be the 




 A cure not for the slight of heart, maggot debridement therapy (MDT) 
(biodebridement, larval therapy, therapeutic myiasis), the intentional application of live 
“medical-grade” fly larvae to wounds in order to effect debridement, disinfection, and 
ultimately wound healing, is entering a renaissance period of sorts (Sherman, 2009). 
While this technique was used quite frequently in the first half of the 1900s, the 
widespread use of antibiotics eliminated its usage. However, now that society is faced 
with the emergence of antibiotic-resistant bacteria, some earlier technologies are being 
reexamined with the knowledge gained over the past century. The technical challenges of 
maggot therapy 100 years ago are now able to be overcome due to the advances in 
dressings that confine maggots to the wound and the ability to obtain germ-free maggots 





disinfect the wound and stimulate healing. These mechanisms of action are thought to 
occur most effectively in the presence of the animal, but attempts to isolate the “magic 
molecule” have been only somewhat successful. While some antibacterial factors have 
been discovered, they have not been compared head to head against use of the whole 
maggot (Arora et al., 2011). Maggot therapy may be most effective when there is a 
synergistic effect of multiple antimicrobial components or the physical movement of the 
maggot itself may aid in the removal of the necrotic tissue. Importantly, biofilm 
inhibition and eradication was able to be achieved with just the excretions and secretions 
from the maggot (Cazander et al., 2009). While results appear to be positive, this therapy 
faces major hurdles to becoming widely used. The number one aversion to maggot 
therapy is the obvious “yuk factor;” patients must overcome the thought of live insects 
crawling on their bodies (Steenvoorde et al., 2005). Furthermore, some users reported 
pain. On the doctor’s end, they must contend with keeping the maggots alive, a problem 
not normally dealt with when considering typical antimicrobials. Another issue is proper 
containment and eventual disposal of the maggots, as they are essentially “mobile 
fomites” and can transfer whatever infection they are trying to eradicate around a hospital 
or treatment facility.      
 
Other treatments 
In addition to the above mentioned therapies, there are numerous other treatments 
for S. aureus infections that are in various stages of development or not as commonly 
used in the clinic. A somewhat intriguing S. aureus control strategy is the use of the 





et al., 2011). In another approach, researchers have recently discovered that 
magnetotactic bacteria that possess magnetic nanocrystals could kill S. aureus by a 
magnetic hyperthermia mechanism (Chen et al., 2016). There has also been a push 
toward more in depth understanding of “natural” therapies in recent years, despite some 
of these treatments being used successfully for centuries. These include the 1000-year-old 
remedy known as an eye salve, consisting of garlic, onion, wine, and bile, honey, and 
various extracts from medicinal plants such as tea tree oil  (Brudzynski and Lannigan, 
2012; Carson et al., 2002; Chusri et al., 2013; Harrison et al., 2015). Other anti-
staphylococcal options that are being investigated include small molecules, antimicrobial 
peptides (AMPs), and quorum sensing inhibitors (Haisma et al., 2016; Jin et al., 2015; 
Tan et al., 2015). In addition to therapeutics, there is a need for disinfecting surfaces 
contaminated with S. aureus. Currently, alcohols, chlorhexidine, hexachlorophene, 
cetrimide, and triclosan are commonly used in places such as hospitals and gyms, and 
additional sanitizers are being investigated (Wootton et al., 2009; Yuen et al., 2015).        
 
Antibiotic Discovery and Resistance Development  
The identification of infectious agents and their associated illnesses, along with 
the beginnings of a basic understanding of mechanisms of infection, led to an ability to 
more systematically approach methods of battling pathogenic bacteria. While 
antimicrobial agents have been used throughout history, the advent of the golden age of 
antibiotics is considered to have begun in 1928 with the discovery of the β-lactam 
penicillin by Alexander Fleming (Fleming, 1929). It was introduced for widespread 





infections; however, the first resistance to penicillin was observed by 1945, an ominous 
sign of things to come (Lewis, 2013). In the 1940s, several translation inhibitors were 
discovered and soon thereafter were available to the public; the same resistance patterns 
were observed and interestingly, for tetracyclines, resistance was noted before going to 
market. Two other classes of 50S ribosomal subunit inhibitors, oxazolidinones and 
streptogramins, were discovered in 1955 and 1963, respectively, but were not introduced 
until 2000 and 1998.  Frighteningly, resistance to streptogramin B was observed one year 
after its discovery and it was still allowed to come to market 35 years later.  This period 
of intense discovery was rounded out by three other classes of drugs, glycopeptides 
(vancomycin in 1953), rifamycins (rifampicin in 1957) and quinolones (ciprofloxacin in 
1961), all of which bacteria developed resistance to before or very soon after becoming 
available. After that, a new class of antibiotics was not discovered until 1986 (the 
lipopeptide, daptinomycin).  Resistance was observed only a year later, yet daptinomycin 
was still approved for use by the FDA in 2003. Other newly approved antibiotics are 
derivatives from existing classes of drugs, such as tigecycline in 2005 (a glycylcycline 
derived from tetracycline) and ceftaroline in 2010 (a fifth generation cephalosporin), both 
of which have been met with the emergence of resistant strains. The last new class of 
antibiotics to be approved were the diarylquinolines for treatment of multidrug resistant 
tuberculosis in 2012, six years after resistance had been observed.  Clearly, new 
antibiotics cannot be developed quickly enough or smartly enough to be considered a 







Antibiotic Mechanisms of Action  
Antibiotics are effective because they target processes or structures that are 
essential for bacterial survival (Newton, 1965). Antibiotics can be bactericidal (resulting 
in bacterial death) or bacteriostatic (preventing growth and reproduction). There are 5 
distinct mechanisms that are employed by antibiotics to achieve these goals. The largest 
class of antibiotics hinders peptidoglycan biosynthesis by preventing cell wall cross-
linking directly or interacting with precursors (e.g. penicillins, cephalosporins, 
glycopeptides, carbapenems, monobactams, bacitracin, cycloserine, fosfomycin, 
isoniazid, ethambutol). A second mechanism by which antibiotics function is by 
inhibiting translation; they directly interact with the 30S (e.g. aminoglycosides, 
tetracyclines) or 50S (e.g. macrolides, chloramphenicol, lincosamides, oxazolidinones, 
streptogramins) ribosomal subunits to suppress protein synthesis. Another group of 
antibiotics disrupt cell membrane permeability (e.g. polymyxin, ionophores). Next, 
antibiotics can block DNA (e.g. fluoroquinolones, novobiocin, nitrofurans, 
metronidazole) or RNA (e.g. rifampin, bacitracin) synthesis. Finally, they can possess 
antimetabolite activity that blocks enzyme-catalyzed reactions of the bacterial cell 
metabolism, such as mycolic acid synthesis inhibitors (e.g. isoniazid), folic acid synthesis 
inhibitors (e.g. sulfonamides, dapsone, trimethoprim), and ATP synthase inhibitors (e.g. 
diarylquinolines). The lipopeptide daptomycin is unique in that it has multiple 
mechanisms of action (Pogliano et al., 2012). It initially inserts into the cell membrane, 
where it aggregates, thereby altering membrane curvature. In turn, this change in 
curvature results in the formation of holes in the membrane, causing leakage of ions and 





protein, DNA, and RNA synthesis and ultimately cell death. Excitingly, the first in the 
newest class of antibiotics discovered in 20 years (yet still several years away from 
consumer use), teixobactin, utilizes a new mechanism of inhibition of cell wall synthesis, 
by binding to precursors of both peptidoglycan and teichoic acid (Ling et al., 2015). 
Importantly, the method by which this antibiotic was identified, the iChip, resulted in the 
growth of previously uncultivable bacteria, opening the door for many more 
antimicrobials to be found (Nichols et al., 2010).       
 
Bacterial Resistance to Antibiotics 
Although scientists have developed traditional antibiotics that use many different 
mechanisms by which to combat pathogens, they underestimated the ways in which these 
drugs would fail through evolutionary advantages obtained by the bacteria. Bacterial 
resistance to antibiotics can occur in two distinct ways (Blair et al., 2015). Inherent 
resistance is the ability to resist activity of a particular antimicrobial through intrinsic 
structural or functional characteristics. On the other hand, while some bacteria may be 
naturally resistant to certain agents, acquired bacterial resistance is caused by the 
selective pressure imposed by the introduction of an antibiotic.  Bacteria acquire these 
mechanisms through mutations, horizontal gene transfer, or vertical gene transfer. 
Mutation involves the modification of the native DNA, which results in the production of 
altered bacterial proteins. These mutations can be nucleotide(s) base substitutions/ single 
nucleotide polymorphisms (SNPs), insertions, deletions, or frameshifts. Horizontal/ 
lateral gene transfer (HGT/LGT) is the acquisition of new DNA from other bacteria, 





bacteriophage DNA during infection), or conjugation (transfer of DNA by direct bacteria-
bacteria contact). Vertical gene transfer is the transmission of spontaneously generated 
mutations from the parental generation to offspring. 
The same four mechanisms are utilized in both inherent and acquired resistance: 
the antibiotic may lack affinity for the bacterial target, be unable to enter the cell, be 
exported from the cell, or be inactivated or degraded by enzymes. S. aureus makes use of 
each one of these mechanisms of resistance, by both innate and acquired means. S. 
aureus is naturally resistant to only two commonly used antibiotics: metronidazole and 
aztreonam.  Metronidazole inhibits nucleic acid synthesis, only in its reduced form, 
which must occur in anaerobic conditions (Lofmark et al., 2010).  While S. aureus can 
grow in anaerobic environments, under typical aerobic conditions, metronidazole has no 
effect. Aztreonam has a high affinity for the penicillin-binding protein 3 (PBP-3) of 
aerobic Gram-negative bacteria, and binding causes inhibition of this enzyme to catalyze 
cross linking of the cell wall (Davies et al., 2008). The weaker binding of aztreonam to 
Gram-positive PBP-3 results in no inhibitory effect against S. aureus. While S. aureus 
only possesses natural resistance to these two antibiotics, it has developed acquired 
resistance to almost every other antibiotic currently available to treat S. aureus-induced 
infections.  
The β-lactam antibiotics (penicillins, cephalosporins, monobactams, 
carbapenems) inhibit cell wall synthesis by binding PBPs, and thereby disallowing 
crosslinking of the peptidoglycan. This weakened cell wall results in eventual lysis due to 
osmotic stress.  The most common mechanism of staphylococcal resistance to β-lactam 





carried on a plasmid, which degrades and inactivates these drugs (Sabath, 1982). When 
researchers developed modified β-lactams, in which the β-lactam ring core was protected 
from degradation, staphylococci acquired a new mechanism of resistance via horizontal 
gene transfer from a still unknown source: the mobile genetic element staphylococcal 
cassette chromosome mec (SCCmec) (Katayama et al., 2000). This element carries the 
mec complex composed of mecA, encoding PBP2a (PBP2’), and regulatory elements, as 
well the ccr site specific recombinase genes, and may contain other resistance genes, 
such as those against aminoglycosides, macrolides, tetracycline, or heavy metals.  PBP2a 
is a unique penicillin binding protein in that it has much weaker affinity than other PBPs 
for the β-lactam antibiotics, especially methicillin; therefore transpeptidation of the cell 
wall can still occur in the presence of these antibiotics.      
Vancomycin inhibits cell wall synthesis by binding to the acyl-D-alanyl-D-
alanine in the peptidoglycan precursor lipid II and thereby sterically hindering 
transglycosylation and transpeptidation. Resistance to vancomycin occurs in two distinct 
manners.  The first is through the thickening of the cell wall, through an as yet 
undetermined mechanism. These thicker cell walls make it harder for vancomycin to 
diffuse to its target (Hiramatsu et al., 1997). In addition, these so called VISA strains 
(MIC (minimum inhibitory concentration) from 4-8 µg/ml) display reduced crosslinking, 
which results in more D-ala-D-ala residues available to trap vancomycin.  The second 
method is by acquisition of the vanA operon via an enterococcal plasmid, causing the 
emergence of VRSA strains (MIC ≥16 µg/ml).  This results in the production of 
peptidoglycan precursors in which the peptide stem ends in D-alanyl-D-lactate, which 





Acquisition of vanA also results in strains that are resistant to teicoplanin (Showsh et al., 
2001). Though resistance has yet to be observed for the newest glycopeptides, 
dalbavancin and oritavancin, they utilize the same mechanism of action as vancomycin, 
suggesting that they may also be subject to the same mechanism of resistance. The 
lipoglycopeptide televancin (a semi synthetic derivative of vancomycin) utilizes the same 
mechanism of inhibition of cell wall synthesis as vancomycin, so it is subject to 
development of resistance via acquisition of vanA  (Karlowsky et al., 2015). However it 
additionally disrupts membrane integrity via depolarization and increased 
permeabilization.  Despite this dual mechanism of action, low level resistance has been 
observed in the laboratory and once in the clinic; however it is currently not fully 
understood how S. aureus are able to overcome the secondary action of this antibiotic.              
 
Alternative Antimicrobials Needed  
The efforts to control antibiotic use to counteract the emergence of antibiotic 
resistant bacteria have been numerous and somewhat effective, but may be difficult to 
enforce. Only completely withdrawing specific antibiotics from use in the clinic led to a 
decrease in antibiotic-resistant S. aureus (Aubry-Damon et al., 1997; Barber et al., 1960; 
Ridley et al., 1970). One area in which antibiotic use can be lessened or eradicated is on 
the farm; Denmark, one of the world’s largest producers of pork, has cut antibiotic usage 
on farms by 40% without affecting production (Aarestrup et al., 2010). The European 
Union has already implemented strict guidelines on antimicrobial use in food animal 
production (Maron et al., 2013). In the United States, the CDC has obtained $160 million 





(CDC, 2016).  This approach is outlined in the  National Action Plan for Combating 
Antibiotic-Resistant Bacteria and the National Strategy for Combating Antibiotic-
Resistant Bacteria (CARB); the overall vision is: “The United States will work 
domestically and internationally to prevent, detect, and control illness and death related to 
infections caused by antibiotic-resistant bacteria by implementing measures to mitigate 
the emergence and spread of antibiotic resistance and ensuring the continued availability 
of therapeutics for the treatment of bacterial infections.” Faced with this crisis of an 
impending post-antibiotic era, alternatives to these traditional antibiotics must be 
identified. As discussed, scientists are developing vaccines, quorum sensing inhibitors, 
antimicrobial peptides, iron chelators, and other unique therapies to combat bacterial 
infections. Excitingly, a both old and new field of antimicrobial research that is 
generating much interest is the use of bacteriophages and their lytic enzymes.  
 
Bacteriophage 
Bacteriophages are viruses that infect and replicate within bacteria (Drulis-Kawa 
et al., 2012). One way in which bacteriophages are classified is based upon their 
replication cycle; lysogenic (temperate) phages integrate their DNA with that of the host, 
while lytic (virulent) phages destroy the host immediately after replication of the virion. 
For the double-stranded DNA (dsDNA) phage lytic cycle, the host cell infection process 
consists of four steps.  First, is the adsorption and penetration step. The bacteriophage 
randomly encounters the host bacterium, then reversibly adheres to a specific receptor via 
its tail fibers. The viral genetic material is injected into the host through the tail core, a 





synthesis of proteins and nucleic acid phase, the early proteins are transcribed and 
translated, resulting in the production of many copies of the phage DNA; this is followed 
by the transcription and translation of the late proteins, mostly structural in function. 
Third, virion assembly occurs. The structural proteins are then assembled into the mature 
virus, which is composed of the capsid head encapsulating a copy of the viral DNA and 
the tail components. During this time, endolysin also being produced to degrade the 
peptidoglycan and allow release of the mature bacteriophages. Lastly, the virion is 
released. Once the peptidoglycan is degraded, the viral particles are liberated by host cell 
lysis, thus completing the phage lytic cycle.  
After being discovered by Francis Twort in 1915 (Twort, 1915) and Felix 
d’Herelle in 1917 (d'Herelle, 1917), bacteriophages were briefly considered as potential 
therapeutic agents (d'Herelle, 1931); however, the discovery of the modern day antibiotic 
a decade later pushed them into the background in the Western world, mainly to be used 
as research tools. In the former Soviet Union and Eastern Europe, however, phage 
therapy, the use of bacteriophage for the prevention and treatment of bacterial infections, 
has been pursued with much success throughout the last century (Sulakvelidze et al., 
2001; Sulakvelidze and Morris, 2001). The earliest reported use of bacteriophage 
treatment of  staphylococcal skin disease in humans resulted in clearance of infection 
within 2 days  after bacteriophage were injected into and around surgically opened 
lesions  (Bruynoghe R., 1921).  At the Eliava Institute of Bacteriophage, Microbiology, 
and Virology (EIBMV) of the Georgian Academy of Sciences, Tbilisi, Georgia, and the 
Hirszfeld Institute of Immunology and Experimental Therapy (HIIET) of the Polish 





utilizing bacteriophage therapy against numerous bacterial infections, including those 
caused by S. aureus (Meladze et al., 1982; Slopek et al., 1984; Slopek et al., 1983a, b; 
Slopek et al., 1985a, b, c). In fact, the HIIET is currently conducting a clinical trial 
utilizing bacteriophage preparations against 15 different pathogens (Experimental Phage 
Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections 
NCT00945087) (Vandenheuvel et al., 2015).  
 A reinvigorated worldwide interest in bacteriophage therapy has led to many 
groups using bacteriophage to both treat and prevent S. aureus in different types of small 
mammal models of infection, as staphylococcal infections can present in a multitude of 
ways. The nasal passage is the primary route of infection; as mentioned, S. aureus 
colonizes the anterior nares of 20% of the population persistently and 60% carry 
intermittently, leading to an increased risk of surgical site infections, foreign body 
infections and bacteremia, as well as transmission to non-colonized, especially 
immunocompromised, individuals. To evaluate the efficacy of bacteriophage as a nasal 
decolonization agent, intranasal administration of bacteriophage MR-10 was utilized in a 
mouse colonization model (Chhibber et al., 2014). Bacteriophage MR-10 was able to 
reduce the bacterial load by day 2 as compared to untreated mice, and by day 10, mice 
were completely sterile. Combinatorial treatment with mupirocin resulted in bacterial 
clearance by day 5. Myeloperoxidase activity was also lowered in bacteriophage and dual 
therapy; histopathogical analysis of excised nasal tissue showed reduced inflammation 
when compared to untreated samples. Taken together, these results validate the efficacy 
of bacteriophage (and combinatorial therapy with antibiotic) for nasal decolonization of 





As S. aureus is often a causative agent of wounds and soft tissue infections, 
several groups have set out to investigate the therapeutic efficacy of bacteriophage 
against skin infections. Phage LS2a injected subcutaneously demonstrated the ability to 
prevent and treat abscess formation in a rabbit model of infection (Wills et al., 2005). As 
S. aureus is one of the most common pathogens isolated from diabetic foot wounds, 
Chhibber, et al. developed a mouse model to study bacteriophage treatment during a 
diabetic hindpaw infection (Chhibber et al., 2013). Treatment with bacteriophage MR-10 
was able to reduce the bacterial burden starting on day 1; sterile paws and resolution of 
infection occurred by day 7, whereas untreated mice resolved the infection on day 12, yet 
still had a low bacterial load. Utilizing both MR-10 and linezolid further reduced the 
bacterial counts and resulted in lower oedema and lesion scores, highlighting the benefit 
of combinatorial therapy, as the emergence of resistant mutants can be staved off due to 
differing mechanisms of action.               
Because S. aureus is also a major causative agent of bloodstream-associated 
infections, such as septicemia, invasive endocarditis, and septic arthritis, several groups 





was able to  protect 93% of mice from bacteremia 
induced death, reduced the proinflammatory response during infection, and was effective 
even when given 10 days after the start of the infection (Capparelli et al., 2007). 
Subcutaneously injected bacteriophage P-27/HP sufficiently protected mice from 
bacteremia and death and lowered the bacterial load in the spleen by 6 logs (Gupta and 





successfully prevent death (Matsuzaki et al., 2003), as was the morphologically similar 
ΦMR25 (Hoshiba et al., 2010).  
As mentioned, staphylococcal infections can be exacerbated by the formation of a 
biofilm, especially in the present of a medical device, and because antibiotics are 
ineffective, the only solution is removal of the implant. Several groups have developed 
biofilm and implant-mediated biofilm models to study the effectiveness of bacteriophage 
in biofilm removal. Sb-1 was able to decrease the bacterial load of MRSA in a tibial 
implant model and, when used in conjunction with antibiotics, prevented the formation of 
a biofilm (Yilmaz et al., 2013). In a rabbit model of central venous catheter-
related infection, bacteriophage K, given as an antimicrobial lock therapy, reduced the 
ability of bacteria to colonize and form biofilms (Lungren et al., 2014).  A cocktail of S. 
aureus bacteriophage was shown to effectively reduce the biofilm mass in a 
sheep model of sinusitis (Drilling et al., 2014).   
As most of the bacteriophage treatment studies utilize an intraperitoneal (ip) 
method of infusion, the results may be somewhat artificial. To understand if 
bacteriophage would be just as effective when given orally, as they might be in a hospital 
setting, mice were given S. aureus bacteremia and treated with bacteriophage A5. Results 
showed that both ip and oral administration were able to reduce the bacterial load in the 
liver to the same extent, indicating the validity of the ip model and also that 
bacteriophages could enter the circulatory system via the oral route (Zimecki et al., 
2008). 
Because some individuals are carriers of S. aureus, prophylactic treatment before 





may also be valuable for immunocompromised individuals. The need to steer away from 
using antibiotics as prophylactics due to the promotion of resistance, led researchers to 
study the use of bacteriophage as an alternative. In one study, immunosuppressed mice 
that were given bacteriophage A5/L 30 minutes before infection with S. aureus 
bacteremia had lower bacterial cell counts in their organs and lower cytokine levels in 
their blood than those that did not receive pretreatment (Zimecki et al., 2009). In addition, 
bacteriophage seemed to stimulate myelocytic and lymphocytic cell renewal and antibody 
production, indicating a beneficial effect on the immune system. This group also 
determined that this bacteriophage extended the survival and had the same beneficial 
effects on immunosuppressed mice that underwent a bone marrow transplant, bolstering 
the case for using bacteriophages as prophylactic measures (Zimecki et al., 2010).    
To study bacteriophage therapy on respiratory infection induced S. aureus    
septicemia, a common result of healthcare-associated, hospital-acquired, or ventilator-
associated staphylococcal pneumonia, mice were intranasally inoculated with S. aureus at 
a dose effective to cause lethality at 3 days, primarily caused by fibrosis, bleeding, and 
neutrophil infiltration (Takemura-Uchiyama et al., 2014). Mice that were treated with 
bacteriophage S13’ 6 hours post-infection had a 70% survival rate 2 weeks later, had 
significantly lower concentrations of bacteria in their livers and spleens, and had lower 
concentrations of TNF-a and IL-6 in their blood. 
 While rodents provide a satisfactory model for studying staphylococcal infection 
and resolution by bacteriophage treatment, scientists have developed an invertebrate 
model to alleviate some of the hassle associated with mammalian studies. The use of 





mellonella (the waxworm) are excellent model organisms because no Institutional 
Animal Care and Use Committee (IACUC) protocol is necessary and they are 
inexpensive.   Furthermore, they are a proven model used to study bacterial pathogenicity 
and pharmacokinetics, pharmacodynamics, and toxicology of drugs, as they provide 
comparable data to mouse models of infection. The therapeutic effects of two 
bacteriophages were examined in a silkworm model of S. aureus infection (Takemura-
Uchiyama et al., 2013). Treatment with bacteriophage 10 minutes after the start of the 
infection was able to rescue approximately 80% of the silkworms by day 2; in the mouse 
model, 100% of the mice survived when given bacteriophage S25-3, while 50% of the 
mice remained alive when treated with bacteriophage S13’. This study indicates that 
valid information on the therapeutic efficacy of bacteriophages can be gleaned from this 
invertebrate model and can be extrapolated to mammalian systems.      
 
Bacteriophage-Derived Peptidoglycan Hydrolases: Endolysins  
Phage therapy is effective because, as mentioned, late in the bacteriophage lytic 
cycle, two enzymes are produced: a holin, which oligomerizes to create holes in the 
cytoplasmic membrane, and an endolysin (Young et al., 2000). Endolysins are 
peptidoglycan hydrolases produced by bacteriophage to degrade the now accessible 
peptidoglycan “from within” for release of progeny phage.  Researchers have taken 
advantage of this peptidoglycan-degrading mechanism by applying endolysins to the 
outside of Gram-positive bacteria, which lack an outer membrane, resulting in lysis “from 
without” (Fig. 1-2).  Due to the internal turgor pressure of 20-50 atmospheres, the 













Figure 1-2. Thin-section transmission electron micrographs of ClyS-treated S. 
aureus. (A) After exposure of S. aureus to 250 μg of ClyS for just 3 minutes, cells 
displayed localized degradation of the cell wall, resulting in osmotic stress-induced lysis 
and visualized by extrusion of the cytoplasm. (B) The bacteriolytic activity of the 
endolysin ultimately results in cell death and the presence of “ghosts” can be observed. 














and ultimately the result is death due to osmotic stress. This phenomenon means that the 
whole bacteriophage is not necessary to achieve antimicrobial efficacy; use of the 
endolysin alone causes the same result. The use of only the endolysin (a single protein 
entity) makes endolysin therapy a much more attractive option, as there are numerous 
benefits to eliminating the whole phage from a preventative or treatment regimen.  
The main benefit to the use of an endolysin over the whole bacteriophage is the 
simplification of a complex system. From both a health care and regulatory standpoint, 
use of a controlled single protein is an improvement over the use of a complicated self-
replicating virus (Gill and Hyman, 2010; Pirnay et al., 2011). The stripping of the 
bacteriophage to just the bare essentials needed for antimicrobial activity also allows for 
future improvement efforts. As evolved as endolysins are, scientists are always trying to 
improve and adapt them for use as antimicrobials. While it is not impossible to 
genetically engineer a bacteriophage to improve lytic efficacy (Westwater et al., 2003), it 
is certainly much easier to alter individual proteins. Engineering desirable properties in 
enzymes can be achieved using either rationale-based (e.g. sequence comparison, 
structure-guided site directed mutagenesis (SDM), or in silico computational modeling) 
or random techniques (e.g. random mutagenesis, gene shuffling, or directed evolution) 
(Schmelcher et al., 2012a). These proteins can be easily engineered for increased lytic 
activity, enhanced or alternative binding, or other improvements in protein characteristics 
such as thermostability. Importantly, bacteriophage resistance has been observed (Labrie 
et al., 2010), while multiple efforts to isolate endolysin resistant bacteria have been 
unsuccessful. Lastly, bacteriophages are associated with strain-specificity, which is not 





have to be strain-typed, a process that takes longer and is more expensive than just a 
species identification. In order to deal with this problem, proponents of bacteriophage 
therapy have suggested the use of cocktails; however, the regulatory issues are magnified 
in a multi-component system. Endolysins are typically species-specific and can even be 
genus-specific; in rare cases, they have a broader host range. The not-too-narrow 
spectrum of endolysins makes them preferable as they can be used as a general treatment 
against a particular bacterial infection without having to know the exact strain.         
  
Endolysin Structure    
Endolysins from bacteriophages that infect Gram-positive hosts are typically 
composed of two modular domains: an N-terminal catalytic domain (also known as an 
enzymatically active domain (EAD) or enzyme catalytic domain (ECD)) and a C-
terminal cell wall binding domain (CBD) (Fig. 1-3) (Borysowski et al., 2006). The CBD 
is responsible for bringing the protein in contact with the bacterial cell, typically through 
an interaction with a carbohydrate, although the receptor is choline in the case of 
pneumococcal endolysins or the peptidoglycan directly for staphylococcal endolysins 
(Fischetti, 2003; Garcia et al., 1983; Lu et al., 2006).  After the protein has bound to its 
target, the business end can accomplish its enzymatic task. The catalytic domain is 
responsible for the hydrolytic cleavage of highly conserved bonds in the peptidoglycan. 
Peptidoglycan is a polymer made of repeating sugar components (β-(1,4) linked N-
acetylmuramic acid (MurNac) and N-acetylglucosamine (GlcNac)), with a peptide chain 
(L-alanine, D-glutamic acid, L-lysine, D-alanine in non-bacilli Gram-positive bacteria) 















Figure 1-3. Modular architectures of Gram-positive endolysins. (A) A typical 
globular enzyme consisting of ECD only. (B) Typical bimodular N-terminal ECD and C-
terminal CBD joined by a linker region. Trimodular structures of (C) dual catalytic 
domains and 1 CBD or (D) 3 ECDs. (E) The unique multimeric configuration of the 












(pentaglycine for S. aureus)) to other peptide chains to create a meshlike structure (Fig. 
1-4).  Peptidoglycan provides important structural integrity for the bacterial cell and is an 
ideal target for an antimicrobial as it is essential for bacterial survival. The catalytic 
domains of endolysins can be classified into four groups depending on the target bond to 
be cleaved. In the glycan component, N-acetylmuramidases are responsible for the 
cleavage on the reducing end of the N-acetylmuramic acid, while N-acetyl-β-D- 
glucosaminidases cleave at the reducing end of N-acetylglucosamine. N-acetylmuramoyl- 
L-alanine amidases cleave the bond connecting the glycan component and the peptide 
stem. Lastly, endopeptidase is a broad term encompassing any endolysin that cuts 
between two amino acids found in the stem peptide or interpeptide bridge. While there 
are multiple catalytic domains that have been associated with staphylococcal endolysins, 
the most commonly found class is the cysteine, histidine-dependent amidohydrolase/ 
peptidase (CHAP) domain. These domains have been associated with both N-
acetylmuramoyl-L-alanine amidase and endopeptidase activity. A sequence comparison 
of endolysins in the same enzyme class shows that the catalytic domains are highly 
conserved, whereas the binding domains are more variable (Oliveira et al., 2013).     
Interestingly, the domains of endolysins interact not only with the bacterial cell, 
but it has been shown that they interact with each other. Structural evidence obtained 
using the pneumococcal endolysin Cpl-1 crystallized in free and choline-bound states 
showed that, in the absence of the binding substrate, the endolysin formed a hairpin, 
rendering the catalytic domain inactive; however, choline recognition by the CBD 
allowed for the undoing of the hairpin and the proper positioning of the catalytic domain 





















Figure 1-4. S. aureus peptidoglycan and endolysin cleavage sites.  The structure of S. 
aureus peptidoglycan consists of sugar components (β-(1,4) linked N-acetylmuramic acid 
and N-acetylglucosamine)  and a peptide stem of 4 amino acids (L-alanine, D-glutamic 
acid, L-lysine, D-alanine) crosslinked through an interpeptide bridge (pentaglycine) to 
another unit. The dotted arrows denote the sites targeted for cleavage by the catalytic 






Staphylococcal Endolysin Cell Wall Binding Domains  
SH3b CBD 
 All endolysins displaying activity against staphylococcal species (except one, 
described further below) possess an SH3b cell wall binding domain. SH3 (src homology 
3) domains in eukaryotes and viruses are implicated in mediating protein-protein binding 
through interactions with proline-rich sequence motifs (Weng et al., 1995); however, the 
SH3b domain in prokaryotes, while displaying sequence similarity to the SH3 domain, 
shows an alternative folding in the RT loop (Whisstock and Lesk, 1999). The SH3b 
domain is found in both staphylococcal and streptococcal endolysins, usually in 
combination with a CHAP domain or a CHAP plus another catalytic domain. The 
staphylococcal endolysins Twort, LysH5, ΦSh2, Φ11, Sal1, and LysK contain both 
CHAP and Amidase-2 EADs with SH3b CBD, staphylococcal endolysin 2638A contains 
M23 and Amidase-2 EADs with SH3b, and the GBS (Group B streptococcus) endolysin 
B30 has CHAP and Acm glycosidase EADs with SH3b (Abaev et al., 2013; Becker et al., 
2008; Becker et al., 2015; Donovan et al., 2006b; Donovan et al., 2006c; Jun et al., 2011; 
Obeso et al., 2008; Schmelcher et al., 2012b). SH3b-containing endolysins against other 
species of bacteria utilize various other catalytic domains.  
In addition to endolysins, SH3b domains have also been found in association with 
other classes of proteins, such as other enzymes, adaptor proteins, or peptidoglycan 
binding proteins. SH3b encompasses such a broad group of proteins because this domain 
is actually further classified into SH3b1 and SH3b2 and divided even more into the 
subgroups SH3_1-9; as of yet only SH3_3 and SH3_5 have been found to be associated 





domains interact with a carbohydrate moiety embedded in the cell wall (or choline in the 
case of pneumococci), whereas SH3b domains are predicted to bind peptidoglycan, 
specifically the peptide component (Schmelcher et al., 2012a). For staphylococcal SH3b 
domains, that peptide component is proposed to be the pentaglycine crossbridge, unique 
to S. aureus (Grundling and Schneewind, 2006; Lu et al., 2006); the streptococcal SH3b 
ligand is currently unknown, but may be the free amino group of the N-terminal alanine 
in the stem peptide (Xu et al., 2010).   
There are currently many discrepancies in our understanding of the endolysin 
SH3b domains, mainly having to do with the residues important for the binding 
interaction. Although the staphylococcal SH3_5 has been extensively investigated 
structurally and bioinformatically, there are conflicting reports about the amino acids 
responsible for binding. For example, the ALE-1 endolysin contains an SH3_5 domain 
that was shown to specifically recognize the pentaglycine crossbridge of S. aureus; 
however, some of the amino acid residues implicated in being responsible for this binding 
were outside of the canonical 63 amino acid SH3b domain and were variable from the 
residues determined to be important in the SH3_5 domain from LysGH15, despite the 
almost 50% identity between these two enzymes (Becker et al., 2009b; Gu et al., 2014; 
Lu et al., 2006). Additionally confounding is the classification of both streptococcal and 
staphylococcal endolysin SH3b as SH3_5, yet these CBDs are distinctly different from 
each other in sequence; while both contain the consensus Y(6-8x)G(xx)W(6-8x)G, they 
have virtually nothing else in common.  
Further complicating our understanding of these domains, some SH3b domains do 





the catalytic domain or the SH3b domain, as binding studies have not been performed. A 
catalytic domain that can cleave a bond shared by multiple species could perhaps act 
upon many different bacteria regardless of the binding domain. Examples include LysB4 
(VanY  L-alanoyl-D-glutamate endopeptidase + SH3_5) which shows activity against 
Bacillus cereus, Bacillus subtilis, and Listeria monocytogenes,  LysBPS13 (PGRP + 
SH3_5) and Ply21 (N-acetylmuramoyl-L-alanine amidase + SH3_5) effectively lyses 
several bacilli species, and CP25L (N-acetylmuramoyl-L-alanine amidase + SH3_3) 
which is active against clostridial and bacilli species (Gervasi et al., 2014; Park et al., 
2012; Son et al., 2012). One endolysin (PlySs2) containing an SH3_5 domain does not 
display genus/species specificity and maintains activity against both staphylococci and 
streptococci (and some other species). In this case, however, it has been determined that 
this phenomenon is due to the promiscuity of the catalytically diverse CHAP catalytic 
domain and not due to the SH3b binding domain (Gilmer et al., 2013; Yang et al., 2015). 
This SH3b domain has been shown to directly bind streptococci, but does not interact 
with staphylococci (Huang et al., 2015). Despite this, because this SH3b domain, in both 
its natural and chimeric forms, is linked to a CHAP domain (which can cleave bonds 
present in both staphylococci and streptococci), the full length endolysin possesses 
activity against multiple bacterial species. 
 
ΦNM3 CBD 
 As mentioned, all discovered CBDs from endolysins against S. aureus have been 
classified as SH3b domains, except for one.  The CBD of the endolysin from the ΦNM3 





and is described in the literature as “non-SH3b like” (Bae et al., 2006). The native ΦNM3 
CBD is linked to a CHAP catalytic domain and it specifically binds staphylococci 
(Daniel et al., 2010). The ΦNM3 CBD has been the subject of engineering studies, due to 
its divergence from the typical staphylococcal cell wall binding domain (SH3b). ClyS, 
composed of the PlyTW endopeptidase EAD and the ΦNM3 CBD, displayed potent in 
vivo efficacy against S. aureus, decolonizing mouse nasal cavities, providing protection 
against systemic infection, and reducing the bacterial load in a skin infection after being 
topically applied (Daniel et al., 2010; Pastagia et al., 2011). ClyH (Ply187 CHAP + 
ΦNM3 CBD) also eliminated MRSA in a mouse model of systemic infection (Yang et 
al., 2014b)  
 
Endolysin Advantages 
The use of endolysins is not only preferred over using whole bacteriophage, as 
mentioned, but has many benefits over the use of classical antibiotics as well. Most 
importantly, no resistance to endolysins has been observed, despite efforts to isolate 
resistant mutants (Pastagia et al., 2011). Whereas antibiotics act against easily mutable 
targets (Spratt, 1994), the activity of an endolysin is due its binding and cleavage of 
highly conserved substrates. Furthermore, there is no chance of non-target resistance due 
to this high specificity. The usage of broad spectrum antibiotics may allow for the 
overgrowth of certain species of normal flora, resulting in a state of dysbiosis; thus, they 
could also encourage the development of resistance in populations of bacteria that 
normally occupy a small niche (Nelson et al., 2012; Schmelcher et al., 2012a). This 





caused by antibiotic-induced disruption of normal flora. The use of antibiotics can cause 
diarrhea and nausea/vomiting or vaginal and oral yeast infections due to the depletion of 
typical species that live in these environments and the overgrowth of infectious bacteria 
(Tedesco et al., 1974), whereas an endolysin would only eliminate the targeted pathogen. 
The most common side effect associated with antibiotics is an allergic reaction, ranging 
from the mild (red, itchy, flaky, or swollen skin rash) to the severe (peeling and blistering 
skin or eye problems) and life-threatening (anaphylaxis) (Anderson, 1992). Despite the 
proteinaceous nature of endolysins, they have been shown to be non-immunogenic and 
do not cause any of the allergic reactions associated with antibiotics. Endolysins also hold 
promise in the elimination of biofilms (Sass and Bierbaum, 2007; Son et al., 2010), 
whereas antibiotics are ineffective against bacteria in this lifestyle (Fig. 1-5) (Hoiby et al., 
2010). Additionally, antibiotics can only be utilized in the field of medicine, whereas 
endolysins can not only be used for public health, but have other applications, such as 
disinfectants or detection agents in the field of food safety or as biotechnological tools.     
From an economic standpoint, pharmaceutical companies do not want to spend 
money developing a traditional antibiotic when the payoff is so low, due to the fact that 
their product may soon be obsolete, when resistance emerges. Therefore, hardly any new 
antibiotics are coming through the pipeline; this, combined with the inability to use 
certain current antibiotics, puts society in a frightening situation (Boucher et al., 2013). 
The promise of endolysins’ inability to develop resistance, along with the potential of 
extending the use of antibiotics formerly thought to be ineffective through combinatorial 
therapy with endolysins, means that the pharmaceutical industry can continue to invest in 







Figure 1-5. Scanning electron micrographs of LysH5-treated S. aureus biofilms. (A) 
Biofilms formed by S. aureus 15981 after 24 hours show cells attached to each other and 
the surface and covered in a layer of EPS. (B) After endolysin treatment, bacteria in the 
biofilm have been lysed and all material has been removed from the surface. Figure from 














S. aureus Endolysins 
Many laboratories have been searching for endolysins effective against S. aureus 
for the last two decades. Difficulties in obtaining staphylococcal endolysins in particular 
include issues with solubility, yield, and stability.  Despite these problems, scientists have  
identified or constructed approximately 50 endolysins with anti-staphylococcal activity 
(Table 1-1). Measurements of endolysin activity can be obtained using many different 
methods (zymogram, plate lysis assay, turbidity reduction, minimum inhibitory 
concentration (MIC), colony forming unit (CFU) counts, etc.), and experiments have 
been performed on numerous strains under variable conditions; thus it is notoriously 
difficult to compare one endolysin to another. Standardization of the determination of 
endolysin activity has been attempted, but needs to be effectively enforced (Briers et al., 
2007; Mitchell et al., 2010).   
 
Antimicrobial Potential  
 As mentioned, a major benefit to using an endolysin over a traditional antibiotic is 
the pathogen’s inability to develop resistance. Despite many attempts to isolate resistant 
mutants, researchers have been unsuccessful. LysH5 and chimeric endolysins composed 
of HydH5 fused to lysostaphin or just the lysostaphin CBD were unable to select for 
resistant mutants after 10 days in both solid and liquid media, while lysostaphin MICs 
increased 100-fold and 1000-fold, respectively (Rodriguez-Rubio et al., 2013b). 
Similarly, when exposed to increasing amounts of PlySs2 over 8 days, neither a MSSA 






Table 1-1. S. aureus endolysins. 
Endolysin Activity 
PlyTW shows  N-acetylmuramoyl-L-alanine amidase activity via 
HPLC analysis (Loessner et al., 1998), has specific activity of 
0.2 OD600/min/mg, increases 3 fold when amidase-2 domain is 
removed (Becker et al., 2015) 
  
Lys16 crude lysate lyses 12 strains of S. aureus (Takac et al., 2005)  
  
P68 Protein 17 50 ng/ml results in 2 log killing (Takac and Blasi, 2005) 
  
LysWMY displays activity on zymogram (Yokoi et al., 2005) 
  
LysK crude lysate causes 2 log killing (O'Flaherty et al., 2005), 
purified LysK has specific activity of 0.04 OD600/min/mg, MIC 
= 32 µg/ml (Becker et al., 2008) 
  
443-Lyso, 182-Lyso  has specific activity of 0.127 and  0.059 OD600/min/mg, 
respectively (Donovan et al., 2006a) 
   
Φ11 has specific activity of 1.5 OD600/min/mg (Donovan et al., 
2006c), 20 µg/ml reduces OD600 60% in 20 minutes, 10 µg 
removes biofilms (Sass and Bierbaum, 2007) 
  
MV-L 5 µg reduces CFU counts by 2-5 logs in 30 minutes, 50 µg 
protects 100% of mice in MRSA nasal colonization model 
(Rashel et al., 2007) 
  
λSA2 digests cell walls as per mass spectrometry analysis (Pritchard 
et al., 2007), displays weak activity in plate lysis assay 
(Donovan and Foster-Frey, 2008) 10 µM reduces OD600 by 
>75% in 30 minutes (Roach et al., 2013) 
  
LysH5 5 U/ml reduces OD600 by 1.25 in 600 seconds, 160 U/ml 
decreases bacterial counts by 6 logs in 4 hours in pasteurized 
milk (Obeso et al., 2008), MIC = 50 U/ml (Garcia et al., 2010), 
has specific activity of 166.85 U/mg (Rodriguez-Rubio et al., 
2012a), 0.15 µM reduces in vitro biofilm bacterial counts by 1-
3 logs (Gutierrez et al., 2014)  
  
P16-17 displays activity on zymogram, 10 µg/ml reduces bacterial 
counts by 95% in 1 hour (Manoharadas et al., 2009) 
  
CHAPK 0.5 nmol reduces OD600 by 90% in 30 minutes (Horgan et al., 





(Fenton et al., 2011b)  925 µg/60 µl decreases bacterial counts 
in nares of mice by 2 logs (Fenton et al., 2010a), 500 µg/ml 
reduces biofilm bacterial count by 4 logs, 200 µg/ml reduces 
bacterial count on pig skin by 2 logs (Fenton et al., 2013) 
  
SAL-2 5 µg displays activity on plate lysis assay,  20µg removes 
biofilms (Son et al., 2010) 
  
ClyS 250 µg results in OD600 decrease of 0.6  and 3 log killing in 30 
minutes, 1 mg reduces the bacterial load in the nasal cavities of 
mice by 2 logs and protects 88% from MRSA septicemia 
(Daniel et al., 2010), 10% (wt/wt) dose causes a 3 log 
reduction in a mouse skin infection model (Pastagia et al., 
2011) 
  
SAL-1 MIC = 0.2 – 3.2 µg/ml, 5 μg reduces OD600 by 0.5 in 15 
minutes (Jun et al., 2011), 10 μg/ml removes biofilms, 
12.5 mg/kg rescues mice in iv septicemia model (Jun et al., 
2013) 
  
P-27/HP 10 µg/ml reduces CFU counts by 4 logs in 2 hours, 250 µg/ml 





displays activity on zymogram, 500 µg/ml kills 82% of 
bacteria (Lai et al., 2011) 
  
PRF-119 MIC = 0.024–0.780 µg/ml (MSSA),  MIC = 0.024–1.563 
µg/ml (MRSA) (Idelevich et al., 2011) 
  
HydH5, CHAP, LYZ2 HydH5 and catalytic domains alone (20 µg) reduce bacterial 
counts by 40%, 25%, and 23%, respectively (Rodriguez et al., 
2011) 
  
LysGH15 40 μg/ml reduces OD600 80% in 30 minutes, 50 μg protects 
100% of mice from MRSA induced bacteremia and reduces the 
bacterial load in the spleen 2 logs (Gu et al., 2011a; Gu et al., 
2011b)  
  
P128 50 µg/ml reduces OD600 by 0.8 in 30 minutes, 100 µg 
decolonizes 44% of rat nares (Paul et al., 2011), MIC = 1- 64 
µg/ml, MBC = 1-64 µg/ml, 1.5 µg/ml reduces bacterial counts 
by 5 logs in simulated nasal fluid (Vipra et al., 2012), 10 µg/ml  
kills 3-5 logs in serum, plasma, and whole blood (George et al., 
2012), 6 µg reduces OD600 by 65-75% in 30 minutes 









have specific activities of ~.01 OD600/min/mg, display activity 
on plate lysis assay (Becker et al., 2009b), reduces bacterial 
counts in mouse intramammary infection (0.63 and 0.81 log for 
λSA2-E-Lyso-SH3b and λSA2-E-LysK-SH3b), λSA2-E-LysK-
SH3b combinatorial treatment with lysostaphin reduces 
bacterial counts 3.36 logs (Schmelcher et al., 2012c) 
  
 Lys168-87, Lys170-87 10 μg displays activity on plate lysis assay, 10 μg/ml reduces 
OD600 by 40% in 1 hour (Fernandes et al., 2012) 
  
ΦSH2 has specific activity of 0.02 OD600/min/mg, increases 3 fold 






display activity on zymogram and plate lysis assay, have 
specific activity of 0.03-0.1 OD600/min/mg (Rodriguez-Rubio 
et al., 2012b), reduce CFU counts by 2 logs after 6 hours, 1.65 
µM CHAPSH3b kills up to 3 logs in 30 minutes in raw and 
pasteurized milk (Rodriguez-Rubio et al., 2013a), cleaves 
peptidoglycan as per mass spectrometry analysis (Rodriguez-
Rubio et al., 2013b) 
  
2638A 0.5 µM yields specific activity of 0.07 OD600/min/mg (Abaev 
et al., 2013) 
  





32 µg/ml reduces OD600 >70% in 30 minutes, 128 µg/ml 
reduces CFU counts by 2-5 logs, 1 mg protects 90% of mice 
from MRSA bacteremia (Gilmer et al., 2013), MIC = 2-8 
µg/ml, removes biofilms, 5 mg/kg rescues 70% of mice from 
MRSA-induced bacteremia (Schuch et al., 2014) 
  
Ply187AN-KSH3b has specific activity of 1.2 OD600/min/mg (Mao et al., 2013), 
MIC = 4-8 µg/ml, reduces in vitro biofilms counts by 5 logs, 1 
μg/μl administered intravitreally at 6 h or 12 h postinfection 
reduces bacterial counts by 2 or 1 log, respectively, and 
attenuates symptoms of endophthalmitis (Singh et al., 2014) 
  
LysDW2 displays activity on zymogram (Keary et al., 2014) 
  







Ply187N-V12C  MIC = 2 µM, 50 pmol results in a clearing zone (Dong et al., 
2015) 
  
ClyR 25 μg/ml reduces OD600 by 0.05-0.4 in 20 minutes (Yang et al., 
2015)  
  
MR-10 18 μg/ml and 36 μg/ml reduces biofilm bacterial counts  by ~1 
log in 6 hours in ica-negative and ica-positive MRSA, 
respectively (Chopra et al., 2015)  
  
80α, Φ11, LysK, P68, 
Twort, 2638A, ΦSH2, 
WMY  
200 μg protects 100% of mice (80α, Φ11, LysK, 2638A, 
WMY), 60% of mice (ΦSH2), 50% of mice (Twort) from 
death induced by MRSA septicemia (Schmelcher et al., 2015) 
  
LysDB displays activity on zymogram, 10 μg/ml reduces the OD600 
by 60% in 100 minutes, constitutive expression by a starter 
culture reduces the bacterial counts by 4 logs after 6 weeks 
compared to control cheese (Guo et al., 2016) 
  
Hy133 MIC = 0.125 μg/ml - 0.5 μg/ml (Idelevich et al., 2016) 
  
K-L has specific activity of 5 OD600/s/mg (Filatova et al., 2016), 
reduces intracellular bacterial load by ~50% in MAC-T cells 
and ~1 log in a mouse model of osteomyelitis, 1.4 µM reduces 
bacteria in a dynamic biofilm by 76% (Becker et al., 2016) 
  
Trx-SA1 displays activity on plate lysis assay, 20 mg given once per day 
intramammary reduces bacterial counts over 3 days (Fan et al., 
2016)  
 
A summary of endolysins possessing activity against S. aureus and results obtained from 










MIC) to this endolysin, while both strains developed resistance to mupirocin (Gilmer et 
al., 2013).   
 While technically not an endolysin, lysostaphin has peptidoglycan hydrolase 
activity and its M23 lytic domain has often been utilized in chimeric engineering studies.  
Importantly, as mentioned, lysostaphin resistant S. aureus has been isolated both in vitro 
and in vivo (Climo et al., 1998; Stranden et al., 1997). One mechanism by which this 
occurs involves mutations in femA or femB, which are responsible for adding the second 
and third or fourth and fifth glycines to the staphylococcal cross bridge, respectively 
(Ehlert et al., 1997). A mono- or triglycine cross bridge is therefore more resistant to 
recognition and cleavage by lysostaphin. The other mechanism of lysostaphin resistance 
involves acquisition via shuttle vector of the lysostaphin immunity factor (lif)/ 
endopeptidase resistance gene (epr) (Thumm and Gotz, 1997).  S. aureus that express 
this protein display serines instead of glycines in their peptidoglycan cross bridges, which 
cannot be recognized and therefore cleaved by lysostaphin. However, lysostaphin 
resistance is not a terrible acquisition as it is incompatible with resistance to β-lactam 
antibiotics (Climo et al., 2001), even in strains that are originally MRSA. Thus, the 
acquisition of lysostaphin resistance by MRSA renders these strains now susceptible to β-
lactams; it has also been shown that antibiotic treatment used concurrently with 
lysostaphin prevented lysostaphin resistant mutants from arising. Additionally, 
lysostaphin resistant mutants are not as fit, as shown by reduced growth rate, increased 
susceptibility to high temperatures, and less virulence in a mouse kidney infection model 





 The high specificity of endolysins for their bacterial targets means that they can 
be safely used in medical applications; because the cleavage and binding targets are not 
present in eukaryotic cells, endolysins will not negatively interact with them. Endolysins 
have been used effectively in many animal models without causing harmful, irritating, or 
abnormal side effects (Fenton et al., 2010b). Additonally, endolysins have not displayed 
toxicity in tissue culture; PlyC did not compromise the membrane integrity of A549 lung 
epithelial cells, even though this endolysin has the unique capability to become 
internalized (Shen et al., 2016). Similarly, endolysins that were engineered to target 
intracellular staphylococci by adding a protein transduction domain (PTD) did not harm 
cells in tissue culture (Becker et al., 2016). These studies show that an endolysin can 
interact with the eukaryotic cell membrane without negatively impacting the health of the 
cell. Co-cultures of bacteria with eukaryotic cells lines have shown that the endolysin 
(whether it can go intracellular or not) will specifically lyse the target bacteria without 
harming non-bacterial cells. A major concern, however, is the fallout from massive and 
rapid bacterial lysis: an influx of proinflammatory cellular debris (teichoic acids, 
lipoteichoic acids and peptidoglycan), leading to life-threatening complications, such as 
septic shock and multiple organ failure (Nau and Eiffert, 2002). The use of interval 
dosing instead of continuous infusion may alleviate this issue (Entenza et al., 2005; 
Witzenrath et al., 2009).      
Because endolysins are proteins, they have the ability to elicit an immune 
response. Mice that were injected with the pneumococcal endolysin Cpl-1 did in fact 
generate antibodies, and the resulting hyperimmune serum slightly decreased the efficacy 





1 to protect mice during an S. pneumoniae challenge (Loeffler et al., 2003). No adverse 
immunogenic side effects or inactivation of endolysin were also reported in several other 
studies (Jado et al., 2003; Rashel et al., 2007).  It has been proposed that the affinity of 
the CBD for the bacterial surface is higher than that of IgG for the endolysin, thus 
explaining the maintenance of potent activity in vivo (Loessner et al., 2002). The short 
half-life of endolysins (Loeffler et al., 2003) can be compensated for by addition of 
polyethylene glycol to the protein (Walsh et al., 2003).  In the case of abolished or 
severely decreased enzymatic activity (Resch et al., 2011a), it has been shown that 
dimerization can improve the pharmacokinetics of endolysins (Resch et al., 2011b). 
Excitingly, endolysins have displayed synergistic behavior when used in 
combination with each other or antibiotics, resulting in lower doses, increased efficacy, 
and reduced risk of resistance development. Synergy when using multiple endolysins can 
be explained by the cleavage of multiple different bonds at the same time, or cleavage by 
one endolysin could facilitate access to the cleavage target of a second endolysin (Becker 
et al., 2008; Schmelcher et al., 2012c). Synergy between antibiotics and endolysins is 
important because it can potentially reinvigorate the use of antibiotics that were 
previously thought to be ineffective. Staphylococcal resistance to vancomycin and 
daptomycin was suppressed in the presence of the endolysin CF-301, which was shown 
to accelerate binding of these antibiotics to the bacterial cell, and utilization of 
combinatorial therapy proved to be more effective that any of the individual treatments 








The antimicrobial potential of these enzymes has recently resulted in the 
formation of endolysin-specific companies that are trying to harness their 
commercialization power. In fact, large corporations took interest in bacteriophage as 
commercial entities immediately after their initial discovery, but as mentioned, the 
antibiotic era pushed them into the background; L'Oréal marketed five preparations 
including Bacté-staphy-phage, and in the U.S., the Eli Lilly Company had seven phage 
products for human use, including Staphylo-lysate (Sulakvelidze et al., 2001).   
An obvious application for the use of endolysins is in the medical field. 
Utilization of endolysins as preventative or treatment options has been highlighted in this 
age of increasing antibiotic resistance. The Dutch company Micreos has been marketing 
Staphefekt™ since 2013, when it became the first endolysin product for human use 
against S. aureus skin conditions with an infectious component, such as acne, eczema, 
rosacea and skin irritation.  Staphefekt™ is a chimeolysin composed of the M23 glycyl 
glycyl endopeptidase domain from lysostaphin, the amidase domain from 2638, and the 
SH3b domain from 2638 that displays potent anti-staphylococcal activity (Offerhaus and 
Eichenseher, 2015). Speaking to the potential of this product, Micreos secured $13 
million in early 2016 for further clinical development and declared using Staphefekt™ to 
treat diabetic wound infections, ulcers, and burn wounds is in their pipeline. In 2015, 
Contrafect Corp. became the first company in the U.S. have an endolysin (CF-301 for the 
treatment of S. aureus bacteremia) enter and complete a phase I clinical trial in healthy 
volunteers and no adverse effects were observed. It was granted Fast Track Designation 





model of MRSA-induced bacteremia, and will be proceeding to phase II clinical trials 
(Gilmer et al., 2013). The numerous successful animal studies conducted utilizing 
endolysins against S. aureus (and other pathogens) indicate that this is just the beginning 
in the application of these enzymes for human medicine.       
Not only can human health be improved by endolysins, but animal health stands 
to benefit as well. A veterinary or animal agriculture application of endolysins could 
improve the lives of animals and humans and could pave the way for a human health 
application, as the regulatory hurdles for product use in animals are greatly lowered. As 
mentioned, S. aureus is one of the four causative agents of bovine mastitis.  Thus, this 
represents an opportunity for the introduction of endolysins for the treatment or 
prevention of staphylococcal-induced bovine mastitis. Several laboratories have 
investigated the activity of staphylococcal endolysins in milk and milk-simulating 
conditions, as a preliminary step in determining their efficacy as potential anti-mastitis 
agents; while activity was reduced in milk when compared to buffer, several endolysins 
displayed specific lytic activity against S. aureus (Donovan et al., 2006a; Donovan et al., 
2006c; Mao et al., 2013). The efficacy of chimeric endolysins λSA2-E-Lyso-SH3b and 
λSA2-E-LysK-SH3b was validated in a mouse model of staphylococcal mastitis 
(Schmelcher et al., 2012c).  The ultimate test of the application of endolysins as anti-
mastitis agents was in transgenic cows expressing lysostaphin; protection against mastitis 
was effectively achieved, indicating the viability of this option (Wall et al., 2005). While 
lysostaphin is technically not an endolysin, its structural and behavioral similarity 
indicate that this technique could be replicated with endolysins. Treating staphylococcal-





many species are affected by S. aureus infections, staphylococcal endolysins could have a 
broad veterinary application.    
 An additional animal agricultural use for endolysins is as a disinfectant. An 
endolysin could be sprayed around animal housing facilities or on equipment as a safer 
alternative to the harsh chemicals currently used to decolonize surfaces and prevent the 
transmission of bacteria from surface to animal (or human). A proof of concept showed 
that a streptococcal endolysin, PlyC, could be aerosolized and effectively eliminate 
Streptococcus equi on surfaces (nylon, cotton, leather, neoprene, polyester, wood, 
stainless steel, glass) and under conditions (detergents, chelators, serum, hard water) 
found in horse stables (Hoopes et al., 2009).  
Food safety is one area that could benefit greatly from the usage of endolysins, 
both as antimicrobial agents and as detection devices. Just as endolysins could be used on 
the farm to decontaminate surfaces, they could additionally be used in food processing 
plants. As S. aureus is a major causative agent of food borne illness, utilizing an 
endolysin to eliminate this pathogen on equipment or on the food itself would save both 
in food waste and in trips to the hospital. The activity of endolysins against biofilms 
makes them an ideal choice for use in decontaminating the many surfaces that food 
products touch in a processing facility (Schmelcher and Loessner, 2016). Additionally, 
they can be added directly to the product; food items that S. aureus has been associated 
with include meat products, poultry products, salads, bakery products, and it is a common 
contaminant during processing of milk into cheeses and other dairy products. Endolysins 
(Lysdb and LysH5) have been engineered to be secreted from starter culture 





S. aureus contamination (Garcia et al., 2010; Guo et al., 2016; Obeso et al., 2008). A 
major obstacle in using endolysins against bovine mastitis or during milk processing is 
the reduction of activity in milk. Additionally, many studies have employed the use of 
pasteurized and/or homogenized milk, not raw milk, thereby not replicating the 
endolysin’s application in the real world. Raw milk is a complex substance, containing 
eukaryotic cells and bacteria, and a lipid, protein, and carbohydrate profile different from 
processed milk (Jenness, 1974). If these enzymes have already shown decreased activity 
in milk free of contaminating factors and displaying different attributes, they may 
perform even more poorly when applied in the desired environment.  
Endolysins could also be utilized in food safety as agents for the detection of 
pathogens. For example, CBDs bound to paramagnetic beads have been shown to 
effectively and quickly detect specific pathogens in food by polymerase chain reaction 
(PCR), fluorescent imaging, or surface plasmon resonance (SPR) (Kong et al., 2015; 
Kretzer et al., 2007; Walcher et al., 2010). CBDs have also been utilized in a chemical 
impedance sensor to identify bacteria in milk (Tolba et al., 2012).    
Currently, companies such as Micreos and Intralytix have bacteriophage products 
targeting pathogens, including Listeria, Salmonella, and E. coli, available for use on food 
equipment and products that are approved by the FDA as “generally recognized as safe” 
(GRAS). As of yet, there are no GRAS endolysin products for use in the food processing 
industry, but the wealth of publications supporting their efficacy against many different 
pathogens on surfaces and food items indicates that they have the potential for this 





While not relevant to staphylococcal endolysins, another application includes the 
use of endolysins as alternatives to antibiotics in the aquaculture industry (Richards, 
2014). Additionally, endolysins could be utilized in plant agriculture; for example, 
transgenic potatoes expressing lysozyme were shown to be resistant to soft rot induced by 
Erwinia carotovora (During, 1993). One agricultural use that could be applied to 
staphylococcal endolysins is the use of plants as bioreactors; the pneumococcal 
endolysins Cpl-1 and Pal and the GBS endolysin PlyGBS were able to be produced in 
tobacco plant chloroplasts at enormously high levels (Oey et al., 2009a; Oey et al., 
2009b). 
Endolysins also have an application as biotechnological tools. They can be used 
as rapid and specific agents for obtaining nucleic acids or proteins (Loessner et al., 1995).  
They could be used to gently generate empty bacterial cell envelopes (“ghosts”) for use 
as vaccines (Panthel et al., 2003). They could also be used in an auto-inducible lytic 
system in the development of bacterium based vaccines (Zhang et al., 2009). CBDs could 
be used as anchors to surface display proteins that could be used for live vaccine 
development, library screening, biocatalysis, and bioadsorption (Lee et al., 2003).      
 
Phage GRCS and PlyGRCS 
 In an effort to identify a novel bacteriophage therapy to combat S. aureus-
associated bacteremia, staphylococcal phage GRCS was isolated from raw sewage taken 
from a municipal sewage treatment system (Sunagar et al., 2010). Phage GRCS was 
classified as a member of the Podoviridae family based upon the observation of short 





exhibited lytic activity in vitro against MSSA and MRSA. Because of the pressing need 
for new treatments against staphylococcal infections, phage GRCS was tested in a mouse 
model of bacteremia. Administration of phage GRCS 30 minutes post-infection protected 
100% of the mice and outperformed oxacillin, even when given in multiple doses (Fig. 1-
6). The bactericidal effect of phage GRCS was confirmed by observation of lower CFU 
of S. aureus in blood obtained from the mice 24 hours post infection, as compared to both 
PBS control and those treated with oxacillin. Delay of administration of phage GRCS 
post infection up to 4 hours resulted in 100% protection, and even postponing treatment 
20 hours still rescued 20% of mice. Importantly, although titers of IgG and IgM mildly 
increased over 4 weeks after multiple injections of phage GRCS, it appears to be non-
adversely immunogenic, as no anaphylactic reactions, changes in core body temperature, 
or other adverse events were observed.          
Due to the high association of diabetes and multi drug resistant bacteremia, phage 
GRCS was also tested for its protective ability against S. aureus in a mouse model of  
streptozotocin-induced diabetes. While the diabetic mice were slightly more susceptible 
than non-diabetic mice to the S. aureus bacteremia, a 90% survival rate was achieved 
when phage GRCS was administered 30 minutes post infection. Furthermore, although a 
delay in phage treatment of diabetic mice led to less protection than that observed in non-
diabetic mice at the same time points, it was still able to rescue 20% of mice when given 
16 hours post infection. 
The in vivo efficacy of phage GRCS suggests that it is a viable antimicrobial 






                          
 
Figure 1-6. Bacteriophage GRCS efficacy in a mouse model of S. aureus bacteremia. 
Survival curves of (A) diabetic and (B) non-diabetic mice indicate that treatment with 
bacteriophage GRCS can protect mice from death by lethal bacteremic infection induced 








However, the desire to steer away from the use of whole phage for aforementioned 
reasons led us to investigate the bactericidal potential of the GRCS endolysin.  To this 
end, the phage linear double-stranded DNA genome was sequenced (Swift and Nelson, 
2014), an endolysin-like ORF was identified by bioinformatics analysis, and PlyGRCS 
was cloned, expressed, and tested for antimicrobial activity.  This thesis represents the 



















Chapter II: Biochemical and biophysical characterization of PlyGRCS, 
























This chapter, in part, is published as: 
 
Linden, S.B., Zhang, H., Heselpoth, R.D., Shen, Y., Schmelcher, M., Eichenseher, F., and 
Nelson, D.C. (2015). Biochemical and biophysical characterization of PlyGRCS, a 
bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus. 






The increasing rate of resistance of pathogenic bacteria, such as Staphylococcus 
aureus, to classical antibiotics has driven research towards identification of other means 
to fight infectious disease. One particularly viable option is the use of bacteriophage-
encoded peptidoglycan hydrolases, called endolysins or enzybiotics. These enzymes lyse 
the bacterial cell wall upon direct contact, are not inhibited by traditional antibiotic 
resistance mechanisms, and have already shown great promise in the areas of food safety, 
human health, and veterinary science. We have identified and characterized an endolysin, 
PlyGRCS, which displays dose-dependent antimicrobial activity against both planktonic 
and biofilm S. aureus, including methicillin-resistant S. aureus (MRSA). The host range 
for this enzyme includes all S. aureus and S. epidermidis strains tested, but not other 
Gram-positive pathogens. The contributions of the PlyGRCS putative catalytic and cell 
wall binding domains were investigated through deletion analysis. The cysteine, 
histidine-dependent amidohydrolase/peptidase (CHAP) catalytic domain displayed 
activity by itself, though reduced, indicating the necessity of the binding domain for full 
activity. In contrast, the SH3_5 binding domain lacked activity but was shown to interact 
directly with the staphylococcal cell wall via fluorescent microscopy. Site-directed 
mutagenesis studies determined that the active-site residues in the CHAP catalytic 
domain were C29 and H92, and its catalytic functionality required calcium as a co-factor. 
Finally, biochemical assays coupled with mass spectrometry analysis determined that 
PlyGRCS displays both N-acetylmuramoyl-L-alanine amidase and D-alanyl-glycyl 





These results indicate that PlyGRCS has the potential to become a revolutionary 






















It has been estimated that 70% of the bacteria that cause hospital-acquired 
infections are now resistant to one or more antibiotics (Taubes, 2008). One of the most 
alarming antibiotic-resistant bacterial species is Staphylococcus aureus. Specifically, 
methicillin-resistant S. aureus (MRSA) are the group of S. aureus strains resistant to the 
entire class of β-lactam antibiotics. Hospital-acquired MRSA (HA-MRSA) often leads to 
severe and life-threatening infections, such as those at surgical sites, in the bloodstream, 
or pneumonia, while community-acquired MRSA (CA-MRSA) typically leads to 
superficial skin infections that can ultimately progress to induce severe invasive 
complications, such as necrotizing fasciitis (Lowy, 1998) (Tang and Stratton, 2010). 
Approval of new antibiotics, including linezolid (oxazolidinone class) in 2000, 
daptomycin (cyclic lipopeptide class) in 2003, and tigecycline (glycylcycline class) in 
2005, provides alternatives to vancomycin, which was formerly the only antibiotic 
treatment for MRSA (Micek, 2007). These new antibiotics, along with increased 
awareness and adherence to universal decolonization practices have led to a significant 
decrease in the incidence of MRSA in intensive care units (Huang et al., 2013). 
Nonetheless, the most recent Centers for Disease Control report indicates there are still 
over 80,000 severe MRSA infections per year in the United States resulting in over 
11,000 deaths (CDC, 2013). The same report labeled MRSA as a “serious” public health 
threat and vancomycin-resistant S. aureus (VRSA) as a “concerning” threat, underscoring 
the need for development of alternative therapeutics. 
To counteract bacterial resistance and ameliorate the problems caused by S. 





(Borysowski et al., 2011; Nelson et al., 2012). Endolysins are enzymes released by 
bacteriophages during the lytic cycle of viral infection. Once produced within the 
bacterial cytoplasm by replicating bacteriophage, these enzymes hydrolyze bonds in the 
bacterial cell wall (i.e. peptidoglycan) until lysis is complete. The idea of utilizing 
endolysins therapeutically is based on the phenomenon of “lysis from without”, a phrase 
used to describe the destruction of the bacterial envelope without production of phage 
virions (Abedon, 2011).  
The classical structure of endolysins that act on Gram-positive cell walls employs 
a modular architecture consisting of an N-terminal catalytic domain linked to a C-
terminal cell wall binding domain (CBD). The catalytic domain is responsible for 
cleaving specific covalent bonds in the peptidoglycan structure that are essential for 
maintaining its intrinsic structural integrity. The CBD confers endolysin specificity by 
recognizing and noncovalently binding to species- or strain-specific epitopes associated 
with the cell envelope. It is the high specificity derived by the combined actions of the 
catalytic and CBD domains that cause endolysins to be highly refractory to the resistance 
commonly observed upon treatment with classical antibiotics (Fischetti, 2005; Schuch et 
al., 2002). This is due to the evolution of bacteriophage to target specific, conserved 
bonds in the peptidoglycan of a bacteria cell wall, ensuring that the progeny phage will 
survive (Low et al., 2011). Even if resistance were to develop, endolysins can be 
engineered through domain shuffling or used in combination with other endolysins or 
antibiotics to prolong the use of these enzymes (Shen et al., 2012). Thus, they are 





This study investigates PlyGRCS, the endolysin from the GRCS bacteriophage 
which was isolated from sewers in India (Sunagar et al., 2010). While a phage therapy 
study was performed on this bacteriophage, this analysis is the first of its kind to 
investigate the PlyGRCS endolysin. We have found that PlyGRCS exhibits strong 
activity against S. aureus and have conducted a biochemical and biophysical 
characterization of this enzyme.  
 
Materials and Methods 
Bacterial Strains  
Bacterial species, strains, and any associated antimicrobial resistance phenotypes 
are shown in (Table 2-1). All staphylococci containing the NRS strain designations were 
provided by the Network on Antimicrobial Resistance in Staphylococcus aureus 
(NARSA) which is distributed by BEI Resources depository in Manasas, VA, USA, 
under the direction of the National Institute of Allergy and Infectious Diseases and the 
National Institutes of Health. A Streptococcus suis clinical isolate was obtained from Dr. 
Randy Shirbroun at Newport Laboratories in Worthington, MN, USA. Streptococcus 
pyogenes and Enterococcus facealis were obtained from Drs. Vincent Fischetti and 
Alexander Tomasz, respectively, at The Rockefeller University, USA. A Bacillus pumulis 
clinical isolate was obtained from Dr. John Mayo at Louisiana State University, USA. 
The remaining strains, Streptococcus pneumonia, Streptococcus uberis, and 
Streptococcus equi, were obtained from the American Type Culture Collection (ATCC) 





Table 2-1. PlyGRCS spectrum of lytic activity. 
  
Bacterial species, strains tested PlyGRCS CHAPGRCS 
MRSA NRS-385 + - 
MRSA NRS-382 + - 
MRSA NRS-384 + + 
MRSA NRS-71 ++ + 
VISA NRS-14    ++ - 
Staphylococcus epidermidis NRS-101 ++ + 
Streptococcus suis 730082 - - 
Streptococcus pyogenes D471 - - 
Streptococcus pneumococcus TIGR4 - - 
Streptococcus uberis 700407 - - 
Streptococcus equi 9528 - - 
Bacillus pumulis BJ0055   - - 
Enterococcus facealis EF24 - - 
 
Activity of PlyGRCS (6 µg) or CHAPGRCS (6 µg) against various species was evaluated 
via plate lysis assays. The strength of lytic zones was defined qualitatively: strong lytic 
zone = ++, weak lytic zone = +, no lytic zone = -. Examples of strong and weak lytic 
zones are shown below: 
Strong lytic zone =              





Streptococcal strains were grown in Todd-Hewitt broth, supplemented with 1% yeast 
extract (THY) (Alpha Bioscience), or on THY plates; staphylococcal strains, B. pumulis, 
and E. facealis were grown in trypticase soy broth (TSB) (Becton-Dickinson), or on TSB 
plates; Escherichia coli was cultivated in Luria Broth (LB) (Alpha Bioscience), or on LB 
plates. Unless otherwise indicated, all chemicals were purchased from Sigma and were of 
the highest purity available. 
 
Cloning, Domain Constructs, and Site Directed Mutagenesis 
  The phage GRCS genome has recently been elucidated (GenBank Accession 
KJ210330) (Swift and Nelson, 2014). Bioinformatic analysis using BLAST and PFAM 
programs [both from the National Center for Biotechnology Information (NCBI)] 
predicted a putative endolysin for ORF15 (AHJ10590), which we named PlyGRCS, that 
contains an N-terminal cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) 
catalytic domain and a C-terminal bacterial src-homology 3 (SH3_5) binding domain. As 
such, individual domain clones for CHAP (i.e. CHAPGRCS) and SH3_5 (i.e. SH3_5GRCS) 
were amplified using the primer pairs shown in Table 2-2. For the full-length PlyGRCS, 
the CHAP-F and SH3_5R primers were utilized. All reverse primers incorporated a 
6XHis purification tag. Specific point mutations to putative active-site residues (C29S 
and H92A) were made with phosphorylated primers (Table 2-2) using the Change-IT 
Multiple Mutation Site Directed Mutagenesis Kit (Affymetrix USB) according to the 
manufacturer’s instructions. All PCR products were cloned into pBAD24, transformed 






Table 2-2. Primers. 
















Primers utilized in this study to amplify the full-length PlyGRCS, each domain 
















MD). The ApE program (University of Utah) was utilized for DNA sequence analysis 
and manipulations.  
 
Expression and Purification  
E. coli were grown at 37°C in baffled flasks to an OD600 = 1 in LB supplemented 
with 100 µg/ml ampicillin. Expression was induced with 0.25% arabinose overnight at 
18°C. Crude protein extracts were purified by a Bio-Scale Mini Profinity IMAC 
Cartridge (Bio-Rad) and eluted in 10 ml fractions of 20 mM, 50 mM, 100 mM, 250 mM, 
and 500 mM imidazole, followed by SDS-PAGE analysis.  Fractions containing proteins 
of the correct predicted molecular weight were pooled and dialyzed against PBS pH 7.4 
with 300 mM NaCl. 
  
Quantification of Lytic Activity 
Lytic activity was based on turbidity reduction assay, as previously described 
(Nelson et al., 2012). Briefly, bacterial cells were centrifuged (4,000 RPM, 5 minutes, 
4°C), resuspended in buffer and mixed 1:1 (v/v) with endolysin to a final OD600 = 1. 
OD600 readings were taken every 15 seconds for 20 minutes at 37°C. Endolysin activity 
was equated to the Vmax dictated by the linear portion of the resulting killing curve. Each 








Characterization of PlyGRCS 
To determine dose response, PlyGRCS was serially diluted and each dosage (100 
µl) was added in triplicate to a 96-well polystyrene microtiter plate (Nest Biotech Co, 
Ltd) just before addition of bacterial cells (100 µl) according to the turbidity reduction 
assay described above. For optimum pH determination, bacterial cells were suspended in 
40 mM boric acid/phosphoric acid (BP) buffer, pH 3–11, and were challenged against 
PlyGRCS. The influence of NaCl on PlyGRCS activity was tested in BP buffer at the 
experimentally determined pH optimum using the same assay. The effect of divalent 
cations was determined using the turbidity reduction assay with several modifications. 
First, PlyGRCS was incubated at room temperature in PBS or PBS supplemented with 5 
mM EDTA for 10 minutes. Secondly, the EDTA-treated samples received either no 
further treatment, or were supplemented with 6 mM CaCl2 or 6 mM MgCl2. Finally, the 
lytic active of the samples was then immediately assayed and compared to PlyGRCS in 
PBS prior to EDTA inactivation. Kinetic stability was evaluated as described (Son et al., 
2012), with minor modifications. Lytic assays were performed in optimal conditions after 
PlyGRCS was incubated at indicated temperatures for 30 minutes and subsequently 
recovered on ice for 5 minutes. 
 
Cell Wall Binding 
  An overnight culture of S. aureus NRS-14 was concentrated 5X in BP buffer and 
was incubated at room temperature with 10 µg SH3_5GRCS containing the 6XHis tag for 
10 minutes. A control without SH3_5GRCS was also utilized. The samples were washed 





antibody (Gen Script). After washing with PBS, AlexaFluor-488 conjugated goat anti-
mouse IgG (H+L) antibody (1 µl) (Invitrogen) was incubated with samples for an 
additional 10 minutes. Samples were washed again with PBS before being visualized via 
fluorescence and bright field microscopy. An Eclipse 80i epifluorescent microscope 
workstation (Nikon) with X-Cite 120 illuminator (EXFO) and Retiga 2000R CCD 
camera was used. NIS-Elements software (Nikon) was used for image analysis.  
 
Host Range Analysis 
Host range analysis was performed as described (Schmelcher et al., 2012c), with 
minor modifications. Bacterial cells were diluted in sterile PBS to an OD600 = 1 and 
spread on each plate. 10 µl spots (600 µg/ml) of PlyGRCS or CHAPGRCS were applied. 




An overnight culture of S. aureus NRS-14 (1 ml per well) was placed into 24-well 
CELLBIND plates (Corning) containing 500 µl of TSB per well. After an additional 24 
hour incubation at 37°C, media was aspirated and samples were washed with PBS to 
remove unattached cells. Two-fold serial dilutions of PlyGRCS in triplicate were added 
in 1 ml BP buffer pH 7 and incubated at 37°C for one hour. Liquid was aspirated and 
samples were washed with distilled water before drying. Biofilms were stained with .01% 





samples were washed with PBS and dried before the addition of 1 ml 10% SDS to extract 
the crystal violet from the biomass for quantification at OD595. 
 
Bactericidal Analysis 
Sterile-filtered PlyGRCS was 2-fold serially diluted in PBS supplemented with 1 
mM CaCl2 and an equal volume of either various concentrations of enzyme or buffer only 
was added to 10
5
 S. aureus NRS-14 in a microtiter plate. Samples were incubated at 37ºC 
for 1 hour, then serially diluted, plated on TSB agar, and incubated overnight at 37ºC to 
obtain CFU counts. The MBC (minimum bactericidal concentration) was determined as 
the minimum concentration of enzyme that killed ≥99.9% of bacteria.  
 
Circular Dichroism (CD) Spectropolarimetry 
CD experiments for wild-type (WT) and active-site mutants were performed on a 
Chirascan CD spectrometer (Applied Photophysics) equipped with a thermoelectrically 
controlled cell holder. CD spectra were obtained in the far-UV range (190-260 nm) in a 1 
mm path length quartz cuvette at 1 nm steps with 5 second signal averaging per data 
point. Spectra were collected in triplicate, followed by averaging, baseline subtraction, 
smoothing and conversion to mean residue ellipticity (MRE) by the Pro-Data software 
(Applied Photophysics). Secondary structure prediction was performed using the 
Provencher and Glockner method (Provencher and Glockner, 1981) provided by 
DICHROWEB (Whitmore and Wallace, 2004). Melting experiments were performed by 





from 20°C to 95°C using a 1°C/min heating rate. MRE was monitored at 218 nm in a 1 
mm path length quartz cuvette at 0.5°C °C steps with 5 second signal averaging per data 
point. The melting data was smoothed, normalized and fit with a Boltzmann sigmoidal 
curve. The first derivative of the melting curve was then taken to determine the 
temperature (Tm) at which the folded and unfolded protein species in solution were at 
equilbrium (Fallas and Hartgerink, 2012).  
  
Biochemical Assays 
For analysis of reducing sugars released from the peptidoglycan, the 
dinitrosalicylic acid (DNSA) assay was used (Danner et al., 1993). S. aureus NRS-14 
peptidoglycan was purified as previously described (Pritchard et al., 2004; Schmelcher et 
al., 2012d) and was treated for one hour at 37ºC with 50 µg/ml of PlyGRCS in optimal 
conditions. Samples were centrifuged and the supernatant was added to an equal volume 
of 87.7 mM DNSA (20 g/L in .7 M NaOH). After boiling for 5 minutes, samples were 
allowed to cool and the absorbance was read at OD535. Known concentrations of glucose 
were used to create a standard curve. To determine an increase in free amine groups, the 
trinitrophenylation reaction originally described by Satake et al. and modified by 
Mokrasch was used (Mokrasch, 1967; Satake et al., 1960). Purified peptidoglycan 
(OD600=1) was treated with PlyGRCS (50 µg/ml) for one hour at 37ºC. Samples were 
pelleted and the supernatant was filtered through a 0.22 µM filter. The sterile filtrate was 
added to sodium tetraborate and trinitrobenzenesulfonic acid and incubated for 30 






Cleavage Analysis by Mass Spectrometry 
For determination of cut sites within the staphylococcal peptidoglycan, purified 
cell walls were digested with PlyGRCS and the resulting fragments were analyzed via 
mass spectrometry as previously described (Becker et al., 2009a; Pritchard et al., 2004). 
Briefly, SA113 ΔtagO cell walls (Atilano et al., 2010; Weidenmaier et al., 2004) were 
digested in 25 mM Tris, 200 mM NaCl, pH 7.4 at 37°C for 18 hours with 50 µg/ml of 
PlyGRCS, filtered through 5000-MW cutoff Vivaspin 500 units (Sartorius North 
America Inc., Bohemia, NY), and desalted using C18 Zip Tips (Millipore, Zug, 
Switzerland). Controls included peptidoglycan digested with the amidase domain of 
2638A, a known N-acetylmuramoyl-L-alanine amidase (M. Schmelcher, unpublished 
data), or undigested peptidoglycan. To further define the PlyGRCS cut site, double 
digests with PlyGRCS and a truncation construct containing only the CHAP domain of 
LysK (CHAP-K),  a known D-alany-glycyl endopeptidase (Becker, Dong et al. 2009), 
were performed. The samples were eluted from the Zip Tips with 50:50:0.01 (v/v/v) 
CH3OH:H2O:HCOH (pH ~2), and NanoESI-MS analysis was performed on a Q-TOF 
Ultima API mass spectrometer (Micromass, UK).  
 
Results 
Expression of PlyGRCS and Domain Constructs  
The phage GRCS genome was recently sequenced (KJ210330) (Swift and Nelson, 
2014) and bioinformatic analysis predicted an endolysin for ORF15 (AHJ10590), which 
we named PlyGRCS. This enzyme contains a putative N-terminal CHAP domain, which 





a C-terminal bacterial src-homology 3 (SH3_5) domain that functions as a CBD in many 
staphylococcal and streptococcal endolysins (Nelson et al., 2012). The closest homologs 
to PlyGRCS are a hypothetical protein from S. aureus 2011-60-1490-31 (EZV76040.1, 
98% identity), an amidase from Staphylococcus phage 44AHJD (NP_817310.1, 96% 
identity), ORF009 of Staphylococcus phage 66 (YP_239469.1, 97% identity), the SAL-2 
amidase from Staphylococcus phage SAP-2 (YP_001491539.1, 96% identity), and an 
unnamed protein product of Staphylococcus phage S24-1 (YP_004957430.1, 92% 
identity). To study the full-length enzyme and elucidate the contributions of each domain, 
we cloned the full length PlyGRCS, as well as its isolated CHAP domain (CHAPGRCS, 
amino acids 1-140) and SH3_5 domain (SH3_5GRCS, amino acids 150-250) into 
expression vectors. All three constructs were expressed as soluble proteins and purified to 
homogeneity by nickel affinity chromatography via the C-terminal 6XHis tags on each 
protein.  
 
Characterization of PlyGRCS 
PlyGRCS displayed a dose-response curve from 28 to 1.75 µg/ml when tested in a 
turbidity reduction assay using stationary phase S. aureus NRS-14 cells (Fig. 2-1A). The 
highest dose corresponded to a 70% decrease in optical density in just 15 minutes (50% 
decrease in < 10 minutes). When tested at equimolar concentrations, CHAPGRCS 
displayed ~8% of full-length PlyGRCS activity (Figure 2-2). In contrast, SH3_5GRCS did 
not display any lytic activity. However, this domain alone possessed the ability to 







Figure 2-1. Biochemical characterization of optimal conditions for PlyGRCS 
activity. The influence of (A) dose, (B) pH, (C) NaCl, and (D) divalent cations on 
PlyGRCS activity against stationary phase S. aureus NRS-14. Error bars represent the 
standard deviation, and all experiments were done in triplicate. Statistical analysis was 







Figure 2-2. PlyGRCS contains an N-terminal catalytic domain. Turbidity reduction 
analysis reveals CHAPGRCS displays ~8% of full-length PlyGRCS activity, while 
SH3_5GRCS does not display any lytic activity, indicating the importance of both domains 
for full activity. Error bars represent the standard deviation, and all experiments were 































purification tag on the staphylococcal surface (Fig. 2-3). Control experiments without 
SH3_5GRCS did demonstrate binding of the antibody (data not shown). Therefore, while 
the CHAP domain is independently capable of lysing S. aureus, the full antimicrobial 
efficacy of the endolysin is dependent on the simultaneous presence of both the CHAP 
and SH3_5GRCS domains.  
Lytic activity of PlyGRCS was then tested in BP buffer with a pH range from 3.0 
to 11.0 to determine optimum conditions. Optimal pH was determined to be 7.0, with an 
active range between 6.0 and 8.0 (Fig. 2-1B). PlyGRCS activity was markedly reduced at 
pH extremes. Based on the above observations, subsequent turbidity reduction and 
antimicrobial assays were performed in BP buffer pH 7.0. Because the activity of many 
endolysins, including various staphylococcal endolysins (Becker et al., 2008; Garcia et 
al., 2010), is enhanced by the addition of NaCl, we investigated the activity of PlyGRCS 
in the presence of NaCl ranging from 0 to 500 mM. Surprisingly, NaCl had little effect 
(±10%) on PlyGRCS activity up to 125 mM and only slightly inhibited activity at higher 
concentrations (~35% decrease at 500 mM) (Fig. 2-1C). Several CHAP domain-
containing staphylococcal endolysins (Donovan et al., 2006c; Fenton et al., 2011b), as 
well as streptococcal endolysins (Celia et al., 2008; Pritchard et al., 2004), have been 
shown to require calcium for activity. Furthermore, the structure of the staphylococcal 
LysGH15 CHAP domain shows calcium in an EF-hand-like structure (Gu et al., 2014) 
and the CHAP domain of PlyGRCS shares identity in three critical aspartic acid residues 
known to complex this cation in LysGH15 and other calcium binding proteins, although 







Figure 2-3. PlyGRCS contains a C-terminal cell wall binding domain. SH3_5GRCS 
directly interacts with S. aureus NRS-14. Images represent brightfield (left) and 
fluorescent (right) images viewed at 1000X magnification. Cell wall binding was 















mind, the activity of PlyGRCS was analyzed in either the presence or absence of calcium. 
PlyGRCS was first incubated with EDTA to remove all divalent cations from solution. 
EDTA-treated PlyGRCS was devoid of lytic activity (Fig. 2-1D). Next, EDTA-treated 
PlyGRCS was incubated with excess CaCl2. Calcium-treated PlyGRCS displayed nearly 
twice the lytic activity when compared to PlyGRCS prior to EDTA treatment. To 
determine divalent metal dependence of PlyGRCS is specific to calcium, the activity of 
the EDTA-treated endolysin was measured after the addition of an alternative divalent 
metal, magnesium. The activity of magnesium-treated PlyGRCS mimicked that of the 
EDTA-treated sample, suggesting that the divalent metal dependence of PlyGRCS is 
calcium-specific.  
Finally, the kinetic and thermodynamic stability of PlyGRCS was investigated. 
PlyGRCS displayed > 90% residual lytic activity after incubating at temperatures ranging 
from 4°C to 37°C for a total of 30 minutes. At temperatures of ≥ 40°C, lytic activity was 
not observed (Fig. 2-4A). Melting experiments performed on a CD spectrophotometer 
show cooperative unfolding of PlyGRCS with a Tm of 43.5°C (Fig. 2-4B), which further 
confirms the lack of activity at ≥ 40°C observed during the kinetic stability experiment. 
CHAPGRCS (Fig. 2-4C) and SH3_5GRCS (Fig. 2-4D) had similar Tm values of 44.8°C and 
44.5°C, respectively. The observed PlyGRCS stability profile is consistent with that of 
other phage lysins. For example, the S. aureus endolysin LysK is kinetically inactivated 
at 42.0°C and the Streptococcus pneumoniae endolysin Cpl-1  displays a Tm of 43.5°C 







Figure 2-4. PlyGRCS temperature stability. (A) Stationary phase S. aureus NRS-14 
treated with 25 μg/ml of PlyGRCS after being held at indicated temperatures for 30 min 
and recovered on ice for 5 min. Error bars represent the standard deviation, and all 
experiments were done in triplicate The thermal stability of (B) full-length PlyGRCS as 
well as (C) CHAPGRCS and (D) SH3_5GRCS was determined by means of CD melting 
experiments. Samples were heated from 20 to 95 °C at 1 °C/min in 20 mM sodium 







PlyGRCS Host Range  
In order to determine the host range of PlyGRCS, activity was tested against 13 
different bacterial strains including methicillin-resistant and vancomycin-intermediate 
resistant S. aureus, methicillin-resistant S. epidermidis, and several other representative  
Gram-positive pathogens (Table 2-1). At 6 µg, lytic activity was seen against all 
staphylococcal strains, with PlyGRCS exhibiting the greatest strength against S. aureus 
strains NRS-71 and NRS-14 and S. epidermidis NRS-101. As expected, CHAPGRCS did 
not exhibit as much activity, causing only weak clearing zones on plates of S. aureus 
strains NRS-384 and NRS-71 and S. epidermidis NRS-101. No lytic activity was 
observed on any other strains. Thus, PlyGRCS has an activity spectrum confined to 
staphylococcal species, as no activity was observed against streptococci or representative 
bacilli and enterococci species listed in Table 2-1. 
 
Biofilm Assay  
Considering the ability of S. aureus to form biofilms and thus present a further 
barrier to traditional treatments, we investigated the anti-biofilm properties of PlyGRCS. 
When 1 day biofilms were treated with PlyGRCS for 1 hour, a dose response decrease in 
the amount of biofilm was visualized, with as little as 6.25 µg/ml affecting a ~50% 
decrease in biofilm biomass (Fig. 2-5).  
 
Bactericidal Effects of PlyGRCS 
It has been noted that the minimal inhibitory concentration (MIC) assay may not 






Figure 2-5. Antibiofilm activity of PlyGRCS. S. aureus NRS-14 was allowed to form 
static biofilms for 24 h and treated with PlyGRCS at indicated concentrations for 1 h. The 
amount of biofilm is represented by the quantification of crystal violet staining of 
biomass at OD595. Error bars represent the standard deviation, and all experiments were 













enzyme acts (Kusuma and Kokai-Kun, 2005). Therefore, we employed the minimum 
bactericidal concentration (MBC) assay, which is the lowest concentration of enzyme that 
kills ≥99.9% (i.e. 3 logs) of the test inoculum (Jones et al., 1985). When tested against a 
VISA strain in stationary phase, 25 µg/ml PlyGRCS resulted in 3 log killing, 12.5 µg/ml 
yielded a 2.5 log decrease, and 6.25 µg/ml reduced bacterial counts by 2 logs (data not 
shown). Of note, VISA strains possess thicker cell walls than other S. aureus strains. This 
phenotype may cause the bacteria to be more resilient to endolysin treatment, and hence 
require higher than normal MBC values (Howden et al., 2010; Sieradzki and Tomasz, 
2003). Nonetheless, our results compare favorably to other anti-staphylococcal 
endolysins. PlySs2 represents the only other staphylococcal endolysin with reported 
bactericidal activity against a VISA strain, requiring 128 µg/ml to decrease the colony 
counts of mid-log phase cells by 2 logs (Gilmer et al., 2013).  
 
Confirmation of N-terminal CHAP Catalytic Domain 
 By definition, CHAP domains contain two invariant residues, a cysteine and a 
histidine (Bateman and Rawlings, 2003; Rigden et al., 2003). Presumably, the cysteine 
acts as a catalytic nucleophile and the histidine may function as a general base to 
deprotonate the thiol group of the cysteine. To determine the contributions of these 
putative critical residues in PlyGRCS, we used site-directed mutagenesis to alter C29 and 
H92, the residues identified by a PFAM alignment of PlyGRCS to archetypical CHAP 
domains. Circular dichroism analysis demonstrated that both the C29S and H92A point 
mutants had similar secondary structures to WT PlyGRCS (data not shown). No lytic 





turbidity reduction assay (Fig. 2-6); however, H92A still exhibited lytic activity, although 
reduced to 40% compared to WT. At present, it is not clear why activity is associated 
with the H92A mutant, although similar mutagenesis of active-site histidine residues in 
cysteine proteases have likewise displayed reduced, but measurable activity(Ekici et al., 
2008; Khayat et al., 2001). While not proven, it is possible that other residues near the 
active-site residues could substitute for the histidine as an electron acceptor during the 
nucleophilic attack by the cysteine.  
 
Cleavage Specificity of the CHAP Domain  
 CHAP domains are associated with N-muramoyl-L-alanine amidase (amidase) or 
endopeptidase activity (Bateman and Rawlings, 2003). Specifically, CHAP domains of 
staphylococcal endolysins have been characterized as amidases or D-alanyl-glycyl 
endopeptidases (Schmelcher et al., 2012a). To determine the specific catalytic nature of 
the PlyGRCS CHAP domain, two biochemical assays were employed to analyze the 
reducing sugar (indicative of glycosidase activity) or amine (indicative of 
amidase/endopeptidase activity) release upon PlyGRCS treatment. As predicted, 
PlyGRCS did not show any glycosidase activity. However, free amines were detected 
when S. aureus cell walls were treated with PlyGRCS, revealing that the catalytic activity 
is indeed an amidase or endopeptidase (Fig. 2-7A).   
 To further elucidate which hydrolytic activity PlyGRCS possesses, enzymatically 
digested S. aureus peptidoglycan preparations were subjected to electron spray 
ionization-mass spectrometry (ESI-MS). Unexpectedly, the PlyGRCS digest (Fig. 2-7B, 






Figure 2-6. PlyGRCS contains an N-terminal catalytic domain with an active site 
cysteine and histidine. Stationary phase S. aureus NRS-14 was treated with 25 μg/ml 
PlyGRCS, PlyGRCS-C29S, or PlyGRCS-H92A. The reduction in activity of PlyGRCS-
C29S and PlyGRCS-H92A indicates that these are the active site residues. Error bars 
represent the standard deviation, and all experiments were done in triplicate. Statistical 
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Figure 2-7. Catalytic Mechanism of PlyGRCS. (A) The TNBS assay (left) and DNSA 
assay (right) performed on PlyGRCS-digested peptidoglycan reveal that PlyGRCS 
displays amidase or endopeptidase activity, but not glycosidase activity. Error bars 
represent the standard deviation, and all experiments were done in triplicate. (B) ESI-MS 
analysis of PlyGRCS digested peptidoglycan results in a spectrum (top) containing a peak 
at m/z =702.35, indicating that PlyGRCS possesses endopeptidase and amidase activities. 
This peak is absent in peptidoglycan digested with a known N-acetylmuramoyl-L-alanine 
amidase (second spectrum), or undigested peptodiglycan (third spectrum). Double digest 
with PlyGRCS and CHAP-K (bottom spectrum) yields a spectrum identical to that of 
PlyGRCS alone. (C) Schematic showing the A2QKG5 fragment corresponding the 702.35 
peak generated by both an N-acetylmuramoyl-L-alanine amidase activity (black arrows) 
and a D-alanyl-glycyl endopeptidase activity (white arrows). (D) PlyGRCS 
peptidoglycan digest data showing both the A2QKG5 (702.35 m/z peak) and the larger, 
doubly charged A4Q2K2G10 moiety (684.84 m/z peak). Analysis performed by M. 






presence of two enzymatic activities, an N-acetylmuramoyl-L-alanine amidase and either 
a D-alanyl-glycyl endopeptidase or a glycyl-glycyl endopeptidase, to yield the fragment 
A2QKG5 (single letter amino acid code) (Fig. 2-7C). Moreover, a larger double-charged 
ion (m/z=684.84) was also observed that likely corresponds to the fragment A4Q2K2G10 
 (without a water molecule), resulting from incomplete peptidoglycan digest (Fig. 2-7B 
and D). Presence of the 702.35 and 684.84 peaks was reproducible on independent 
digests and ESI-MS experiments. Control experiments with peptidoglycan digested with 
the 2638A amidase domain, a known N-acetylmuramoyl-L-alanine amidase (Fig. 2-7B, 
second spectrum), or undigested peptidoglycan (Fig. 2-7B, third spectrum) did not 
contain the 702.35 or 684.84 peaks suggesting that generation of the 702.35 and 684.84 
fragments by PlyGRCS was not an artifact of a single enzymatic activity acting on 
uncrosslinked or partially cleaved peptidoglycan. Furthermore, a double digest with 
PlyGRCS and CHAP-K, which reportedly has D-alanyl-glycyl endopeptidase activity 
(Becker et al., 2009a), was performed to elucidate the specific nature of the 
endopeptidase activity. Because this spectrum was identical to that of the PlyGRCS alone 
digested peptidoglycan, it was determined that PlyGRCS possesses a D-alanyl-glycyl 
endopeptidase activity, as a glycyl-glycyl endopeptidase activity would have yielded a 
different fragment pattern. Taken together, these data imply that PlyGRCS, which has a 
single catalytic CHAP domain, can cleave two distinct bonds in the staphylococcal 









The use of endolysins provides a targeted treatment for bacterial infections that 
circumvents traditional antibiotic resistance mechanisms (Spratt, 1994). In this study, the 
novel endolysin PlyGRCS was characterized and demonstrated bacteriolytic activity 
against MRSA successfully. The endolysin dosage used in this study demonstrates that 
the efficacy of PlyGRCS is comparable to or better than other published staphylococcal 
endolysins (Gilmer et al., 2013; Jun et al., 2011; Sass and Bierbaum, 2007) and since the 
optimal conditions for PlyGRCS activity were determined to be in the physiological 
range, this enzyme has the capability to be used as an antimicrobial agent. Even more 
impressive is the ability of PlyGRCS to act against stationary phase staphylococci as well 
as medically relevant biofilms, a further hindrance to traditional antibiotic therapy. The 
ability of endolysins, like PlyGRCS to disrupt biofilms may lead to their use in 
conjunction with classical antibiotics. In this scenario, the endolysin would provide the 
initial disturbance to the biofilm structure, thereby allowing the antibiotic to subsequently 
access the now susceptible target bacteria. It has already been shown that antibiotics 
applied in combination with endolysins bind more efficiently to their planktonic target 
bacterial cells; this same phenomenon may also be observed in biofilms as well (Schuch 
et al., 2013).  
Identification of the PlyGRCS cleavage sites is a critical finding. To our 
knowledge, this is the first reported case of a single CHAP domain, or any individual 
endolysin catalytic domain, that possesses the ability to cleave two disparate bonds in the 
bacterial peptidoglycan. Initially we thought the results could be attributed to a single 





created by two cleavage events. However, spectra from repeated experiments on 
undigested control peptidoglycan and control digests with enzymes of known specificity 
collectively indicate that PlyGRCS is capable of liberating the fragment A2QKG5 from 
the staphylococcal peptidoglycan. This would necessitate cleavage of the amide bond 
formed between MurNAc and Ala residues as well as the hydrolysis of the amide bond 
formed between D-Ala and Gly residues or one of the Gly-Gly bonds. Further 
experiments with a double digest, including PlyGRCS and CHAP-K, a D-alanyl-glycyl 
endopeptidase, showed an identical pattern to the PlyGRCS only spectrum, indicating 
that the endopeptidase activity of PlyGRCS is identical to CHAP-K. While these findings 
indicating both amidase and endopeptidase activities associated with the single CHAP 
domain containing PlyGRCS were surprising, it is noteworthy that CHAP domains have 
been associated with an N-acetylmuramoyl-L-alanine amidase activity in the 
streptococcal PlyC endolysin (McGowan et al., 2012) as well as D-alanyl-glycyl 
endopeptidase activity in multiple staphylococcal endolysins (Schmelcher et al., 2012a). 
Moreover, the recently crystallized CHAP domain from the staphylococcal endolysin 
LysGH15 shows highest structural homology to the aforementioned CHAP domain of 
PlyC, with a root-mean-square deviation (RMSD) = 2.32 Å (Gu et al., 2014), further 
supporting our interpretation that these domains can exhibit multiple activities. Finally, 
consistent with the findings of our biochemical assays, both amidase and endopeptidase 
activities would yield free amine groups via cleavage of peptide moieties and additionally 
would not liberate reducing sugars, which requires the cleavage of at least one of the two 





The implications of a single catalytic domain with two cleavage specificities are 
numerous for bioengineering efforts. First, it is well known that endolysins display 
synergy with other endolysins of different cleavage specificities. For example, killing of 
pneumococci is enhanced when the endolysins Cpl-1, an N-acetylmuramidase, and PAL, 
an N-acetylmuramoyl-L-alanine amidase, are used together compared to twice the 
concentration of either enzyme alone (Loeffler and Fischetti, 2003). Likewise, 
mutagenesis of active-site residues was used to show synergy between two catalytic 
domains, an N-acetylmuramoyl-L-alanine amidase and a glycosyl hydrolase, within the 
PlyC endolysin (McGowan et al., 2012) . While not proven, it is believed that synergy 
arises from cleaving the peptidoglycan at two different locations, which is more 
destabilizing to the superstructure than repetitive cleavages at one location and would 
result in accelerated osmolysis of the bacterial cell. Additionally, cleavage of one bond 
may facilitate access to the second target, further contributing to this synergistic effect.   
A second benefit of a catalytic domain with dual activities is that it would be less 
susceptible to development of resistance. While there are currently no specific reports of 
bacterial strains developing resistance to phage-encoded endolysins, resistance to 
peptidoglycan hydrolases as a general class has been reported. Notably, modifications to 
the peptidoglycan backbone can render N-acetylmuramidases (i.e. lysozymes) ineffective 
(Davis and Weiser, 2011; Vollmer, 2008). More specific to the staphylococcal 
peptidoglycan, resistance to lysostaphin, a bacterial derived glycyl-glycine 
endopeptidase, can be achieved by simple modification of the pentaglycine crossbridge in 





or engineered to have more than one catalytic activity would circumvent resistance 
development targeting the specificity of one activity. 
 This study is only the beginning in understanding PlyGRCS. As protein 
therapeutics, PlyGRCS and other endolysins are amenable to domain shuffling, directed 
evolution, and bioengineering approaches to further enhance efficacy and/or specificity. 
The unique dual substrate activity of the PlyGRCS catalytic domain offers an ideal 
starting point for chimeragenesis studies with other domains from staphylococcal-specific 
endolysins.   
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Chapter III: Anti-Biofilm Activity of PlyGRCS: Removal, Prevention, 
and Bacteriolytic Efficacy of a Bacteriophage Endolysin Against Multi-






















 The ability of Staphylococcus aureus to form biofilms represents a major 
virulence factor and contributes to its ability to cause chronic infections. Furthermore, S. 
aureus can form biofilms on medical devices, leading to colonization of areas of the body 
where it would not normally be able to persist. Biofilms are notoriously difficult to 
eradicate, as they are resistant to antibiotics and are resilient against the host immune 
system. Currently, the treatment for S. aureus biofilm infections is debridement or 
removal of the affected implant, which is not a desirable outcome, and as such, 
alternative therapies are needed. PlyGRCS, an endolysin which has shown antimicrobial 
activity against planktonic S. aureus, represents such an alternative option. In this study, 
we investigate the use of PlyGRCS against staphylococcal biofilms. PlyGRCS displays 
the ability to remove biofilms from abiotic surfaces at concentrations much lower than its 
minimum inhibitory concentration. In addition to its ability to disperse biofilms, as shown 
by crystal violet staining, in vivo imaging, and confocal microscopy, PlyGRCS also kills 
bacteria within biofilms. PlyGRCS removes S. aureus biofilms formed under dynamic 
conditions in medical-grade catheters, mimicking an in vivo infection. Finally, PlyGRCS 
possesses the ability to kill bacteria within biofilms grown on epithelium, without 
harming the eukaryotic cells. In summary, we show that PlyGRCS has a potential 










Staphylococcus aureus is one of the most commonly isolated antibiotic-resistant 
bacteria in both the community and in the hospital setting (Lowy, 1998). It is particularly 
frightening as methicillin-resistant S. aureus (MRSA) infections alone have a 15% 
morbidity rate just in the United States (CDC, 2013), and as we enter a post-antibiotic 
era, that number may increase drastically. Further complicating this situation is the ability 
of S. aureus to participate in the biofilm lifestyle; the biofilm mode of growth is an 
important key to pathogenesis, as biofilms are resistant to host defense and the most 
commonly used treatment for bacterial infections, antibiotics (Otto, 2008).  Bacterial 
biofilms are microbial communities of physiologically and metabolically diverse cells 
attached to each other and a surface, encased in a matrix of extracellular polymeric 
substance (EPS), and formed by a highly regulated process, influenced by environmental 
and genetic factors (Archer et al., 2011).  
While not necessary for S. aureus biofilm formation, the presence of medical 
devices such as catheters, heart valves, stents, cosmetic, dental, and prosthetic implants, 
and additional indwelling devices allows S. aureus to persist in areas of the body in 
which it would not normally be able to colonize and cause diseases that are infinitely 
harder to treat (Costerton et al., 2005). Infections caused by S. aureus biofilms include 
urinary tract infections, endocarditis, peri-implantitis, osteomyletis, and other persistant 
infections. Implant mediated biofilm infections caused by non-S. aureus (non-coagulase 
staphylococci, Gram-negative bacilli) may be attempted to be treated by antibiotics (at 





aureus, the protocol in every hospital in the U.S is to remove the affected device (Mermel 
et al., 2009).     
Because the widespread use of antibiotics has contributed to the development of 
bacterial resistance and due to the inability of antibiotics to disperse and kill biofilm 
bacteria, alternative methods to combat biofilm-associated bacterial infections must be 
investigated. One promising technique is the use of endolysins, peptidoglycan hydrolases 
that are released by bacteriophages during the lytic cycle of viral infection (Nelson et al., 
2012). While naturally produced in the cytoplasm, resulting in lysis from the inside out, 
researchers have found that endolysins can be applied externally to the bacterial cell to 
achieve the same end goal. The canonical structure of an endolysin consists of an N-
terminal catalytic domain responsible for cleavage of a specific peptidoglycan bond and a 
C-terminal cell wall binding domain that interacts with a ligand on the bacterial surface. 
Endolysins display several traits that make them ideal for treatment of bacterial 
infections. The specificity for both cleavage site and binding site ensures that resistance is 
unlikely to be observed.  However, even if resistance were to develop, the modular 
domain architecture makes endolysins amenable to engineering efforts. 
Moreover, use of endolysins is a better option for treating biofilm-associated 
bacterial infections because the reasons for the ineffectiveness of antibiotics against 
biofilm bacteria do not apply to endolysins. First, the formation of a biofilm prevents an 
antibiotic from reaching its target, whereas endolysins can easily penetrate and can even 
be attracted to the bacterial cell surface (Keren et al., 2004). Second, the heterogeneous 
nature of a biofilm results in subpopulations of persister cells and metabolically inactive 





effective; however, endolysins are effective regardless of bacterial metabolic state or 
phase of growth. Antibiotics have even been shown to induce changes in planktonic 
bacteria that result in an increased propensity for forming biofilms (Kaplan et al., 2012), 
a phenomenon that does not occur upon application of endolysins (Gutierrez et al., 2014). 
We have previously identified and characterized PlyGRCS, the endolysin from 
the S. aureus bacteriophage GRCS, and have shown that it possesses activity against 
static S. aureus biofilms. This study is an in depth investigation into the further 
application of PlyGRCS as an anti-biofilm therapeutic.    
 
Materials and Methods 
Bacterial Strains  
All bacterial strains were routinely grown at 37°C. Staphylococcal strains were 
grown in trypticase soy broth (TSB) (Becton-Dickinson), or on TSB plates; S. aureus 
AH1350 was grown in TSB with 1000 µg/ml spectinomycin (TSBspec) for plasmid 
maintenance; Escherichia coli was grown in Luria Broth (LB) (Alpha Bioscience), or on 
LB plates, with 100 µg/ml ampicillin for plasmid maintenance. AH1350, a GFP 
derivative of RN4220, was a kind gift of Alex Horswill (via Mark Shirtliff). Unless 
otherwise denoted, all chemicals were obtained from Sigma and were of the highest 
purity available. 
 
Expression and Purification  
PlyGRCS was expressed and purified as in (Linden et al., 2015). Briefly, E. coli 





ampicillin. Arabinose (0.25%) was used for induction of expression for 4 hours at 37°C 
and then overnight at 18°C. Cells were harvested, lysed by sonication, and crude protein 
extracts were purified by a Bio-Scale Mini Profinity IMAC Cartridge (Bio-Rad).  
Fractions containing the desired protein were then pooled and dialyzed against PBS pH 
7.4 plus 300 mM NaCl and 0.25 mM CaCl2. 
 
Minimum Inhibitory Concentration 
Serial dilutions of PlyGRCS or antibiotics in PBS 1 mM CaCl2 were added to an 
equal volume of bacteria (100 µl) (overnight cultures diluted 1:10000 in 2X TSB (2X 
TSBspec for AH1350)). Samples were incubated at 37ºC overnight, and the MIC 
(minimum inhibitory concentration) was determined to be the lowest concentration of 
enzyme that allowed the medium to remain clear.   
 
Minimum Bactericidal Concentration 
Serially diluted PlyGRCS or antibiotics in PBS 1 mM CaCl2 or buffer control 
(100 µl) were added to an equal volume of bacteria (~105 CFU/ml). Samples were 
incubated at 37ºC for 60 minutes, then serially diluted, plated, and incubated overnight, 
whereupon CFU counts were obtained. While the MBC (minimum bactericidal 
concentration) is often defined as the lowest amount of antibacterial agent required to 
totally kill an organism, we define the MBC as the minimum concentration of enzyme 
that caused a 3 log (≥ 99.9%)  decrease in the amount of bacteria as compared to the 






Static Biofilm Eradication Assay 
For treatment of established static biofilms, aliquots of overnight S. aureus 
AH1350 cultures (1 ml per well) were placed into 24-well CELLBIND plates (Corning) 
containing 500 µl of TSBspec and 2.5 mM glucose. After allowing for formation of 
biofilms (24 hr), media was aspirated and samples were washed with PBS to remove 
unattached cells. PlyGRCS at indicated concentrations or controls were added in 1 ml 
PBS plus 0.25 mM CaCl2 and incubated at 37°C for one hour. Liquid was aspirated, at 
which point samples were imaged using the In Vivo Imaging System (IVIS) Lumina XR 
(Caliper Life Sciences/ Perkin Elmer).  Biofilms were washed with PBS and, after drying, 
were stained with 0.1% crystal violet for 10 min at room temperature. Upon removal of 
excess crystal violet, samples were washed with PBS and dried before the addition of 1 
ml 1% SDS to extract the crystal violet from the biomass for quantification at OD595 on a 
spectrophotometer. 
 
Microscopy of Static Biofilms 
For observation of cell death via fluorescent microscopy, static S. aureus AH1350 
biofilms were grown as described above for 24 hours in poly-L-lysine coated 8-well 
Nunc™ Lab-Tek™ Chambered Coverglass slides. Medium containing planktonic cells 
was discarded and the remaining biofilm-associated cells were washed with PBS, then 
treated with 200 µl PlyGRCS (100 µg/ml) in PBS with 0.25 mM CaCl2 or controls and 30 
µM propidium iodide (PI) for 15 min. Biofilms were examined with an Eclipse 80i 
fluorescence microscope with a 20x/1.3 objective lens (Nikon, Melville, NY, USA) using 





2000R camera with Q Capture Pro software (both from Q-imaging, Surrey, Canada). To 
quantify the viable cells, the mean fluorescent intensity of live (green channel) and dead 
(red channel) cell populations was calculated using NIS-Elements software (Nikon) and 
compared to a fluorescence calibration curve generated from a known ratio of live and 
dead cells stained with PI. 
For observation of biofilm degradation via confocal laser scanning microscopy, 
images were acquired using a Carl Zeiss 710 inverted microscope in combination with 
the Zeiss Argon laser scanning confocal imaging system. Images and z-stack analysis 
were obtained with a 20x/1.3 objective lens and analyzed by Zen 2010 digital imaging 
software (Carl Zeiss). In order to visualize the degradation of the biofilm matrix by 
PlyGRCS, S. aureus AH1350 biofilms were grown as described in 4-well Nunc™ Lab-
Tek™ Chambered Coverglass slides, coated with 0.1% gelatin, for 48 hours. Medium 
containing planktonic cells was discarded and the remaining biofilm-associated cells 
were washed with PBS, then treated with 1ml PlyGRCS (100 µg/ml) or oxacillin (100 
µg/ml) in PBS 0.25 mM CaCl2. Three dimensional image stacks were recorded at 
indicated times. 
 
Determination of Cell Death 
Static S. aureus AH1350 biofilms were grown as described above for 24 or 48 
hours on poly-L-lysine coated black 96 well plates, then were treated for 30 minutes with 
100 µl PlyGRCS (100 µg/ml) in PBS 0.25 mM CaCl2 or controls and 30 µM propidium 
iodide (PI). Fluorescence of live (530 nm) and dead (630 nm) cell populations was 





fluorescence calibration curve generated from a known ratio of live and dead cells stained 
with PI, the percentage of viable cells was obtained from the ratio of mean fluorescent 
intensities. 
 
Dynamic Biofilm Eradication Assay 
For treatment of established dynamic biofilms, the Stovall flow cell system was 
used, as per manufacturer instructions, with the flow cell chambers replaced by catheters 
(Excel International siliconized arteriovenous fistula, tube length 12”, tube i.d. 0.14”). An 
overnight culture of VISA NRS-14 was diluted 1:10 into fresh media (TSB with 2.5 mM 
glucose) and 3 ml was injected into each catheter via a 27 G syringe. The system was 
incubated statically for 1 hour to allow for adherence, after which flow was initiated and 
continued for 18 hours at 0.5 ml/min. PBS with 2.5 mM glucose and 0.25 mM CaCl2 was 
allowed to flow through the system for 20 minutes after which 3 ml PlyGRCS (1 mg/ml) 
in PBS with 2.5 mM glucose and 0.25 mM CaCl2 or controls lacking PlyGRCS were 
injected and incubated statically for 24 hours. Then, PBS with 2.5 mM glucose and 0.25 
mM CaCl2 was flowed at 0.5 ml/min for 20 minutes. For quantification of bacteria 
survival after treatment, catheters were sonicated to disrupt biofilm, then were flushed 
and samples were serially diluted, plated, and incubated overnight, whereupon CFU 
counts were obtained. 
 
Biofilm Induction/Inhibition Assays  
Two-fold serially diluted PlyGRCS in PBS and 0.25 mM CaCl2 (100 µl) or 





well CELLBIND plates (Corning).  Samples were incubated at 37°C overnight after 
which liquid was aspirated and biofilms were stained with crystal violet as described 
above.  
  
PlyGRCS Toxicity on MAC-T Cells 
MAC-T bovine mammary epithelial cells were grown in a 2 well chamber slide in 
DMEM-F12 and 10% FBS until 80% confluent. Media was removed and cells were 
washed 3X with HBSS. Serum-free media with 1 µg/ml PI (1 ml per well) and PlyGRCS 
(100 µg/ml) or 0.02% Triton X 100 was added and cells were incubated for 30 minutes at 
37 ºC. Samples were washed with HBSS and cells were fixed with 4% PFA at room 
temperature for 15 min. Samples were mounted with Prolong Gold DAPI antifade and 
imaged on an Eclipse 80i fluorescence microscope with a 20x/1.3 objective lens (Nikon, 
Melville, NY, USA) using an X-cite 120 illuminator (EXFO, Quebec, Canada).     
 
Biofilm Formation of S. aureus on MAC-T and Treatment  
MAC-T cells were grown until 100% confluent as described above in an 8 well 
chamber slide (approximately 10
6
 cells in each well). Media was removed and cells were 
washed with HBSS. DMEM/F12 with 10% FBS (500 µl) and 5 µl DAPI was added to the 
wells and incubated for 30 min at 37 ºC. Media was removed and samples were washed 
with HBSS. An overnight culture of  S. aureus AH1350 diluted 1:100 in  DMEM-F12 
with 10% FBS and 1 mg/ml spectinomycin and 500 µl was added to the wells and 
incubated for 1 hour at 37 ºC to allow for attachment   Media was removed and samples 





and 1 mg/ml spectinomycin was added to the wells to allow biofilm formation for 5 hours 
at 37 ºC. Media was removed and samples were washed with HBSS. DMEM/F12 with 1 
mg/ml spectinomycin and 1 mg/ml PlyGRCS (or no PlyGRCS control) was added to the 
wells and one section in the center of the wells was imaged on a Carl Zeiss 710 inverted 
microscope in combination with the Zeiss Argon laser scanning confocal imaging system 
at several time points. At the end of the experiment, the supernatant was plated, along 
with bacteria recovered from a wash step. The remaining adherent biofilm bacteria were 
plated after treatment with Triton X 100 (.025%) and Trypsin (.25%) to remove the 
MAC-T cells from the wells.   
 
Results 
Minimum Inhibitory and Bactericidal Concentration 
To set a benchmark for PlyGRCS activity against S. aureus, the minimum 
inhibitory concentration for endolysin and antibiotics was determined. It was found that 
planktonic S. aureus (MSSA, MRSA, and VISA) are susceptible to both traditional 
commonly used antibiotics and PlyGRCS at concentrations ranging from 128-256 µg/ml 
(Table 3-1). Of note, due to the mass differences between antibiotics and PlyGRCS (~29 
kDa), on a molar basis of comparison, 20-85X more antibiotic than PlyGRCS would be 
needed at comparable molar concentrations.    
Because of the speed at which endolysin activity occurs, the minimum 
bactericidal concentration (MBC) may be a more accurate measurement of antimicrobial 
efficacy (Kusuma and Kokai-Kun, 2005). Significantly, at only 16 µg/ml, the MBC for 





Table 3-1. Antimicrobial susceptibility.  
Strain Minimum Inhibitory Concentration 
 PlyGRCS PEN OXA VAN CAM 
 29.3 kDa .34 kDa .40 kDa 1.45 kDa .32 kDa 
      
AH1350 >256 µg/ml >64 µg/ml (R) .125 µg/ml 2 µg/ml 4 µg/ml 
 >8.74 µM >188.24 µM .312 µM 1.38 µM 12.5 µM 
      
NRS-14 128 µg/ml .5 µg/ml .5 µg/ml 4 µg/ml (I) 4 µg/ml 
 4.37 µM 1.47 µM 1.25 µM 2.76 µM 12.5 µM 
      
ATCC27217 128 µg/ml <.0625 µg/ml (S) .125 µg/ml 1 µg/ml 8 µg/ml 
 4.37 µM <.183 µM .312 µM .690 µM 25 µM 
      
NRS-71 256 µg/ml 64 µg/ml (R) >64µg/ml (R) 1 µg/ml 2 µg/ml 
 8.74 µM 188.24 µM 160 µM .690 µM 6.25 µM 
      
 
The minimum inhibitory concentration (MIC) obtained for PlyGRCS and indicated 










determined during the same time frame (Fig. 3-1). This is indicative of the quick 
bactericidal and lytic activity of endolysins. 
 
Disruption of Static Biofilms 
Having determined that PlyGRCS possesses inhibitory and bactericidal activity 
against planktonic S. aureus, we wished to evaluate its efficacy against bacteria in the 
biofilm mode of growth. After one hour of treatment, PlyGRCS at even the lowest dose 
tested (6.25 µg/ml), was able to disrupt static biofilms as visualized by both fluorescent 
imaging using IVIS and crystal violet staining (Fig. 3-2). Importantly, PlyGRCS was 
more effective than even a high dose of oxacillin, even though AH1350 is a methicillin- 
sensitive S. aureus and indeed was inhibited by approximately 1000X less oxacillin in the 
MIC assay. Notably, the PlyGRCS doses needed for biofilm disruption were less than the 
MIC and MBC for this strain (both of which could not be achieved at 256 µg/ml, the 
maximum concentration tested for this strain).  
After observation of biofilm disruption at the macroscopic level, we assessed the 
ability of PlyGRCS to destroy the three dimensional structure of the biofilm matrix by 
confocal laser scanning microscopy (Fig. 3-3). Upon treatment with PlyGRCS, the 
fluorescence decreased over time (a middle slice is shown as a representative image), and 
visualization of the entire Z-axis showed diffusion of the fluorescence away from the 
structured biofilm as early as 15 minutes post-treatment, indicating that the biofilm was 
being degraded and perhaps that lysis was occurring. At 30 minutes, the biofilm 
superstructure was completely degraded. In contrast, treatment with oxacillin resulted in 








Figure 3-1. Bactericidal activity of PlyGRCS. PlyGRCS kills S. aureus in a dose 
dependent manner.  The minimum bactericidal concentration (16 µg/ml) against S. 
aureus NRS-14 was determined after incubating endolysin and bacteria for 1 hour. Error 




























































Figure 3-2. Removal of static biofilms by PlyGRCS. Disruption of S. aureus AH1350 
biofilms can be visualized by measuring (A) fluorescence via IVIS or (B) crystal violet 
staining.  Error bars represent the standard deviation, and all experiments were done in 
triplicate. Statistical analysis was performed by unpaired t test. ** P < 0.01. 
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Figure 3-3. Degradation of staphylococcal biofilms. Confocal microscopy (200X 
magnification) shows the complete disruption of S. aureus AH1350 biofilms upon 
addition of (A) PlyGRCS (100 µg/ml), while (B) oxacillin (1000X MIC) does not disturb 
the structure. 
5 min 0 min 15 min 
30 min 60 min 120 min 
A 
B 





Killing of S. aureus in Static Biofilms  
The limits of crystal violet staining and biofilm disruption assays are that these 
techniques only allow for the determination of biomass. As the previous assays only 
established that PlyGRCS was able to disrupt static biofilms, we wished to determine if 
the bacteria in the biofilm were actually being killed or if the structural integrity was 
simply being destroyed. To this end, we assessed the killing ability of PlyGRCS in S. 
aureus biofilms, by staining with propidium iodide (Fig. 3-4A). Prior to treatment, 
biofilms were mostly green, indicating viable bacteria; however dead cells, visible by red 
staining by propidium iodide, naturally occur in a low but measurable frequency in 
biofilm populations. When biofilms were treated with 100 µg/ml oxacillin, the percentage 
of viable bacteria did not decrease when compared to control biofilms as quantified by 
fluorescent signals; in contrast, 100 µg/ml of PlyGRCS was able to eliminate ~60% of 
the bacteria in 24 hour biofilms and ~30% of the bacteria in 48 hour biofilms. We were 
also able to visualize this phenomenon microscopically (Fig 3-4B); control biofilms were 
composed predominately of viable bacteria, with few dead cells, while biofilms that were 
treated with PlyGRCS were mostly removed from the surface and most of the cells that 
did remain attached were killed on contact.   
 
Treatment of Dynamic Biofilms  
The environment in which a biofilm forms is often not static, but rather involves a 
dynamic flow, especially in medical devices. Importantly, these dynamic biofilms are 
much harder to eradicate due to the increased shear force exerted upon them (Shaw et al., 






















Figure 3-4. Killing of bacteria in staphylococcal biofilms. PlyGRCS kills S. aureus 
AH1350 grown in static biofilms as visualized by (A) spectrophotometric readout of 
fluorescence and (B) fluorescent microscopy. Live cells are green (GFP) and dead cells 
are red (propidium iodide). Overlay image is shown on the right and brightfield image is 
shown on the left. Images were obtained at 200X magnification. Error bars represent the 








































in a medically relevant setting, we constructed a modified Stovall flow cell system to 
include catheters. S. aureus biofilms were grown in the catheters under flow for 18 hours, 
then treated with PlyGRCS for a dwell time of 24 hours, after which the detached 
biofilms were flushed out of the catheter and the remaining attached bacteria were 
quantified.  PlyGRCS was able to efficiently remove on average 10
3
 cfu/ml (Fig. 3-5). 
This is the first reported use of an endolysin against a dynamic staphylococcal biofilm 
grown in a medical grade device. 
 
Biofilm Prevention 
Important considerations when using a typical antimicrobial treatment are the 
notions that a subpopulation of persister cells may be selected and biofilm formation may 
be induced. Notably, antibiotics have been shown to be ineffective towards preventing 
biofilms or may actually induce biofilm formation. To determine if PlyGRCS would 
induce biofilm formation, S. aureus were exposed to sub-MIC concentrations of 
PlyGRCS and then assessed for their ability to form biofilms. When S. aureus was 
allowed to form biofilms in the presence of low concentrations of oxacillin or penicillin, 
an increase in the amount of biomass was observed (Fig. 3-6). Treatment with 
vancomycin slightly decreased the amount of biofilm formation at very low 
concentrations; however, approaching the MIC caused a slight upward trend in biofilm 
formation (a phenomenon observed with other VISA strains). In contrast to the increase 
in biofilm formation observed when S. aureus was incubated with select antibiotics, 






















Figure 3-5. Eradication of dynamic biofilms.  (A) Schematic of biofilm flow setup 
(Sternberg and Tolker-Nielsen, 2006). Arrow indicates direction of flow. (a) Input media 
(b) Peristaltic pump (c) Bubble trap (d) Catheter (e) Waste (B) Lock treatment with 
PlyGRCS removes S. aureus NRS-14 biofilms formed in a catheter under flow conditions 
as measured by the amount of bacteria recovered from the catheter after a 24-hour 
incubation. Error bars represent the standard deviation, and all experiments were done in 








































Figure 3-6.  Biofilm behavior in the presence of sub-inhibitory concentrations of 
antimicrobials.  Biofilm formation was induced in the presence of low concentrations of 
typical antibiotics, such as oxacillin (top left), penicillin (top right), and vancomycin 
(bottom left), while PlyGRCS (bottom right) prevents the formation of S. aureus NRS-14 
biofilms, as shown by crystal violet staining. Error bars represent the standard deviation, 




























































































































PlyGRCS Interaction with MAC-T Cells and Removal of Biofilms 
In addition to formation of biofilms on abiotic material, the ability of S. aureus to 
form biofilms directly on the epithelium led us to question whether PlyGRCS could also 
be an effective treatment in this scenario. First, to ensure the safety of PlyGRCS on 
eukaryotic cells, we incubated the endolysin and MAC-T bovine epithelial cells and 
assessed the membrane integrity. PlyGRCS-treated MAC-T cells did not show any 
propidium iodide staining, indicating that their membranes had not been compromised by  
the addition of the enzyme (Fig. 3-7). Finally, we determined the ability of PlyGRCS to 
eliminate S. aureus biofilms that had been formed on MAC-T cells.  As visualized by 
confocal microscopy, there was a marked reduction in the amount of green fluorescence, 
indicating that the bacteria expressing GFP were being lysed (Fig. 3-8). Quantification of 
S. aureus from the PlyGRCS-treated samples showed an approximately 1 log reduction 
as compared to the untreated biofilms.             
 
Discussion 
In the age of increasing resistance to traditional antibiotics, identifying the next 
generation of antimicrobial agents, such as endolysins, is a crucial and pressing matter. 
Furthermore, the inability of antibiotics to be effective against bacteria in biofilms 
highlights the importance of finding alternative therapeutics. Even more alarming, is that 
the recommended treatment for infections caused by implant-mediated S. aureus biofilms 
is removal of the device, which is clearly not an acceptable solution.   
 In this study, the endolysin PlyGRCS successfully demonstrated biofilm 


















Figure 3-7. PlyGRCS interaction with eukaryotic cells. PlyGRCS-treated MAC-T 
bovine epithelial cells (nuclei stained with DAPI) do not show membrane 
permeabilization (bottom left panel), while the Triton X 100-treated control shows 
compromised cell membranes, as evidenced by red propidium iodide staining (bottom 
right panel).  Brightfield images are shown in the top panels. Images were obtained at 








































Figure 3-8. PlyGRCS treatment of S. aureus biofilms on MAC-T cells. (A) Confocal 
microscopy (maximum intensity projections) showing the reduction of biofilm bacteria 
(S. aureus AH1350-GFP) after treatment with PlyGRCS. MAC-T nuclei are stained with 
DAPI (blue). Images were obtained at 200X magnification. (B) Quantification of S. 
aureus recovered after treatment with PlyGRCS vs. PBS. Bacteria were taken from the 
supernatant (sup), after two washes (wash), and still adhered to the MAC-T cells 
(adherent).  Error bars represent the standard deviation, and all experiments were done in 







































be a property shared by other endolysins, the endolysin dosage used in this study 
demonstrates that the efficacy of PlyGRCS is comparable to or better than other 
published staphylococcal endolysins (Drilling et al., 2016; Fenton et al., 2013; Gilmer et 
al., 2013; Gutierrez et al., 2014; Jun et al., 2013).  As of yet, the only in vivo applications 
of endolysins against staphylococcal biofilm related infections are Ply187, which reduced 
the intravitreal bacterial load and attenuated symptoms of endophthalmitis,  and chimeric 
endolysins λSA2-E-Lyso-SH3b and λSA2-E-LysK-SH3b, which reduced bacterial counts 
in a mouse model of mastitis (Schmelcher et al., 2012c; Singh et al., 2014); our initial in 
vitro work shows that PlyGRCS has promise to succeed in utilization in a biofilm 
infection model.   
Importantly, PlyGRCS was able to efficiently remove staphylococcal biofilms 
formed in a catheter under dynamic conditions representative of a medically relevant 
scenario. During attempts to remove implant mediated non-S. aureus biofilms from 
infected patients, healthcare practitioners may utilize antimicrobial lock therapy, in which 
the affected device is filled with highly concentrated antibiotic and closed off for up to 48 
hours, after which the solution is removed, hopefully removing the biofilm along with it; 
however it is not always effective (40-70% catheter salvage rate, depending on the 
organism), and as mentioned the first line of action against implants containing S. aureus 
biofilms is to bypass ALT and just remove the implant (Justo and Bookstaver, 2014; 
Poole et al., 2004). The ability of lock therapy using PlyGRCS to remove dynamically 
formed S. aureus biofilms from a catheter represents a major breakthrough in treatment 





 As S. aureus can form biofilms in the absence of a medical device, and these 
biofilms are implicated in both human and animal infections such as mastitis, having a 
safe and efficacious treatment for such infections is necessary. PlyGRCS activity was 
displayed not only against biofilms grown on abiotic surfaces, but also on a monolayer of 
bovine epithelial cells. Importantly, this activity was specific against the bacteria and did 
not harm the eukaryotic cells. While no adverse effects have been observed in animal 
models so far, the rapid bacteriolytic activity of endolysins may require some fine-tuning 
of dosage before use in the clinic, especially in bloodstream related infections, as a 
sudden influx of proinflammatory cellular debris (teichoic acids, lipoteichoic acids, 
toxins, and peptidoglycan) could lead to life-threatening complications, such as septic 
shock and multiple organ failure (Nau and Eiffert, 2002). However, for decolonization of 
the skin as a prophylactic measure before surgery or on a cow’s udder before milking, the 
fallout from a lytic therapy may be less severe. As one of the four major causative agents 
of bovine mastitis, S. aureus biofilms play a major role in chronic intramammary 
infections that result in significant losses for the dairy industry, and as a result, a viable 
anti-biofilm agent is critically needed (Oliveira et al., 2007).     
While biofilms are clearly a problem in the medical field, the formation of 
biofilms on food and food processing equipment represents a major safety issue in the 
food industry. Food-borne illness caused by S. aureus results in hundreds of thousands of 
emergency room visits per year and economic losses in the billions of dollars from recalls 
and healthcare related costs (Kadariya et al., 2014). Additionally, biofilms on food 
processing equipment can interfere with proper function by impeding liquid flow and 





losses due to machine repairs and downtime. The current chemical cleaners and 
disinfectants are not 100% effective, need to be completely removed from surfaces after 
use, and furthermore, a shift toward “green” biological products is underway. In fact, 
bacteriophage preparations against Listeria, E. coli, and Salmonella are already labelled 
GRAS (do not need to be removed from equipment and food after use and can be 
consumed by humans) and are being utilized in food processing facilities (Sharma, 2013). 
The fact that endolysins, including PlyGRCS, can remove bacterial biofilms from 
surfaces indicates that they too can find an application in this industry.        
PlyGRCS is a robust enzyme and has many beneficial properties that warrant 
further investigation into development of this enzyme as a potential antimicrobial agent 
against staphylococcal biofilms. Future studies should be performed to determine the 
synergistic ability of PlyGRCS with other endolysins and antibiotics. Engineering 
approaches to enhance PlyGRCS activity should also be performed to increase 
thermostability properties for long-term storage, augment catalytic activity, or modulate 
binding to allow for a greater turnover rate. Finally, in vivo activity analysis of PlyGRCS 
in animal models of (implant-mediated) biofilm formation should be conducted. 
The use of endolysins provides a more effective treatment for bacterial biofilm 
infections than antibiotics. The usage of sub-inhibitory concentrations of many antibiotics 
has been shown to enhance staphylococcal biofilm formation, thought to be mediated by 
an overall stress response, whereas the quick acting lytic activity of endolysins does not 
allow time for such a response to be mounted (Poole, 2012). We have shown here that 
PlyGRCS is actually inhibitory to biofilm formation. Endolysins also have a potential 





prolong the use of these enzymes. Additionally, they may breathe new life into dying 
antibiotics, in a combinatorial therapy approach, where the endolysin would provide the 
initial disturbance to the biofilm structure, providing the antibiotic access to now 
susceptible target bacteria (Schuch et al., 2014). Most importantly, no research has been 
able to demonstrate the development of bacterial resistance; PlyGRCS may be even more 
refractory to resistance as it has two catalytic activities despite its single catalytic domain 
(Linden et al., 2015). Additionally, as antibiotics can only be utilized during an active 
infection (and are ineffective against biofilms anyway) and not for decontamination of an 
abiotic surface, having an agent such as an endolysin that can have a two-pronged 
application as a medical therapeutic and a surface disinfectant represents a superior 
antimicrobial option.   
In conclusion we show that PlyGRCS displays specific bacteriolytic activity 
against S. aureus biofilms, indicating that this endolysin has the potential to be utilized as 
a skin decolonizing agent to prevent nosocomial and livestock-associated infections, a 
treatment for (implant-mediated) biofilm infections, and decontamination of food and 
















Chapter IV: Unpublished Dissertation-Related Data  
Introduction 
The previous two chapters represent our current understanding of the biochemical 
and biophysical characteristics of PlyGRCS, as well as its anti-biofilm behavior. 
However, this is only the beginning in our comprehensive knowledge of and 
experimentation on this endolysin. Toward our ultimate goal of utilizing PlyGRCS as a 
therapeutic against S. aureus infection, we have begun in vivo testing, as well as 
engineering experiments aimed at optimizing its activity. The unpublished, preliminary 
results from these studies are presented in this chapter.   
The dearth of new traditional antibiotics, along with rising antimicrobial 
resistance rates highlights the application of endolysins as alternative antibacterial 
therapeutics. Because of the approximately 150,000 cases of S. aureus bacteremia per 
year in the U.S. alone, resulting in a 20% morbidity rate, this type of infection represents 
an opportunity to benefit from endolysin treatment (van Hal et al., 2012). However, to 
date, there have been few in vivo studies on endolysin treatment of S. aureus bacteremia 
(Gilmer et al., 2013; Gu et al., 2011a; Jun et al., 2013; Schmelcher et al., 2015; Schuch et 
al., 2014) . Importantly, the only endolysin that has attempted and completed Phase I 
clinical trials in the U.S. is CF-301 (Gilmer et al., 2013; Schuch et al., 2014). ContraFect 
Corporation intends to utilize this endolysin as a treatment against S. aureus bloodstream 
infections. However, all of the mouse experiments on this endolysin (and all other S. 
aureus endolysins, except for Sal-1) utilize an intraperitoneal infusion of both the 
bacterial load and the endolysin treatment. While some of the ip infused components 





model, as the peritoneal cavity provides a buffer of protection, not allowing the rapidly 
lysed components to quickly circulate in the bloodstream and cause a massive cytokine 
storm (Nau and Eiffert, 2002). In the clinic, the endolysin treatment would be 
administered intravenously, and therefore the dosage has to be completely verified using 
the same method in the mouse model. In fact, during the phase I clinical trial, human 
patients were given CF-301 over a single 2- hour intravenous (iv) infusion, and no major 
adverse events were observed (Cassino et al., 2016). However, as this was in the absence 
of an active S. aureus infection and there have been no mouse studies conducted on iv 
infusion of both CF-301 and S. aureus, so it is unknown what may happen when bacteria 
and this endolysin meet in the bloodstream. Alarmingly, the planned dose of CF-301 for 
phase II trials is 0.25 mg/kg, which resulted in a 100% death rate of mice within 18 hours 
when S. aureus and CF-301 were infused ip. To more accurately represent the real world 
application of an endolysin treatment against S. aureus septicemia, we have decided to 
use a mouse model in which both bacteria and endolysin are administered intravenously.               
While we felt that the potent activity of PlyGRCS warranted pursuing in vivo 
studies utilizing the native enzyme, we also wanted to subject PlyGRCS to 
chimeragenesis to see if we could create an endolysin with improved efficacy. 
Engineering endolysins through chimeragenesis has proved to be an easy (due to the 
modular architecture of these enzymes) and effective technique of modification 
(Schmelcher et al., 2012a). Chimeric endolysins have been constructed to display 
characteristics such as increased catalytic activity, modified cleavage specificity, altered 
binding (strength and target), enhanced solubility and thermostability, and other desirable 





Schmelcher et al., 2011). Because the PlyGRCS CHAP domain already displayed such 
potency due to its dual catalytic activities, the SH3b CBD was chosen for replacement. 
All other staphylococcal endolysins possess SH3b domains, except for the ΦNM3 
endolysin; thus, the ΦNM3 CBD was chosen as the desired replacement domain (Bae et 
al., 2006). The ΦNM3 CBD lacks homology to any annotated domains in the database, 
but has been shown to specifically bind S. aureus and has been successful in previous 
chimeragenesis experiments (Daniel et al., 2010; Pastagia et al., 2011; Yang et al., 2014a; 
Yang et al., 2014b). Furthermore, the substrate for the staphylococcal SH3b binding 
domain is predicted to be the pentaglycine crossbridge of the S. aureus peptidoglycan, 
and exposure of S. aureus to the SH3b containing lysostaphin has been shown to select 
for lysostaphin-resistant mutants with altered crossbridges  (Grundling and Schneewind, 
2006; Stranden et al., 1997). While the ΦNM3 CBD epitope is unknown, desire to steer 
away from a binding domain that may induce resistance prompted us to investigate this 
alternative CBD. We felt that these engineering efforts might result in an endolysin with 
enhanced activity or other improved characteristics. 
 
Materials and Methods 
Murine Bacteremia Model 
 PlyGRCS was purified as previously described (Linden et al., 2015), with an 
added 0.1% Triton X-114 purification step after application of lysate to the column for 
removal of endotoxin (Reichelt et al., 2006). Therapeutic treatment after septicemia 





Lake, NY). As per the protocol, 8 week-old C57Bl6 female mice were obtained from 
Jackson Laboratories (Bar Harbor, ME) and acclimatized to the facility for two weeks. 
Mice were handled according to all applicable institutional, state, and Federal animal care 
guidelines under animal care protocols approved by the Institutional Animal Care and 
Use Committee (IACUC). Mice were injected intravenously with approximately 5x10
7
 
CFU of S. aureus (ATCC 27217), an LD90, which induced septicemia and death in mice 
after 2 to 3 days. Thirty minutes after infection the first group of mice was injected 
intravenously with 200 µl of the control vehicle (PBS) and the second group was injected 
with 200 µl of the therapeutic compound (PlyGRCS 200 µg/ml).  Mice were monitored 
twice daily for weight loss and clinical signs defined as follows: 
0 = no visible signs of disease 
1 = slight ruffling of fur 
2 = ruffled fur, reduced mobility 
3 = ruffled fur, reduced mobility, rapid breathing 
4 = ruffled fur, minimal mobility, huddled appearance, rapid and/or labored breathing 
5 = death/euthanize 
Animals displaying moribund signs were humanely euthanized and recorded as dead on 
that particular day. All animals found dead in the cage were recorded as dead on that day. 
Mice, once infected, were monitored twice daily for weight changes and euthanized 
immediately if they became recumbent, failed to move upon stimulation, exhibited an 
inability to eat or drink, or if they lost >20% of their initial body weight as stipulated and 
approved in the IACUC application 15-002. All surviving animals from the study were 





cervical dislocation in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institute of Health.  
 
Chimeragenesis of PlyGRCS 
 The ΦNM3 CBD was cloned into pBAD24 from pET21-CBDΦNM3 using the 
primers CBDΦNM3-F (5’GGGTCTAGAATCGGCAAATCAGCAAGC3’) and CBDΦNM3-
R (5’GGGAAGCTTTTAATGATGATGATGATGATGAAAAACTTCTTTCAC3’), and 
thus named pBAD-CBDΦNM3. The PlyGRCS CHAP domain with a linker region was 
then cloned from pBAD24-PlyGRCS using the primers CHAP-F 
(5’GGGGAATTCATTATGAAATCACAACAACAAGCAAAAGAATGGATATA3’) 
and CHAPlink-R (5’TCTAGAGTTTTGTTTCCAATTTCC3’), and subcloned into 
pBAD24-CBDΦNM3 using the restriction enzymes EcoRI and XbaI, making the final 
chimeric construct (pBAD24-CHAPGRCS-CBDΦNM3. All clones were confirmed by 
sequence analysis (Macrogen, Rockville, MD). Protein was expressed, purified, and 
tested for activity via the turbidity reduction assay and bactericidal assay, as previously 
described (Linden et al., 2015).  
 
Results 
In vivo Efficacy of PlyGRCS 
 Having validated the antimicrobial activity of PlyGRCS in vitro, we wished to 
determine if this endolysin would provide protection against an active infection in an 





injected with an intravenous bolus of enzyme and monitored for adverse effects over 
several days. Mice did not display any outwardly visible intolerance towards PlyGRCS. 
Next, mice were challenged in a model of S. aureus septicemia (Fig. 4-1). After 60 hours, 
90% of the mice that were left untreated had died, while PlyGRCS treatment resulted in 
rescuing 30% of the mice. While these results were non-significant, these initial 
experiments are encouraging for the further development of PlyGRCS as a therapeutic 
against S. aureus infections.      
       
Lytic Activity of PlyGRCS Chimera  
 The activity of the PlyGRCS chimera (CHAPGRCS-CBDΦNM3) was first compared 
to that of the WT endolysin via the turbidity reduction assay. On all S. aureus strains 
tested, CHAPGRCS-CBDΦNM3 displayed lytic activity; however, somewhat 
disappointingly, it did not perform as successfully as WT PlyGRCS (Fig. 4-2A-B). 
Interestingly, both enzymes displayed preferences for the same strains, indicating that it 
is in fact the change in binding domains that caused the difference in activity.        
 Next, the bactericidal capability of CHAPGRCS-CBDΦNM3 was assessed.  It was 
determined that 32 µg/ml of endolysin reduced the bacterial count of VISA NRS-14 by 1 
log in 1 hour (Fig. 4-2C). In comparison, only 2 µg/ml PlyGRCS resulted in the same 
bactericidal activity and increasing the dosage to 32 µg/ml caused a ~3.5 log reduction in 
CFU. As experimental conditions were optimized for the WT enzyme, the weaker 
activity of the chimera could be attributed to necessitating variable buffer components for 
enhanced activity. Further optimization of both conditions and enzyme are ongoing, as 







Figure 4-1. In vivo efficacy of PlyGRCS. Mice were injected intravenously with S. 
aureus (ATCC 27217), followed by PlyGRCS or control (PBS), and evaluated for 
survival (n=10 per group).  PlyGRCS was effective at rescuing 30% of the mice from 
death induced by S. aureus bacteremia after 3.5 days. Data was analyzed using Kaplan-















































































































Figure 4-2. Comparison of PlyGRCS WT and chimera. (A) Turbidity reduction assay 
analysis of PlyGRCS WT and chimera (16 µg/ml) against multiple strains of S. aureus. 
(B) Turbidity reduction assay showing dose response of PlyGRCS WT and chimera 
against S. aureus NRS-14 (C) Bactericidal activity of both endolysins against S. aureus 
























 The experiments in this chapter represent an initial foray into further 
understanding PlyGRCS and important first steps into implementing PlyGRCS as a 
therapeutic option. However, there are many more experiments to perform, 
troubleshooting to undertake, and challenges to overcome before getting to this next 
level.  
Although endolysin therapy possesses many attributes that make it preferred over 
treatment with traditional antibiotics, it also could have some potential drawbacks. The 
first is the nature of endolysin therapy. The fact that this treatment is a lytic therapy may 
prove to be a challenge, especially if we wish to use it directly in the bloodstream to 
combat S. aureus-induced bacteremia. Indeed, the lower success rate of our mouse model 
when compared to other models may be due to the more real-world application of 
intravenous infusion (Schmelcher et al., 2015; Schuch et al., 2014). To study if death was 
caused by the bacteremia or the fallout from the immense amount of bacterial lysis, 
future experiments will include pathology analysis of the organs, as well as an 
investigation of the immune response. If these results show that mice are dying from the 
massive release of bacterial cell components, a lower dose or interval dosing of endolysin 
may need to be used in order to avoid such a robust response. Intravenous infusion of 
PlyGRCS also paves the way for future pre-investigational new drug enabling studies, 
such as safety, tolerability, and pharmacokinetics/pharmacodynamics (Cassino et al., 
2016). Alternatively, targeting other S. aureus-associated diseases may prove to be a 
better route than attempting to pursue a treatment for bloodstream infections. Endolysins 





treating wounds, and decreasing the bacterial load in mastitis infections, and PlyGRCS 
may perform better in one of these models (Pastagia et al., 2011; Rashel et al., 2007; 
Schmelcher et al., 2012c).                     
 Another potential problem with using endolysins is the emergence of resistant 
mutants. While several studies have compared the abilities of both antibiotics and 
endolysins to select for resistant bacteria and results have shown a lack of endolysin-
resistant mutants, this does not mean it is impossible for endolysins to induce resistance 
(Gilmer et al., 2013; Pastagia et al., 2011). Futhermore, the use of lysostaphin, which 
contains a similar SH3b binding domain, has been shown to select for lysostaphin-
resistant mutants, arising from modification of the pentaglycine crossbridge (Climo et al., 
1998). While we have not shown that the SH3b binding domain of PlyGRCS interacts 
with the pentaglycine crossbridge, the possibility that this potential target could be 
modified is cause for concern.        
 In contrast to antibiotics, the ability of endolysins to elicit an immune response 
along with their short half-lives could be additional downsides. Although endolysins have 
been shown to generate antibodies, these antibodies are non-neutralizing and therefore do 
not affect the efficacy of the endolysins (Loeffler et al., 2003). Additionally, these 
antibodies did not cause anaphylaxis or other adverse effects in healthy subjects. 
However, the production of a hyperimmune response in some individuals could result in 
a potentially deadly scenario, so patients will have to be carefully screened to ensure the 
safety of using endolysins in their treatment. The short half-life of endolysins (about 20 
minutes, comparable to other proteins) means that multiple doses would need to be used 





suggested that PEGylation, which has been used to increase the half-life of other 
biological molecules, be applied to endolysins; however, addition of PEG severely 
reduced the activity of Cpl-1 (Resch et al., 2011a).  Excitingly, dimerization of Cpl-1 
both increased its activity and half-life, indicating that this approach may be successful 
for overcoming fast clearance of other endolysins (Resch et al., 2011b).         
 Lastly, the extreme specificity of endolysins as compared to antibiotics could be 
viewed as a negative. In many cases, there is not enough time to identify a pathogen, so a 
broad-spectrum antibiotic is necessarily utilized. While many researchers are currently 
devising methods to more quickly identify bacteria, the current turn-around time of 1-2 
days could mean life or death for some individuals. Having to wait to identify the species 
that is causing an infection to determine which endolysin to use for treatment could lead 
to a preference for antibiotics over endolysins.         
In our efforts to create an endolysin against S. aureus with an atypical binding 
domain, we unfortunately resulted in producing a chimera with less activity than the 
wild-type. However, this does not mean that this chimeric derivative has no future 
application. In fact, endolysins with varying levels of in vitro activity have shown equal 
levels of in vivo activity (Schmelcher et al., 2015). Furthermore, the chimeric endolysins 
ClyS and ClyH, which share the ΦNM3 binding domain, have shown great efficacy in 
multiple in vivo applications (Daniel et al., 2010; Pastagia et al., 2011; Yang et al., 
2014b). Similar doses of ClyH and the chimeric PlyGRCS showed similar results in the 
turbidity reduction assay, and ClyH protected 100% of mice in a MRSA model of 
infection, indicating the same could be achieved with our endolysin. ClyS, at a dose of 





µg) to reduce CFU counts by 1 log. Even so, ClyS went on to perform quite well in vivo, 
eliminating nasal colonization, protecting 85% of mice from death caused by a systemic 
MRSA infection, and reducing the bacterial counts on infected skin. In all, this indicates 
that the chimeric PlyGRCS, despite lower in vitro activity than the wild-type endolysin, 







































Chapter V: Discussion 
Summary of Dissertation 
S. aureus is a significant pathogen, with an arsenal of virulence factors, including 
the propensity to form biofilms. Currently, the emergence of antibiotic-resistant strains 
represents a major pharmaceutical challenge and societal burden, causing millions of 
deaths and illnesses. Thus, the urgent need for alternative antimicrobial approaches 
prompted us to investigate the use of a bacteriophage-encoded endolysin against S. 
aureus.  
PlyGRCS was derived from the bacteriophage GRCS, which had already shown 
activity against S. aureus in a mouse model of infection. We found that this endolysin 
was active under physiological conditions (pH and NaCl).  Activity was greatly enhanced 
by the addition of calcium, and sequence analysis showed the presence of three critical 
aspartic acid residues shown in other endolysins to complex this cation. PlyGRCS 
displayed lytic activity against all strains of S. aureus tested, including MRSA and VISA, 
and also against S. epidermidis. Assays were performed using stationary phase bacteria, 
indicating the potent activity of this enzyme; 16 µg/ml reduced the OD600 of VISA NRS-
14 by ~90% in 20 minutes and caused a 3 log decrease in CFU in 1 hour. PlyGRCS 
enzymatic activity was stable at temperatures up to 37°C; thermodynamic stability 
experiments showed cooperative unfolding of PlyGRCS with a Tm of 43.5°C. 
Several techniques were utilized to understand the mechanistic behavior of 
PlyGRCS. Fluorescence microscopy showed that the C-terminal SH3_5 domain 
specifically bound staphylococci, while the N-terminal domain was confirmed to be 





CHAP domain. Biochemical assays detected free amine release (indicative of 
amidase/endopeptidase activity) upon PlyGRCS treatment; mass spectrometry analysis 
determined that, despite the single catalytic domain, PlyGRCS was able to cleave two 
distinct sites in the peptidoglycan (between the N-acetylmuramic acid and L-alanine and 
between the D-alanine in the peptide stem and the glycine in the interpeptide bridge). 
As alternatives to traditional antibiotics, endolysins display the added benefit of 
activity against biofilms. PlyGRCS was able to disrupt static biofilms at concentrations 
much lower than the MIC, while antibiotics at 1000X MIC had no effect on biofilms. 
PlyGRCS not only disrupted these biofilms, but killed the bacteria within them as well. 
Additionally, PlyGRCS removed dynamic biofilms from medical grade catheters. 
Furthermore, unlike antibiotics, which were shown to promote biofilm formation, 
PlyGRCS prevented the formation of biofilms.    
To study the effects of PlyGRCS treatment in the presence of a eukaryotic system, 
we first established S. aureus biofilms on bovine mammary epithelial cells. PlyGRCS 
was able to remove and kill biofilms grown on these epithelial cells.  Importantly, 
PlyGRCS was non-toxic toward MAC-T cells. Our preclinical evaluation of PlyGRCS in 
a mouse model showed that intravenous application did not result in any adverse effects. 
A single treatment of PlyGRCS (200 µg/ml) was able to protect 30% of mice from death 
induced by S. aureus septicemia until day 3.5 post-infection.           
Lastly, we have begun subjecting PlyGRCS to chimeragenesis to create the most 
ideal endolysin. Engineering efforts showed that replacing the native SH3_5 domain with 
the ΦNM3 CBD resulted in an endolysin that was less active as measured by turbidity 





while 32 µg/ml of the chimeric CHAPGRCS-CBDΦNM3 was necessary to achieve the same 
effect.  However, it is well documented that in vivo efficacy of staphylococcal endolysins 
does not necessarily correlate with in vivo efficacy. Indeed, the endolysin 2638A 
performed poorly in several in vitro lytic and anti-biofilm assays, yet protected all mice 
in a lethal septicemia assay (Schmelcher et al., 2015). Thus, future in vivo testing will be 
needed to fully evaluate the chimeric CHAPGRCS-CBDΦNM3. 
In conclusion, we have shown that PlyGRCS has potent antimicrobial activity 
against planktonic and biofilm antibiotic resistant S. aureus. Our initial work on tissue 
cultured cells and in mice, along with the low likelihood of developing resistance due to 
its dual catalytic activities, specific binding, and the possibility of future engineering 
indicate that PlyGRCS is a promising alternative antibacterial agent for both human and 
animal uses.   
 
Discussion and Future Directions 
Therapeutic Potential 
The ultimate goal of this project was to investigate an endolysin against S. aureus 
that could eventually be used translationally as a new antimicrobial therapy. All in vitro 
experiments performed suggested that PlyGRCS would be a good candidate for in vivo 
testing. The preclinical trial in our mouse model of treatment against S. aureus septicemia 
indicated that PlyGRCS provides some protection; however, there is still obviously a 
long way to go before proceeding to human subjects.     
Despite this, we have already made some progress toward understanding how to 





surprisingly, mice that received endolysin treatment fared worse than mice that were left 
untreated; 8/10 mice died within the first 24 hours and the remaining two were moribund 
and had to be euthanized within the next 24 hours. Interestingly, the mice that received 
PlyGRCS displayed hind leg paralysis, an indication that they died due to septic shock.  
Our theory was that the PlyGRCS dosage used was too high, causing rapid lysis of 
bacteria too quickly, releasing cellular debris and triggering a massive inflammatory 
response ultimately resulting in death of the animals. The initial dosage we used was 
based on several other models of S. aureus bacteremia; however, the typical model for 
MRSA septicemia utilizes ip infusion of both bacteria and endolysin, thus providing a 
cavity of protection, preventing the majority of lysed components from entering the 
bloodstream and thereby not promoting as robust of a response. When we lowered the 
dose to 200 µg/ml, we were able to save 40% of the mice until day 3.5, supporting our 
theory. Therefore, more experiments need to be performed to optimize dosage of 
PlyGRCS. The dosage may need to be lowered even more or perhaps we could give 
multiple injections of a very low dose over an extended period to minimize the amount of 
bacterial lysis at one time. Another possibility is utilizing less bacteria to establish 
infection (LD50 instead of LD90), as there will be a lower amount of bacterial contents 
upon lysis. In fact, the only other example of intravenous endolysin treatment (Sal-1) of 
S. aureus septicemia utilized an amount of bacteria to give a lower mortality rate than 
what we used in our study (Jun et al., 2013). Alternatively, as S. aureus causes a wide 
variety of infections, PlyGRCS may perform better in a different model, such as in a 





 Based on our finding that PlyGRCS can remove dynamic biofilms from medical 
grade devices, an implant-associated biofilm model is also worth investigating. As of yet, 
there have been no in vivo studies on the use of endolysins to treat staphylococcal 
biofilms mediated by medical implants and only recently has a staphylococcal endolysin 
been tested and found effective against an in vitro dynamic biofilm (Becker et al., 2016). 
In fact, the only application of endolysin treatment against an implant mediated biofilm 
appears to be PlyF307, which reduced the A. baumanii load of indwelling subcutaneous 
catheters by 2 logs and destroyed much of the EPS (Lood et al., 2015). This seminal 
experiment indicates that other endolysins, including PlyGRCS, could efficaciously treat 
infections associated with medical devices. Directly treating the implant with an 
endolysin would be much desired over the alternative removal method. Our laboratory 
has acquired a Perkin Elmer In vivo Imaging System (Lumina XR), which we can utilize 
to monitor the infection and treatment in real time, making this both the first investigation 
of an endolysin against an implant-associated S. aureus infection and the first use of the 
IVIS to observe endolysin treatment of an implant mediated infection (Fenton et al., 
2010a; Kadurugamuwa et al., 2003).  
 In addition to the above mentioned experimental variables, adjusting the chemical 
formulation of the PlyGRCS treatment may improve in vivo efficacy. Sal-1, which bears 
about 50% identity in both its CHAP and SH3b domains to PlyGRCS, successfully 
protected mice from intravenously induced MRSA septicemia (Jun et al., 2013). The  Sal-
1 formulation included 10 mM CaCl2 for enchancement of activity; we have already 
included calcium in our PlyGRCS formula. However, the presence of calcium can be 





the difficulties observed in the in vivo experiments. The final formulation of Sal-1 
included stabilizing components 0.01 M L-histidine (pH 6.0), 5% (w/v) sorbitol, and 
0.1% (w/v) Poloxamer 188, the major contributor to stabilization. Before addition of 
these components, Sal-1 aggregation occurred after five minutes of agitation or two hours 
in storage at 4°C; in the presence of these elements, four hours of agitation was required 
to induce aggregation and the formulation was stable for eight weeks at 4°C, while 
maintaining activity. In this formulation, the first Good Laboratory Practice compliant 
safety evaluation of an endolysin, including general toxicology and safety pharmacology 
tests, determined that Sal-1 did not cause any adverse effects in dogs or rats (Jun et al., 
2014). If PlyGRCS stability is not enhanced by the Sal-1 formulation, there are 
alternative ingredients that may allow for an improved in vivo outcome. Other amino 
acids, poloxamers, and polyols display stability enhancing abilities and are commonly 
acknowledged by the pharmaceutical industry as acceptable and safe (Kamerzell et al., 
2011). Additionally, salts, hydrophilic polymers (PEGs, polysaccharides and inert 
proteins), and surfactants are all currently used as stabilizing components in protein 
therapeutic formulations. 
Finally, as in vitro experiments are not always the best indicators of in vivo 
efficacy, CHAPGRCS-CBDΦNM3, despite its lower activity in the turbidity reduction and 
bactericidal assays, may actually prove to be a better enzyme when placed into a mouse 
(Henry et al., 2013; Schmelcher et al., 2015). Furthermore, an enzyme that is less active 
in vitro might be more desirable in vivo, since it may avoid the massive bacteriolytic 







Obtaining structural knowledge helps us to better understand the function of a 
protein and also may pave the way for future design of improved enzymes. As of yet, 
only two S. aureus endolysin crystal structures have been solved: the CHAP domain of 
LysK and all 3 domains of LysGH15 (Gu et al., 2014; Sanz-Gaitero et al., 2014). 
Excitingly, these endolysins are almost identical to each other (only differing by four 
amino acids), and their CHAP and SH3b domains share about 50% identity to PlyGRCS, 
which means they can give us important structural insight into our endolysin. 
 The crystal structures of the CHAP domains of LysK and LysGH15 were 
obtained at the same time and yielded similar results, in terms of overall structural layout, 
residues implicated in interaction and catalysis, and the importance of metal cations. The 
overall structure of the proteins consists of two alpha helices connected by a loop 
containing the catalytic cysteine and a 310-helix which connects to six beta-strands 
arranged in an anti-parallel beta-sheet (with another 310-helix between beta strands 2 and 
3 (Fig. 5-1A).  They both display a long and deep hydrophobic groove with conserved 
residues lining its surface, providing structural evidence for the catalytic center and its 
reaction mechanism of the cleavage of peptidoglycan (Figure 5-1B). The typical CHAP 
Cys-His-Glu-Asn quartet was found to be close to the cleft and is responsible for a 
proteolytic relay event, resulting in the nucleophilic attack of a peptide bond. Most 
importantly, in and around the active site cysteine lays a classical 12-residue 
(positions1D, 3D, 5Y, 7H, and 12D) calcium-binding site. Calcium was found to be 























Figure 5-1. Structural and functional analysis of LysGH15 CHAP. (A) Overall 
structure of the CHAP domain (residues 1–164) coordinating a Ca
2+
 ion, showing its 
secondary structure composition and the globular nature of endolysin domains. (B) An 
alignment of sequences showing sequence conservation and predicted surface rendering 







residues in coordination of the ion were the three aspartic acids, as determined by site 
directed mutagenesis. PlyGRCS contains these three aspartic acids, but has alanine and 




 positions, respectively. The calcium ion is proposed to help 
maintain structure by assisting with positioning of the catalytic residues; additionally, the 
loop containing the calcium binding site contains residues that were shown to potentially 
interact with the peptidoglycan substrate, suggesting a role in determining substrate 
specificity. The importance of the calcium binding site was also demonstrated by an 
observed ∼2°C shift in Tm, in the presence of Ca2+, indicating its effect on 
thermostability. The approximately 50% identity and even higher level of homology 
between these two proteins and PlyGRCS means that information about the structures of 
the CHAP domains of these two enzymes can be applied to future engineering of 
PlyGRCS, discussed in detail in the next section.   
Before the crystal structure of CHAPK was experimentally resolved, in silico 
modeling using I-TASSER and visualized via PyMol were utilized to somewhat 
accurately predict its 3D structure based upon comparison to an already solved protein 
(Fenton et al., 2011a). In the event of our inability to obtain a crystal structure through X-
ray crystallography or NMR spectroscopy, this alternative technique could provide an 
approximation of the conformation of PlyGRCS and insight into interactions between its 
domains and their substrates.      
While it has been determined that the lysostaphin and ALE-1 CBD substrate is the 
pentaglycine crossbridge of S. aureus peptidoglycan, the PlyGRCS SH3b belongs to a 
variable SH3b subgroup (which includes LysGH15 and LysK), indicating that it may 





between LysGH15 SH3b and the peptide “AGGGGG” was shown to be quite weak at 
only 3 mM; additionally, this SH3b and pentaglycine were never co-crystallized, further 
suggesting that they may not interact (Gu et al., 2014). This may also explain why there 
is much discrepancy about the LysGH15 and ALE-1 residues involved in binding, as well 
as slight differences observed in structure of the CBDs from these two endolysins.  
Because we cannot co-crystallize the PlyGRCS SH3b with its substrate if we aren’t sure 
what that substrate is, a computational modelling approach may help to determine this 
ligand. However, we must have some potential candidates for this method, so we have 
constructed a partial list of S. aureus-specific molecules that are accessible to binding by 
the PlyGRCS CBD (Table 5-1). These include teichoic acids, surface anchored proteins, 
carbohydrates, and components of the staphylococcal peptidoglycan. RosettaLigand has 
been successfully used to model small molecule interactions with a protein receptor. In 
fact, this program defined phosphatidylserine as the interacting partner for the binding 
domain of PlyCB that facilitates internalization of the PlyC holoenzyme (Shen et al., 
2016). Additionally, other ligand-receptor modeling programs have been utilized to study 
the interactions between CBDs and their binding targets, providing important structural 
insight and mechanistic understanding (Hirakawa et al., 2009; Perez-Dorado et al., 2007).  
 
Engineering: Next Generation PlyGRCS  
Despite the potent antimicrobial activity of PlyGRCS, we would like to alter some 
of its properties to make it a better enzyme. As mentioned, the modular domains of 


















Figure 5-2. Analysis of SH3b domains.  Sequence alignment of SH3b domains from 11 
staphylococcal endolysins representing five homology groups and 6 stand-alone proteins, 
shows conserved residues that allow for the clustering into two subgroups. (A) Weakly 
conserved subgroup. (B) Highly conserved subgroup. Overlined residues constitute the 
formal SH3b_5 domain (Pfam database). * perfectly conserved residue, : highly 












Table 5-1. Candidates for PlyGRCS SH3b binding partners. 
Molecule Function Ref. 
Polyribitolphosphate wall teichoic 
acid 
 
shape determination, regulation 






antigenicity, regulator of 
autolysis 
(Endl et al., 
1983) 
Peptidoglycan components 
(GlcNac, MurNac, Peptide stem, 




   
MSCRAMMs (microbial surface 
components recognizing adhesive 
matrix molecules) (i.e. FnBPA, 
FnBPB, Cna, ClfA, ClfB, SdrC, 
SdrD, SdrE) 
adhesion, immune evasion 
(Foster and 
Hook, 1998) 
   
NEAT motif family proteins (IsdA, 
IsdB, IsdH) 
iron acquisition 
(Grigg et al., 
2007) 
   
SasB, C, D, F, G, J, K, L, X adhesion, biofilm formation 
(Roche et al., 
2003) 
   
Protein A immune evasion, antigenicity 
(Forsgren and 
Sjoquist, 1966) 
   
AdsA immune evasion 
(Thammavongsa 
et al., 2011) 
   
Bap biofilm formation, invasion 
(Cucarella et al., 
2001) 
   
SraP adhesion 
(Siboo et al., 
2005) 
   
  
Select molecules present in only S. aureus that could be potential substrates for the 







improve efficacy, change host range, or vary other characteristics. Additionally, rational 
design though structure guided site directed mutagenesis, along with random mutagenesis 
techniques including directed evolution, have all proven effective ways of modifying 
endolysins.   
 One possibility, which we have already started to investigate through our ΦNM3 
CBD experiments, is replacing the native SH3b with other CBDs. This can be 
approached in two ways. The first requires changing the CBD but keeping the S. aureus 
species specifity. Staphylococcal endolysins containing SH3b domains are classified into 
five homology groups and 6 stand-alone proteins, leading us to believe that there might 
be 11 different SH3b domains that could be paired with the PlyGRCS CHAP (Becker et 
al., 2009b). However, most of the sequence conservation appears to be within the C-
terminal SH3b domain, and a comprehensive bioinformatic analysis revealed there to be 
only 2 distinct SH3b subgroups (Fig. 5-2). As the native PlyGRCS SH3b domain belongs 
in the “weakly conserved subgroup,” future studies would involve replacing it with an 
SH3b domain from the “highly conserved subgroup,” one of whose members is the 
lysostaphin SH3b. It has already been determined that the λSa2 endopeptidase catalytic 
domain paired with the lysostaphin SH3b displayed approximately 2x greater activity 
than when paired with the LysK SH3b (from the weakly conserved group). As the λSa2 
endopeptidase domain only has one catalytic activity, the dual catalytic activity of 
PlyGRCS CHAP combined with the improved binding of lysostaphin SH3b may create a 
super enzyme. An important note is that increased binding does not necessarily mean 
increased catalysis. In theory, a CBD that binds too tightly and does not release its target 





and can rapidly move between substrates. While affinities of listerial CBDs were 
determined to be in the nanomolar range, there is currently no understanding of the “best” 
binding for optimal endolysin activity and few data are available on the Kd of 
staphylococcal CBDs (Gu et al., 2014; Schmelcher et al., 2010). In this vein, we would 
like to determine the affinities of the highly conserved SH3b, the weakly conserved 
SH3b, and the ΦNM3 CBD, and how the strength of their binding contributes to activity. 
Our facility has recently acquired the Octet RED96 system, which can determine kinetic 
binding constants in real time. These data, combined with information obtained from the 
crystal structure and the role of ionic interaction by way of charge, may help us to define 
an ideal binding domain, as well as identify future points of modification to modulate 
binding.      
In addition to changing the S. aureus-specific CBD for another S. aureus-specific 
CBD, a non-S. aureus CBD could be fused to the PlyGRCS catalytic domain to change 
the target organism. As noted, the catalytic domain is highly active due to its dual 
activities; however, while one of the bonds cleaved by the PlyGRCS CHAP domain is 
present in all bacteria (the linkage between the N-acetylmuramic acid and the L-alanine 
of the peptide stem), the other bond is only present in staphylococcal species (between L-
alanine and a glycine in the crossbridge). We could replace the PlyGRCS SH3b domain 
with a CBD from an endolysin against any other species, but the activity may be 
weakened with only one catalytic activity. Based on this, S. epidermidis, which is a 
causative agent of opportunistic nosocomial infections, may be a good target for modified 
PlyGRCS. We have already determined that PlyGRCS displays weaker activity against S. 





of the CBD to recognize a non-S. aureus target. While there are other endolysins reported 
in the literature to have activity on both S. aureus and S. epidermidis, there are no S. 
epidermidis-specific endolysins.  Additionally, there appear to only be 5 S. epidermidis 
bacteriophage genomes sequenced, leading to the identification of only 5 genes annotated 
as endolysins (with no data on their activity) (Aswani et al., 2014; Daniel et al., 2007; 
Melo et al., 2014a, b). Three of these endolysins have CBDs annotated as SH3b, while 
the other two have C-terminal regions that display no homology to any domains in the 
database. Creating a chimeric enzyme composed of the PlyGRCS CHAP domain and one 
of these predicted CBDs may prove to be extremely effective against S. epidermidis, due 
to dual catalytic activity combined with potential S. epidermidis-specific binding.                
The chimeragenesis approach is just one method by which we could rationally 
design an improved endolysin. Additionally, information gleaned from obtaining the 
crystal structure of PlyGRCS, along with bioinformatic sequence analysis may help us 
understand how to modify the catalytic domain for enhanced activity (Fig. 5-3) (Di 
Tommaso et al., 2011; Notredame et al., 2000). A comparative analysis of Sal-1 and 
LysK found that Sal-1 was approximately twice as active as LysK, despite only differing 
from each other at 3 residues (Jun et al., 2011). It was determined that the Sal-1 
glutamine at position 113 contributed to this enhanced activity; LysK has a glutamic acid 
at this point in the CHAP domain. The LysGH15 CHAP domain also contains a 
glutamine at position 113, and only differs from Sal-1 by one amino acid in the SH3b 
domain (LysGH15 D469; Sal-1 N469). Crystal structures of both the CHAP domains 
from LysK and LysGH15 identify W115 and H117 from the loop between beta-strands B 






















Figure 5-3. Alignment of LysGH15, LysK, Sal-1, and PlyGRCS. An alignment by T-
COFFEE showing the CHAP domains of LysGH15, LysK, Sal-1 (residues 45-159)  and 
PlyGRCS (residues 20-133) and SH3b domains of LysGH15, LysK, Sal-1 (residues 412-
477) and PlyGRCS (residues 164-229). The three reference proteins contain an additional 
central Amidase_2 catalytic domain (residues 207-330).  * perfectly conserved residue, : 





groove that possibly accomodates the peptidoglycan substrate (Gu et al., 2014; Sanz-
Gaitero et al., 2014). The proximity of the 113
th
 amino acid to this site and its effect on 
activity indicates that it may contribute to the structure of the groove. While PlyGRCS 
contains a similarly hydrophobic tyrosine (corresponding to the W115), as well as the 
histidine as part of its active site, the alignment of PlyGRCS with LysK, LysGH15, and 
Sal-1 shows that there is a gap in homology corresponding to amino acids 111-113 of the 
three reference proteins (beween S88 and Q89  in PlyGRCS). Based upon this, inserting 
three residues (SYQ) to fill in this gap may modify the activity of PlyGRCS. Analysis 
ofthe crystal structures of the CHAP domains of LysK and LysGH15 additionally 
identified F36, D47, Y49, Y50, Q53, C54, D56, T59, R71, W73, N75, N136 and W137 
(for LysK) and  D47, Q53, C54, D56, G74, N75, H117, E134, and N136 (for LysGH15) 
as residues in the groove that might contact peptidoglycan (Gu et al., 2014; Sanz-Gaitero 
et al., 2014). The alignment shows that PlyGRCS only differs at these suggested 
peptidoglycan-contacting amino acids corresponding to positions 36, 49, and 59. 
Therefore, making point mutations to PlyGRCS at these corresponding positions may 
prove to alter its activity. Perhaps the most important mutation involves the PlyGRCS 
residue corresponding to position 49 (position 5 in the calcium binding site), as this 
region has been shown to contribute to structural stability, activity, and thermostability. 
PlyGRCS contains an alanine at this position; it was previously shown that LysGH15 
Y49A displayed ~80% of the bacteriolytic activity of the WT endolysin. Although not as 
critical as the residues in positions 1, 3, and 12 of the calcium binding site (which all 
displayed <5% activity when mutated), this 5
th
 position does seem to have some 





calcium ion, there seems to be an additional factor, such as size of the amino acid, which 
affects activity. Therefore, changing this alanine to a tyrosine may enhance the activity of 
PlyGRCS. Additionally, although not one of the suggested peptidoglycan contacting 
residues, the slight reduction in activity when H51 was mutated to alanine in LysGH15 
and LysK indicates that the 7
th
 position in the calcium binding site may be more 
important than previously thought. In PlyGRCS, the amino acid at this position is 
glycine, so mutation to a much larger charged residue, such as histidine, may alter 
activity.         
In addition to rationale design to improve the efficacy of endolysins, random 
mutagensis has also proven to be a valuable technique in the development of better 
enzymes and could be utilized to create a better PlyGRCS. Two methods have already 
been efficacious in producing randomly engineered endolysins with improved activity or 
other desirable characteristics and could easily be adapted to improving PlyGRCS. The 
first utilized an E. coli mutator strain and error-prone PCR to create a GBS endolysin that 
lysed more bacteria at a faster rate (Cheng and Fischetti, 2007). The other was the use of 
directed evolution to increase the thermostability of the streptocococcal endolysin PlyC 
(Heselpoth and Nelson, 2012). In order to use directed evolution to improve the efficacy 
of PlyGRCS, a system would need to be created in which E. coli express and secrete 
PlyGRCS to kill S aureus in competitive growth. Models have been established to show 
that this scenario is theoretically possible (Bull et al., 2015). In the two proposed 
methods, mathematical and computational models show that the selective pressure could 
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Catheter-associated urinary tract infection by Pseudomonas aeruginosa 
is mediated by exopolysaccharide independent biofilms. 
 
Stephanie J. Cole, Angela R. Records, Mona W. Orr, Sara B. Linden, Vincent T. Lee. 
Infect Immun. 2014 May; 82(5): 2048–2058. 
 
Abstract 
Pseudomonas aeruginosa is an opportunistic human pathogen that is especially 
adept at forming surface-associated biofilms. P. aeruginosa causes catheter-associated 
urinary tract infections (CAUTIs) through biofilm formation on the surface of indwelling 
catheters. P. aeruginosa encodes three extracellular polysaccharides, PEL, PSL, and 
alginate, and utilizes the PEL and PSL polysaccharides to form biofilms in vitro; 
however, the requirement of these polysaccharides during in vivo infections is not well 
understood. Here we show in a murine model of CAUTI that PAO1, a strain 
harboring pel, psl, and alg genes, and PA14, a strain harboring pel and alg genes, form 
biofilms on the implanted catheters. To determine the requirement of exopolysaccharide 
during in vivo biofilm infections, we tested isogenic mutants lacking the pel, psl, 
and alg operons and showed that PA14 mutants lacking these operons can successfully 
form biofilms on catheters in the CAUTI model. To determine the host factor(s) that 
induces the ΔpelD mutant to form biofilm, we tested mouse, human, and artificial urine 
and show that urine can induce biofilm formation by the PA14 ΔpelD mutant. By testing 
the major constituents of urine, we show that urea can induce a pel-, psl-, and alg-
independent biofilm. These pel-, psl-, and alg-independent biofilms are mediated by the 
release of extracellular DNA. Treatment of biofilms formed in urea with DNase I reduced 
the biofilm, indicating that extracellular DNA supports biofilm formation. Our results 
indicate that the opportunistic pathogen P. aeruginosa utilizes a distinct program to form 










A chimeolysin with robust bacteriolytic activity and extended-spectrum 
streptococcal host range found by an induced-lysis based rapid 
screening method.  
 
Hang Yang, Sara B. Linden, Jing Wang, Junping Yu, Daniel C. Nelson, Hongping Wei. 
Sci Rep. 2015 Nov; 5: 17257. 
 
Abstract 
The increasing emergence of multi-drug resistant streptococci poses a serious 
threat to public health worldwide. Bacteriophage lysins are promising alternatives to 
antibiotics; however, their narrow lytic spectrum restricted to closely related species is a 
central shortcoming to their translational development. Here, we describe an efficient 
method for rapid screening of engineered chimeric lysins and report a unique 
“chimeolysin”, ClyR, with robust activity and an extended-spectrum streptococcal host 
range against most streptococcal species, including S. pyogenes, S. agalactiae, S. 
dysgalactiae, S. equi, S. mutans, S. pneumoniae, S. suis and S. uberis, as well as 
representative enterococcal and staphylococcal species (including MRSA and VISA). 
ClyR is the first lysin that demonstrates activity against the dominant dental caries-
causing pathogen as well as the first lysin that kills all four of the bovine mastitis-causing 
pathogens. This study demonstrates the success of the screening method resulting in a 

























A bacteriophage endolysin that eliminates intracellular streptococci. 
 
Yang Shen, Marilia Barros, Tarek Vennemann, D. Travis Gallagher, Yizhou Yin, Sara B. 
Linden, Ryan D. Heselpoth, Dennis J. Spencer, David M. Donovan, John Moult, Vincent 




PlyC, a bacteriophage-encoded endolysin, lyses Streptococcus pyogenes (Spy) on 
contact. Here, we demonstrate that PlyC is a potent agent for controlling 
intracellular Spy that often underlies refractory infections. We show that 
the PlyC holoenzyme, mediated by its PlyCB subunit, crosses epithelial cell membranes 
and clears intracellular Spy in a dose-dependent manner. Quantitative studies using model 
membranes establish that PlyCB interacts strongly with phosphatidylserine (PS) whereas 
its interaction with other lipids is weak, suggesting specificity for PS as its cellular 
receptor. Neutron reflection further substantiates that PlyC penetrates bilayers above a PS 
threshold concentration. Crystallography and docking studies identify key residues that 
mediate PlyCB-PS interactions, which are validated by site-directed mutagenesis. This is 
the first report that a native endolysin can translocate epithelial membranes, thus 
substantiating the potential of PlyC as an antimicrobial for Spy in the extra- and 
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The growing prevalence within community and healthcare settings of antibiotic 
resistant Gram-positive and Gram-negative bacterial pathogens is alarming. Particularly 
concerning are reports of bacteria that are resistant to last-resort antibiotics such as 
carbapenems and vancomycin. Thus, novel concepts are needed to face the serious 
challenge posed by multidrug resistant bacterial infections. A promising alternative 
antimicrobial approach to conventional antibiotics involves the use of bacteriophage-
derived protein(s), generically known as “enzybiotics”. Endolysins, one type of 
enzybiotic, are cell-wall, i.e., peptidoglycan hydrolases that act on the host bacterium late 
in the phage replication cycle. These enzymes hydrolyze critical covalent bonds essential 
for maintaining cell wall structural integrity. Due to the absence of an outer membrane, 
extrinsically applied recombinant endolysins have direct access to the bacterial cell wall 
to lyse susceptible Gram-positive pathogens. Highlighting their therapeutic potential, the 
efficacy of endolysins has been validated in vitro and/or in vivo against a variety of 
Gram-positive pathogens, and in the less than 15 years since their first documented use as 
an antimicrobial in 2001, endolysins are now being commercially developed and 
undergoing clinical trials. Alternatively, phage-like or particulate bacteriocins comprise a 
second class of enzybiotics that can be used therapeutically. These multi-protein 
structures resemble bacteriophage tail-like assemblies and are produced by both Gram-
negative and Gram-positive bacteria. Unlike fully-functional bacteriophages, bacteriocins 
are incapable of replicating, though they nonetheless possess a pseudo-injection 














Anti-biofilm activities of a novel chimeolysin against S. mutans in 
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Streptococcus mutans, a common oral bacterium, often survives as a biofilm on 
the tooth surface and contributes to the development of dental caries. In this study, we 
investigated the efficacy of ClyR, a chimeolysin with an extended streptococcal host-
range, against S. mutans biofilms in physiological and cariogenic conditions. 
Susceptibility tests showed that ClyR was active against all clinical S. mutans isolates 
tested as well as S. mutans biofilms that displayed resistance to penicillin. S. mutans 
biofilms formed on hydroxyapatite discs in physiological sugar conditions and cariogenic 
conditions were reduced ~2 logs and 3 logs after treatment with 100 μg/ml ClyR, 
respectively. In comparison, only 1 log reduction was observed in the chlorhexidine 
(ChX) treated group, and no killing effect was observed in the NaF treated group. A 
mouse dental colonization model showed that repeated use of ClyR for 3 weeks (5 
μg/day) reduced the number of colonized S. mutans in the dental plaques significantly 
(p<0.05), without harmful effects on the body weight and the vitality of mice. 
Furthermore, toxicity was not noted at concentrations exceeding those used for these 
studies and ClyR-specific antibodies could not be detected in mice saliva after repeated 
use of ClyR in the oral cavity. Our data collectively demonstrates that ClyR is active 
against S. mutans biofilms both in vitro and in vivo, thus representing a preventative or 














Development of a bacteriophage lysin for therapeutic use against 




Sara B. Linden, Parimala Sharma, Caren J. Stark, James Todd Hoopes, David E. Kerr, 




Bovine mastitis is an inflammation of a cow’s mammary gland, usually due to a 
microbial infection originating from contaminated teats. Several bacterial species have 
the ability to cause bovine mastitis, but Streptococcus uberis is responsible for the 
majority of chronic cases. The current treatment of antibiotics is not only ineffective, but 
undesirable, due to concerns about the emergence of antibiotic resistant bacteria and the 
spillage of milk from cows until antibiotic clearance has occurred. As an alternative, we 
propose the use of the bacteriophage endolysin PlyC, which displays antimicrobial 
activity against select streptococcal species. This study investigates the use of PlyC as an 
antimicrobial enzyme against S. uberis. Our results show that PlyC possesses potent lytic 
activity against all strains of S. uberis tested, including 7 clinical isolates. Importantly, 
despite the ability of other endolysins to display activity against S. uberis, none have 
successfully functioned in raw cow’s milk, presumably due to inactivation by native 
proteins and lipids; however, PlyC at a concentration of just 2 times the MIC affects 3 
logs of killing in just 1 hour in raw milk from mastitic cows. We have also through 
fluorescent microscopy that the binding domain of PlyC selectively interacts with S. 
uberis in the presence of raw cow’s milk. Furthermore, the lack of neutralization by 
antibodies specifically targeted against PlyC bolsters the potential of this enzyme as an 
antimicrobial treatment. Significantly, PlyC is non-irritating as observed on rabbit 
epidermis and mucous membrane, and non-toxic as observed on a bovine mammary cell 
line. Taken together, these microbiological, biophysical, and immunological results 
indicate that PlyC has the potential to be used as a novel therapeutic against S. uberis-












Analysis of the antimicrobial activity of PlySs9, a Streptococcus suis 









The crisis of increasing resistance of pathogenic bacteria to classical antibiotics 
has driven research towards identification of other means to fight infectious disease. One 
particularly attractive option is the use of bacteriophage-encoded peptidoglycan 
hydrolases (endolysins). These enzymes are able to lyse the bacterial cell wall upon direct 
contact when applied externally and lack the drawbacks of typical antimicrobials. 
Endolysins have already shown potential in the areas of food safety, human health, and 
veterinary science. One specific area that could benefit from endolysin application is the 
overwhelming problem of Streptococcus suis infections of pigs. While the economic toll 
on the swine industry can be devastating in the event of an outbreak, it is the zoonotic 
nature of S. suis that is particularly alarming. There are currently no effective approaches 
to eradicate S. suis from pig herds and preventing disease outbreaks has proven extremely 
difficult. Therefore, the overall objective of this proposal is to identify and evaluate novel 


























Recombinant bacteriophage endolysin, PlyC, is non-toxic and does not 
alter blood polymorphonuclear leukocytes or mammary cells in 
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 As bacteria develop resistance to conventional antibiotics, it is relevant to explore 
alternate therapies to treat intramammary infections. A newly proposed treatment method 
utilizes endolysin PlyC, an enzyme produced by bacteriophages that causes targeted lysis 
of the plasma membrane of Streptococcus uberis. A relatively low concentration (1.0 
μg/mL) of recombinant PlyC (rPlyC) can induce lytic activity, suggesting that a low dose 
may successfully eliminate infection. We evaluated the dose effect of rPlyC on 
cytotoxicity and oxidative response of bovine blood neutrophils. We hypothesized that 
rPlyC would be non-toxic and not alter the inflammatory response of neutrophils in vitro. 
Cells were isolated from plasma obtained from healthy, mid-lactation primiparous dairy 
cows (n=12) and incubated with various concentrations of rPlyC (0, 1, 10, and 50 µg/mL) 
for 0.5 and 2 hours. Following incubation, cytotoxicity was measured by non-radioactive, 
colorimetric assay to quantify lactate dehydrogenase. Oxidative response was measured 
by chemiluminescence assay of reactive oxygen species (ROS) production in response to 
0 and 1.6 µg/mL phorbol 12-myristate-13-acetate (PMA) in addition to rPlyC during 
incubation. Data were analyzed as ANOVA using mixed model procedures in SAS 
(version 9.3). As expected, neutrophil cytotoxicity varied across incubation time with 
greater cell toxicity measured at 2 hours incubation as compared to 0.5 hours (P=0.01; 55 
vs. 45±3%) and is primarily attributed to the short half-life of neutrophils. Oxidative 
response was affected by incubation time (P=0.04) and PMA concentration (P<0.01) 
with the greatest ROS production at 0.5 hour incubation in the presence of 1.6 µg/mL 
PMA. Concentration of rPlyC did not affect oxidative response (P=0.73) nor neutrophil 
cytotoxicity (P=0.41). In summary, varying doses of rPlyC are non-toxic and do not alter 
ROS production in bovine neutrophils. The use of rPlyC as an alternative intramammary 
therapy for Streptococcus uberis mastitis is promising as our data indicate that rPlyC may 
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